HETEROCYCLIC COMPOUNDS AS PESTICIDES
The present application relates to thiadiazole compounds, compositions containing such compounds, their use for controlling animal pests including arthropods, insects and nematodes, and to processes and intermediates for the preparation of the thiadiazole compounds. Certain thiadiazole compounds and their use for controlling pests are known from WO 01/40223 A2. Thiadiazole compounds with a pyridine moiety in the 3-position of the thiadiazole ring system and their use for controlling parasites are disclosed in WO 2015/073797 A1. Crop protection compositions, which also include pesticides, have to meet many demands, for example in relation to efficacy, persistence, spectrum, resistance breaking properties, pollinator and beneficial safety of their action and possible use. Questions of toxicity, the combinability with other active compounds or formulation auxiliaries play a role, as well as the question of the expense that the synthesis of an active compound requires. Furthermore, resistances may occur. For all these reasons, the search for novel crop protection compositions cannot be considered to be complete, and there is a constant need for novel compounds having properties which, compared to the known compounds, are improved at least in respect of individual aspects. It was an object of the present invention to provide compounds which widen the spectrum of the pesticides in various aspects. This object, and further objects which are not stated explicitly but can be discerned or derived from the connections discussed herein, are achieved by compounds of formula (I) and salts of compounds of formula (I) in which
It has been found that compounds of the formula (I) have pronounced biological properties and are suitable especially for controlling animal pests, in particular insects and arachnids, encountered in agriculture, in forests, in the protection of stored products and materials and in the hygiene sector and for controlling arthropodal parasites on animals, in particular warm-blooded animals. Preferred are compounds of formula (I) in which
Particularly preferred are compounds of formula (I) in which
Very particularly preferred are compounds of the formula (I) in which
Very particularly preferred are also compounds of the formula (I) in which
A particularly preferred group of compounds are compounds of formula (I-1) wherein R5, R6, R7 and R8 independently represent hydrogen, methyl, ethyl or benzyl,
Another particularly preferred group of compounds are compounds of formula (I-1) Another particularly preferred group of compounds are compounds of formula (I-2) wherein R5, R6, R7 and R8 independently represent hydrogen, methyl, ethyl or benzyl,
Another particularly preferred group of compounds are compounds of formula (I-2) Another particularly preferred group of compounds are compounds of formula (I-3) In the above definitions, unless stated otherwise, halogen is selected from the group of fluorine, chlorine, bromine and iodine, preferably in turn from the group of fluorine, chlorine and bromine. Halogen-substituted radicals, for example haloalkyl, are mono- or polyhalogenated, up to the maximum number of possible substituents. In the case of polyhalogenation, the halogen atoms may be identical or different. Halogen denotes fluorine, chlorine, bromine and iodine, in particular fluorine, chlorine and bromine. The term “alkenoxy” is synonymous with “alkenyloxy”, “alkynoxy” is synonymous with “alkynyloxy”. Saturated or unsaturated hydrocarbyl radicals, such as alkyl or alkenyl, may in each case be straight-chain or branched as far as possible, including in combination with heteroatoms, as, for example, in alkoxy. Optionally substituted radicals may be mono- or polysubstituted, where the substituents in the case of polysubstitution may be the same or different. The radical definitions or elucidations given above in general terms or within areas of preference apply to the end products and correspondingly to the starting materials and intermediates. These radical definitions can be combined with one another as desired, i.e. including combinations between the respective preferred ranges. In a preferred group of compounds of formula (I) A represents A-1. In another preferred group of compounds of formula (I) A represents A-2. In another preferred group of compounds of formula (I) A represents A-3. In another preferred group of compounds of formula (I) D represents B-1. In another preferred group of compounds of formula (I) D represents B-2. In another preferred group of compounds of formula (I) D represents B-3. In another preferred group of compounds of formula (I) D represents B-8. In another preferred group of compounds of formula (I) A represents A-1 and D represents B-1. In another preferred group of compounds of formula (I) A represents A-1 and D represents B-2. In another preferred group of compounds of formula (I) A represents A-1 and D represents B-3. In another preferred group of compounds of formula (I) A represents A-1 and D represents B-8. In another preferred group of compounds of formula (I) A represents A-2 and D represents B-1. In another preferred group of compounds of formula (I) A represents A-2 and D represents B-3. In another preferred group of compounds of formula (I) A represents A-3 and D represents B-1. In another preferred group of compounds of formula (I) A represents A-3 and D represents B-3. In another preferred group of compounds of formula (I) R2 must be not represent hydrogen in A-2, if R1 is fluorine in A-2. In a preferred group of compounds of formula (I-2) R2 must be not represent hydrogen, if R1 is fluorine. It has additionally been found that compounds of the formula (I) can be obtained by the processes described below. Accordingly, the invention also relates to processes for preparing compounds of the formula (I) in which Q represents oxygen and E represents hydrogen. In the groups of compounds below, the individual radicals A and D have the meanings given above. Compounds of formula (I) wherein E represents Ea (Ea=H) and Q=oxygen can be obtained from the amine of formula (II) either by amide coupling with a carboxylic acid of formula (III) or by reaction with an acyl chloride of formula (IV) (synthesis scheme 1). In case of the amide reaction (route A), in addition to the acid (III) and the amine (II) a base such as ethyl-N,N-diisopropylamine and a coupling agent such as bromo(tri-1-pyrrolidinyl)phosphonium hexafluorophosphate (PYBrOP) can be used in a solvent such as dichloromethane. Alternatively coupling agents such as 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) (HATU) can be used in a solvent such as dimethylformamide with or without a catalytic amount of 4-(N,N-dimethylamino)pyridine, at a temperature of e.g. 80° C. In case of the reaction with an acyl chloride (route B) a base is used in systems such as
Acyl chlorides of formula (IV) are commercially available or can be prepared from the corresponding carboxylic acids of formula (III) using a chlorinated agent such as thionyl chloride in a solvent such as toluene. Compounds of formula (I) wherein E represents Eb (Eb being a metal ion or ammonium ion) and Q represents oxygen can be obtained from compounds of formula (I) wherein E represents H using a strong base, for example sodium methoxide as shown in synthesis scheme 2. Compounds of formula (I) wherein E represents Ec (Ec being C1-C6-alkyl), can be obtained by alkylation of the NH of the amide function using a base such as sodium hydride in a solvent such as dimethylformamide with a bromo- or iodo-C1-C6-alkyl reagent. Compounds of formula (I) wherein E represents Ed (Ed being COAr), can be obtained by over-benzoylation using the amine of formula (II) and an excess of base e.g. ethyl-N,N-diisopropylamine and an excess of benzoyl chloride ClCOD. Some amines of formula (II) are commercially available, for example the following ones:
Novel amines of formula (II-2) such as 3-(2,6-difluorophenyl)-1,2,4-thiadiazol-5-amine or
Nitriles of formula (VII) can react with lithium hexamethyldisilazide (LiHMDS) in a solvent such as tetrahydrofuran to give amidines of formula (VI). Alternatively the nitriles of formula (VII) can be transformed into amidines of formula (VI) using a mixture of trimethylaluminium and ammonium chloride in a solvent such as toluene to which the nitrile (VII) is added dropwise at a temperature such as 0° C. The reaction mixture is then heated to e.g. 80° C. In some cases, the amidine is commercially available. Amidines of formula (VI) can be brominated with e.g. N-bromosuccinimide to give the brominated intermediates of formula (V). Intermediates of formula (V) can be cyclized to yield the thiadiazole-amines of formula (II) using an agent such as potassium thiocyanate in a solvent such as methanol. Alternatively the amidines of formula (VI) can be transformed into thiadiazole-amines of formula (II) without isolating the intermediates of formula (V) in a one pot process. The reaction is performed in presence of a base such as triethylamine, using first a brominating agent such as bromine in a solvent such as methanol e.g. at 0° C. subsequently followed by addition of potassium thiocyanate. Compounds of formula (I) wherein E represents Ea (Ea=H) can also be obtained by reaction of the boronic acid of formula (VIII) with the bromo-thiadiazole adduct of formula (IX) (Suzuki coupling, see synthesis scheme 4) using for example the X-phos aminobiphenyl palladium chloride precatalyt as well as a base, e.g. potassium phosphate in a solvent mixture such as tetrahydrofuran/water, at a temperature of e.g. 60° C. The bromo-thiadiazole of formula (IX) can be obtained by amide coupling between the carboxylic acid of formula (III) and the amine of formula (X) in the presence of a coupling agent such as HATU and a base such as ethyl-N,N-diisopropylamine, at a temperature of e.g. 80° C. Bromothiadiazol-amines of formula (X) can be obtained by reaction of ammonia with 3-bromo-5-chloro-thiadiazole (XI). In some particular cases, compounds of formula (I) wherein E represents Ea (Ea=H) have been obtained by Langlois trifluoromethylation reaction using sodium trifluoromethanesulfinate, copper (II) triflate and t-butylhydroperoxide in a solvent such as acetonitrile. This is the case for compounds I-1-62, I-1-65 and I-1-66 as depicted in Table 1. In other particular cases compounds of formula (I) wherein E represents Ea (Ea=H) were obtained by iodination with a iodo source such as N-iodosuccinimide using palladium acetate followed by cyanation using for example copper (I) cyanide. This is the case for compounds I-1-67 and I-1-78 (see Table 1). The processes according to the invention for the preparation of compounds of the formula (I) are preferably performed using a diluent. Useful diluents for performance of the processes according to the invention are, as well as water, all inert solvents. Examples include: halohydrocarbons (for example chlorohydrocarbons such as tetrachloroethylene, tetrachloroethane, dichloropropane, methylene chloride, dichlorobutane, chloroform, carbon tetrachloride, trichloroethane, trichloroethylene, pentachloroethane, difluorobenzene, 1,2-dichloroethane, chlorobenzene, bromobenzene, dichlorobenzene, chlorotoluene, trichlorobenzene), alcohols (for example methanol, ethanol, isopropanol, butanol), ethers (for example ethyl propyl ether, methyl tert-butyl ether, anisole, phenetole, cyclohexyl methyl ether, dimethyl ether, diethyl ether, dipropyl ether, diisopropyl ether, di-n-butyl ether, diisobutyl ether, diisoamyl ether, ethylene glycol dimethyl ether, tetrahydrofuran, 1,4-dioxane, dichlorodiethyl ether and polyethers of ethylene oxide and/or propylene oxide), amines (for example trimethyl-, triethyl-, tripropyl-, tributylamine, N-methylmorpholine, pyridine and tetramethylenediamine), nitrohydrocarbons (for example nitromethane, nitroethane, nitropropane, nitrobenzene, chloronitrobenzene, o-nitrotoluene); nitriles (for example acetonitrile, propionitrile, butyronitrile, isobutyronitrile, benzonitrile, m-chlorobenzonitrile), tetrahydrothiophene dioxide, dimethyl sulphoxide, tetramethylene sulphoxide, dipropyl sulphoxide, benzyl methyl sulphoxide, diisobutyl sulphoxide, dibutyl sulphoxide, diisoamyl sulphoxide, sulphones (for example dimethyl, diethyl, dipropyl, dibutyl, diphenyl, dihexyl, methyl ethyl, ethyl propyl, ethyl isobutyl and pentamethylene sulphone), aliphatic, cycloaliphatic or aromatic hydrocarbons (for example pentane, hexane, heptane, octane, nonane and technical hydrocarbons), and also what are called “white spirits” with components having boiling points in the range from, for example, 40° C. to 250° C., cymene, petroleum fractions within a boiling range from 70° C. to 190° C., cyclohexane, methylcyclohexane, petroleum ether, ligroin, benzene, toluene, xylene, esters (for example methyl, ethyl, butyl and isobutyl acetate, dimethyl, dibutyl and ethylene carbonate); amides (for example hexamethylphosphoric triamide, formamide, N-methylformamide, N,N-dimethylformamide, N,N-dipropylformamide, N,N-dibutylformamide, N-methylpyrrolidine, N-methylcaprolactam, 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidine, octylpyrrolidone, octylcaprolactam, 1,3-dimethyl-2-imidazolinedione, N-formylpiperidine, N,N′-diformylpiperazine) and ketones (for example acetone, acetophenone, methyl ethyl ketone, methyl butyl ketone). It is of course also possible to perform the process according to the invention in mixtures of the solvents and diluents mentioned. When performing the process according to the invention, the reaction temperatures can be varied within a relatively wide range. In general, the temperatures employed are between −30° C. and +150° C., preferably between −10° C. and +100° C. The process according to the invention is generally performed under atmospheric pressure. However, it is also possible to perform the process according to the invention under elevated or reduced pressure—generally at absolute pressures between 0.1 bar and 15 bar. To perform the process according to the invention, the starting materials are generally used in approximately equimolar amounts. However, it is also possible to use one of the components in a relatively large excess. The reaction is generally carried out in a suitable diluent in the presence of a reaction auxiliary, optionally also under a protective gas atmosphere (for example under nitrogen, argon or helium) and the reaction mixture is generally stirred at the temperature required for several hours. The workup is performed by customary methods (cf. the preparation examples). The basic reaction auxiliaries used to perform the process according to the invention may be all suitable acid binders. Examples include: alkaline earth metal or alkali metal compounds (e.g. hydroxides, hydrides, oxides and carbonates of lithium, sodium, potassium, magnesium, calcium and barium), amidine bases or guanidine bases (e.g. 7-methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene (MTBD); diazabicyclo[4.3.0]nonene (DBN), diazabicyclo[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undecene (DBU), cyclohexyltetrabutylguanidine (CyTBG), cyclohexyltetramethylguanidine (CyTMG), N,N,N,N-tetramethyl-1,8-naphthalenediamine, pentamethylpiperidine) and amines, especially tertiary amines (e.g. triethylamine, trimethylamine, tribenzylamine, triisopropylamine, tributylamine, tricyclohexylamine, triamylamine, trihexylamine, N,N-dimethylaniline, N,N-dimethyltoluidine, N,N-dimethyl-p-aminopyridine, N-methylpyrrolidine, N-methylpiperidine, N-methylimidazole, N-methylpyrazole, N-methylmorpholine, N-methylhexamethylenediamine, pyridine, 4-pyrrolidinopyridine, 4-dimethylaminopyridine, quinoline, 2-picoline, 3-picoline, pyrimidine, acridine, N,N,N′,N′-tetramethylenediamine, N,N,N′,N′-tetraethylenediamine, quinoxaline, N-propyldiisopropylamine, N-ethyldiisopropylamine, N,N′-dimethylcyclohexylamine, 2,6-lutidine, 2,4-lutidine or triethylenediamine). The acidic reaction auxiliaries used to perform the process according to the invention include all mineral acids (e.g. hydrohalic acids such as hydrofluoric acid, hydrochloric acid, hydrobromic acid or hydriodic acid, and also sulphuric acid, phosphoric acid, phosphorous acid, nitric acid), Lewis acids (e.g. aluminium(III) chloride, boron trifluoride or its etherate, titanium(IV) chloride, tin(IV) chloride) and organic acids (e.g. formic acid, acetic acid, propionic acid, malonic acid, lactic acid, oxalic acid, fumaric acid, adipic acid, stearic acid, tartaric acid, oleic acid, methanesulphonic acid, benzoic acid, benzenesulphonic acid or para-toluenesulphonic acid). Isomers Depending on the nature of the substituents, the compounds of the formula (I) may be in the form of geometric and/or optically active isomers or corresponding isomer mixtures in different compositions. These stereoisomers are, for example, enantiomers, diastereomers, atropisomers or geometric isomers. Accordingly, the invention encompasses both pure stereoisomers and any mixture of these isomers. Methods and Uses The invention also relates to methods for controlling animal pests, in which compounds of the formula (I) are allowed to act on animal pests and/or their habitat. The control of the animal pests is preferably conducted in agriculture and forestry, and in material protection. Preferably excluded herefrom are methods for the surgical or therapeutic treatment of the human or animal body and diagnostic methods carried out on the human or animal body. The invention furthermore relates to the use of the compounds of the formula (I) as pesticides, in particular crop protection agents. In the context of the present application, the term “pesticide” in each case also always comprises the term “crop protection agent”. The compounds of the formula (I), having good plant tolerance, favourable homeotherm toxicity and good environmental compatibility, are suitable for protecting plants and plant organs against biotic and abiotic stressors, for increasing harvest yields, for improving the quality of the harvested material and for controlling animal pests, especially insects, arachnids, helminths, nematodes and molluscs, which are encountered in agriculture, in horticulture, in animal husbandry, in aquatic cultures, in forests, in gardens and leisure facilities, in the protection of stored products and of materials, and in the hygiene sector. Within the context of the present patent application, the term “hygiene” is understood to mean any and all measures, procedures and practices which aim to prevent disease, in particular infectious disease, and which serve to protect the health of humans and animals and/or to protect the environment, and/or which maintain cleanliness. In accordance with the invention, this especially includes measures for cleaning, disinfection and sterilisation of, for example, textiles or hard surfaces, especially surfaces of glass, wood, concrete, porcelain, ceramics, plastic or also of metal(s), and for ensuring that these are kept free of hygiene pests and/or their faeces. On the other hand, excluded from the scope of the invention in this regard are surgical or therapeutic treatment procedures applicable to the human body or to the bodies of animals and diagnostic procedures which are carried out on the human body or on the bodies of animals. The term “hygiene sector” thus covers all areas, technical fields and industrial applications in which these hygiene measures, procedures and practices are important, in relation for example to hygiene in kitchens, bakeries, airports, bathrooms, swimming pools, department stores, hotels, hospitals, stables etc. The term “hygiene pest” is therefore understood to mean one or more animal pests whose presence in the hygiene sector is problematic, in particular for health reasons. It is therefore a primary objective to avoid or minimize the presence of hygiene pests, and/or exposure to them, in the hygiene sector. This can be achieved in particular through the application of a pesticide that can be used both to prevent infestation and to tackle an infestation which is already present. Preparations which avoid or reduce exposure to pests can also be used. Hygiene pests include, for example, the organisms mentioned below. The term “hygiene protection” thus covers all actions to maintain and/or improve these hygiene measures, procedures and practices. The compounds of the formula (I) can preferably be used as pesticides. They are active against normally sensitive and resistant species and against all or some stages of development. The abovementioned pests include: pests from the phylum of the Arthropoda, in particular from the class of the Arachnida, for example from the class of the Chilopoda, for example from the order or the class of the Collembola, for example from the class of the Insecta, for example from the order of the Blattodea, for example from the order of the Coleoptera, for example from the order of the Dermaptera, for example from the order of the Diptera, for example from the order of the Hemiptera, for example from the suborder of the Heteroptera, for example from the order of the Hymenoptera, for example from the order of the Isopoda, for example from the order of the Isoptera, for example from the order of the Lepidoptera, for example from the order of the Orthoptera or Saltatoria, for example from the order of the Phthiraptera, for example from the order of the Psocoptera, for example from the order of the Siphonaptera, for example, from the order of the Thysanoptera, for example from the order of the Zygentoma (=Thysanura), for example from the class of the Symphyla, for example and also from the class of the Gastropoda, for example animal and human parasites from the phyla of the Platylminthes and Nematoda, for example plant pests from the phylum of the Nematoda, i.e. phytoparasitic nematodes, in particular Furthermore, it is possible to control, from the subkingdom of the Protozoa, the order of the Coccidia, for example The compounds of the formula (I) can optionally, at certain concentrations or application rates, also be used as herbicides, safeners, growth regulators or agents to improve plant properties, as microbicides or gametocides, for example as fungicides, antimycotics, bactericides, viricides (including agents against viroids) or as agents against MLO ( Formulations The present invention further relates to formulations and use forms prepared therefrom as pesticides, for example drench, drip and spray liquors, comprising at least one compound of the formula (I). In some cases, the use forms comprise further pesticides and/or adjuvants which improve action, such as penetrants, e.g. vegetable oils, for example rapeseed oil, sunflower oil, mineral oils, for example paraffin oils, alkyl esters of vegetable fatty acids, for example rapeseed oil methyl ester or soya oil methyl ester, or alkanol alkoxylates and/or spreaders, for example alkylsiloxanes and/or salts, for example organic or inorganic ammonium or phosphonium salts, for example ammonium sulphate or diammonium hydrogenphosphate and/or retention promoters, for example dioctyl sulphosuccinate or hydroxypropyl guar polymers and/or humectants, for example glycerol and/or fertilizers, for example ammonium-, potassium- or phosphorus-containing fertilizers. Customary formulations are, for example, water-soluble liquids (SL), emulsion concentrates (EC), emulsions in water (EW), suspension concentrates (SC, SE, FS, OD), water-dispersible granules (WG), granules (GR) and capsule concentrates (CS); these and further possible formulation types are described, for example, by Crop Life International and in Pesticide Specifications, Manual on development and use of FAO and WHO specifications for pesticides, FAO Plant Production and Protection Papers—173, prepared by the FAO/WHO Joint Meeting on Pesticide Specifications, 2004, ISBN: 9251048576. The formulations, in addition to one or more compounds of the formula (I), optionally comprise further agrochemically active compounds. These are preferably formulations or use forms which comprise auxiliaries, for example extenders, solvents, spontaneity promoters, carriers, emulsifiers, dispersants, frost protectants, biocides, thickeners and/or further auxiliaries, for example adjuvants. An adjuvant in this context is a component which enhances the biological effect of the formulation, without the component itself having any biological effect. Examples of adjuvants are agents which promote retention, spreading, attachment to the leaf surface or penetration. These formulations are prepared in a known way, for example by mixing the compounds of the formula (I) with auxiliaries such as, for example, extenders, solvents and/or solid carriers and/or other auxiliaries such as, for example, surfactants. The formulations are prepared either in suitable facilities or else before or during application. The auxiliaries used may be substances suitable for imparting special properties, such as certain physical, technical and/or biological properties, to the formulation of the compounds of the formula (I), or to the use forms prepared from these formulations (for example ready-to-use pesticides such as spray liquors or seed dressing products). Suitable extenders are, for example, water, polar and nonpolar organic chemical liquids, for example from the classes of the aromatic and non-aromatic hydrocarbons (such as paraffins, alkylbenzenes, alkylnaphthalenes, chlorobenzenes), the alcohols and polyols (which, if appropriate, may also be substituted, etherified and/or esterified), the ketones (such as acetone, cyclohexanone), esters (including fats and oils) and (poly)ethers, the unsubstituted and substituted amines, amides, lactams (such as N-alkylpyrrolidones) and lactones, the sulphones and sulphoxides (such as dimethyl sulphoxide). If the extender used is water, it is also possible to employ, for example, organic solvents as auxiliary solvents. Essentially, suitable liquid solvents are: aromatics such as xylene, toluene or alkylnaphthalenes, chlorinated aromatics or chlorinated aliphatic hydrocarbons such as chlorobenzenes, chloroethylenes or methylene chloride, aliphatic hydrocarbons such as cyclohexane or paraffins, for example mineral oil fractions, mineral and vegetable oils, alcohols such as butanol or glycol and their ethers and esters, ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone, strongly polar solvents such as dimethylformamide and dimethyl sulphoxide, and also water. In principle, it is possible to use all suitable solvents. Examples of suitable solvents are aromatic hydrocarbons, such as xylene, toluene or alkylnaphthalenes, chlorinated aromatic or chlorinated aliphatic hydrocarbons, such as chlorobenzene, chloroethylene or methylene chloride, aliphatic hydrocarbons, such as cyclohexane, paraffins, petroleum fractions, mineral and vegetable oils, alcohols, such as methanol, ethanol, isopropanol, butanol or glycol and their ethers and esters, ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone, strongly polar solvents, such as dimethyl sulphoxide, and also water. In principle, it is possible to use all suitable carriers. Useful carriers include especially: for example ammonium salts and ground natural minerals such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite or diatomaceous earth, and ground synthetic materials such as finely divided silica, alumina and natural or synthetic silicates, resins, waxes and/or solid fertilizers. Mixtures of such carriers can likewise be used. Useful carriers for granules include: for example crushed and fractionated natural rocks such as calcite, marble, pumice, sepiolite, dolomite, and synthetic granules of inorganic and organic meals, and also granules of organic material such as sawdust, paper, coconut shells, corn cobs and tobacco stalks. Liquefied gaseous extenders or solvents can also be used. Particularly suitable extenders or carriers are those which are gaseous at ambient temperature and under atmospheric pressure, for example aerosol propellant gases, such as halohydrocarbons, and also butane, propane, nitrogen and carbon dioxide. Examples of emulsifiers and/or foam-formers, dispersants or wetting agents with ionic or nonionic properties, or mixtures of these surfactants, are salts of polyacrylic acid, salts of lignosulphonic acid, salts of phenolsulphonic acid or naphthalenesulphonic acid, polycondensates of ethylene oxide with fatty alcohols or with fatty acids or with fatty amines, with substituted phenols (preferably alkylphenols or arylphenols), salts of sulphosuccinic esters, taurine derivatives (preferably alkyl taurates), phosphoric esters of polyethoxylated alcohols or phenols, fatty esters of polyols, and derivatives of the compounds containing sulphates, sulphonates and phosphates, for example alkylaryl polyglycol ethers, alkylsulphonates, alkyl sulphates, arylsulphonates, protein hydrolysates, lignosulphite waste liquors and methylcellulose. The presence of a surfactant is advantageous if one of the compounds of the formula (I) and/or one of the inert carriers is insoluble in water and when the application takes place in water. It is possible to use colorants such as inorganic pigments, for example iron oxide, titanium oxide and Prussian Blue, and organic dyes such as alizarin dyes, azo dyes and metal phthalocyanine dyes, and nutrients and trace nutrients such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc as further auxiliaries in the formulations and the use forms derived therefrom. Additional components may be stabilizers, such as low-temperature stabilizers, preservatives, antioxidants, light stabilizers or other agents which improve chemical and/or physical stability. Foam formers or antifoams may also be present. Tackifiers such as carboxymethylcellulose and natural and synthetic polymers in the form of powders, granules or latices, such as gum arabic, polyvinyl alcohol and polyvinyl acetate, or else natural phospholipids such as cephalins and lecithins and synthetic phospholipids may also be present as additional auxiliaries in the formulations and the use forms derived therefrom. Further possible auxiliaries are mineral and vegetable oils. Optionally, further auxiliaries may be present in the formulations and the use forms derived therefrom. Examples of such additives include fragrances, protective colloids, binders, adhesives, thickeners, thixotropic agents, penetrants, retention promoters, stabilizers, sequestrants, complexing agents, humectants, spreaders. In general, the compounds of the formula (I) can be combined with any solid or liquid additive commonly used for formulation purposes. Useful retention promoters include all those substances which reduce the dynamic surface tension, for example dioctyl sulphosuccinate, or increase the viscoelasticity, for example hydroxypropylguar polymers. Suitable penetrants in the present context are all those substances which are usually used for improving the penetration of agrochemical active compounds into plants. Penetrants are defined in this context by their ability to penetrate from the (generally aqueous) application liquor and/or from the spray coating into the cuticle of the plant and thereby increase the mobility of active compounds in the cuticle. The method described in the literature (Baur et al., 1997, Pesticide Science 51, 131-152) can be used to determine this property. Examples include alcohol alkoxylates such as coconut fatty ethoxylate (10) or isotridecyl ethoxylate (12), fatty acid esters, for example rapeseed oil methyl ester or soya oil methyl ester, fatty amine alkoxylates, for example tallowamine ethoxylate (15), or ammonium and/or phosphonium salts, for example ammonium sulphate or diammonium hydrogenphosphate. The formulations preferably comprise between 0.00000001 and 98% by weight of the compound of the formula (I) or, with particular preference, between 0.01% and 95% by weight of the compound of the formula (I), more preferably between 0.5% and 90% by weight of the compound of the formula (I), based on the weight of the formulation. The content of the compound of the formula (I) in the use forms prepared from the formulations (in particular pesticides) may vary within wide ranges. The concentration of the compound of the formula (I) in the use forms is usually between 0.00000001 and 95% by weight of the compound of the formula (I), preferably between 0.00001 and 1% by weight, based on the weight of the use form. The compounds are employed in a customary manner appropriate for the use forms. Mixtures The compounds of the formula (I) may also be employed as a mixture with one or more suitable fungicides, bactericides, acaricides, molluscicides, nematicides, insecticides, microbiologicals, beneficial species, herbicides, fertilizers, bird repellents, phytotonics, sterilants, safeners, semiochemicals and/or plant growth regulators, in order thus, for example, to broaden the spectrum of action, to prolong the duration of action, to increase the rate of action, to prevent repulsion or prevent evolution of resistance. In addition, such active compound combinations may improve plant growth and/or tolerance to abiotic factors, for example high or low temperatures, to drought or to elevated water content or soil salinity. It is also possible to improve flowering and fruiting performance, optimize germination capacity and root development, facilitate harvesting and improve yields, influence maturation, improve the quality and/or the nutritional value of the harvested products, prolong storage life and/or improve the processability of the harvested products. Furthermore, the compounds of the formula (I) can be present in a mixture with other active compounds or semiochemicals such as attractants and/or bird repellants and/or plant activators and/or growth regulators and/or fertilizers. Likewise, the compounds of the formula (I) can be used to improve plant properties such as, for example, growth, yield and quality of the harvested material. In a particular embodiment according to the invention, the compounds of the formula (I) are present in formulations or the use forms prepared from these formulations in a mixture with further compounds, preferably those as described below. If one of the compounds mentioned below can occur in different tautomeric forms, these forms are also included even if not explicitly mentioned in each case. Insecticides/Acaricides/Nematicides The active compounds identified here by their common names are known and are described, for example, in the pesticide handbook (“The Pesticide Manual” 16th Ed., British Crop Protection Council 2012) or can be found on the Internet (e.g. http://www.alanwood.net/pesticides). (1) Acetylcholinesterase (AChE) inhibitors, such as, for example, carbamates, for example alanycarb, aldicarb, bendiocarb, benfuracarb, butocarboxim, butoxycarboxim, carbaryl, carbofuran, carbosulfan, ethiofencarb, fenobucarb, formetanate, furathiocarb, isoprocarb, methiocarb, methomyl, metolcarb, oxamyl, pirimicarb, propoxur, thiodicarb, thiofanox, triazamate, trimethacarb, XMC and xylylcarb; or organophosphates, for example acephate, azamethiphos, azinphos-ethyl, azinphos-methyl, cadusafos, chlorethoxyfos, chlorfenvinphos, chlormephos, chlorpyrifos-methyl, coumaphos, cyanophos, demeton-S-methyl, diazinon, dichlorvos/DDVP, dicrotophos, dimethoate, dimethylvinphos, disulfoton, EPN, ethion, ethoprophos, famphur, fenamiphos, fenitrothion, fenthion, fosthiazate, heptenophos, imicyafos, isofenphos, isopropyl O-(methoxyaminothiophosphoryl) salicylate, isoxathion, malathion, mecarbam, methamidophos, methidathion, mevinphos, monocrotophos, naled, omethoate, oxydemeton-methyl, parathion-methyl, phenthoate, phorate, phosalone, phosmet, phosphamidon, phoxim, pirimiphos-methyl, profenofos, propetamphos, prothiofos, pyraclofos, pyridaphenthion, quinalphos, sulfotep, tebupirimfos, temephos, terbufos, tetrachlorvinphos, thiometon, triazophos, triclorfon and vamidothion. (2) GABA-gated chloride channel antagonists, such as, for example, cyclodiene-organochlorines, for example chlordane and endosulfan or phenylpyrazoles (fiproles), for example ethiprole and fipronil. (3) Sodium channel modulators/voltage-gated sodium channel blockers such as, for example, pyrethroids, e.g. acrinathrin, allethrin, d-cis-trans allethrin, d-trans allethrin, bifenthrin, bioallethrin, bioallethrin s-cyclopentenyl isomer, bioresmethrin, cycloprothrin, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, gamma-cyhalothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, theta-cypermethrin, zeta-cypermethrin, cyphenothrin [(1R)-trans-isomer], deltamethrin, empenthrin [(EZ)-(1R)-isomer], esfenvalerate, etofenprox, fenpropathrin, fenvalerate, flucythrinate, flumethrin, tau-fluvalinate, halfenprox, imiprothrin, kadethrin, momfluorothrin, permethrin, phenothrin [(1R)-trans-isomer], prallethrin, pyrethrins (pyrethrum), resmethrin, silafluofen, tefluthrin, tetramethrin, tetramethrin [(1R)-isomer)], tralomethrin and transfluthrin or DDT or methoxychlor. (4) Nicotinergic acetylcholine receptor (nAChR) agonists, such as, for example, neonicotinoids, e.g. acetamiprid, clothianidin, dinotefuran, imidacloprid, nitenpyram, thiacloprid and thiamethoxam or nicotine or sulfoxaflor or flupyradifurone. (5) Allosteric activators of the nicotinergic acetylcholine receptor (nAChR) such as, for example, spinosyns, e.g. spinetoram and spinosad. (6) Chloride channel activators, such as, for example, avermectins/milbemycins, for example abamectin, emamectin benzoate, lepimectin and milbemectin. (7) Juvenile hormone imitators such as, for example, juvenile hormone analogues, e.g. hydroprene, kinoprene and methoprene or fenoxycarb or pyriproxyfen. (8) Active compounds with unknown or nonspecific mechanisms of action such as, for example, alkyl halides, e.g. methyl bromide and other alkyl halides; or chloropicrine or sulphuryl fluoride or borax or tartar emetic. (9) Selective antifeedants, for example pymetrozine or flonicamid. (10) Mite growth inhibitors, for example clofentezine, hexythiazox and diflovidazin or etoxazole. (11) Microbial disruptors of the insect gut membrane, for example (12) Oxidative phosphorylation inhibitors, ATP disruptors such as, for example, diafenthiuron or organotin compounds, for example azocyclotin, cyhexatin and fenbutatin oxide or propargite or tetradifon. (13) Oxidative phosphorylation decouplers acting by interrupting the H proton gradient such as, for example, chlorfenapyr, DNOC and sulfluramid. (14) Nicotinergic acetylcholine receptor antagonists such as, for example, bensultap, cartap hydrochloride, thiocylam, and thiosultap-sodium. (15) Chitin biosynthesis inhibitors, type 0, such as, for example, bistrifluron, chlorfluazuron, diflubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, noviflumuron, teflubenzuron and triflumuron. (16) Chitin biosynthesis inhibitors, type 1, for example buprofezin. (17) Moulting inhibitors (in particular for Diptera, i.e. dipterans) such as, for example, cyromazine. (18) Ecdysone receptor agonists such as, for example, chromafenozide, halofenozide, methoxyfenozide and tebufenozide. (19) Octopaminergic agonists such as, for example, amitraz. (20) Complex-III electron transport inhibitors such as, for example, hydramethylnone or acequinocyl or fluacrypyrim. (21) Complex-I electron transport inhibitors, for example from the group of the METI acaricides, e.g. fenazaquin, fenpyroximate, pyrimidifen, pyridaben, tebufenpyrad and tolfenpyrad or rotenone (Derris). (22) Voltage-gated sodium channel blockers, for example indoxacarb or metaflumizone. (23) Inhibitors of acetyl-CoA carboxylase such as, for example, tetronic and tetramic acid derivatives, e.g. spirodiclofen, spiromesifen and spirotetramat. (24) Complex-IV electron transport inhibitors such as, for example, phosphines, e.g. aluminium phosphide, calcium phosphide, phosphine and zinc phosphide or cyanide. (25) Complex II electron transport inhibitors, such as, for example, cyenopyrafen and cyflumetofen. (28) Ryanodine receptor effectors, such as, for example, diamides, e.g. chlorantraniliprole, cyantraniliprole and flubendiamide, further active compounds such as, for example, Afidopyropen, Afoxolaner, Azadirachtin, Benclothiaz, Benzoximate, Bifenazate, Broflanilide, Bromopropylate, Chinomethionat, Cryolite, Cyclaniliprole, Cycloxaprid, Cyhalodiamide Dicloromezotiaz, Dicofol, Diflovidazin, Flometoquin, Fluazaindolizine, Fluensulfone, Flufenerim, Flufenoxystrobin, Flufiprole, Fluhexafon, Fluopyram, Fluralaner, Fluxametamide, Fufenozide, Guadipyr, Heptafluthrin, Imidaclothiz, Iprodione, Lotilaner, Meperfluthrin, Paichongding, Pyflubumide, Pyridalyl, Pyrifluquinazon, Pyriminostrobin, Sarolaner, Tetramethylfluthrin, Tetraniliprole, Tetrachlorantraniliprole, Tioxazafen, Thiofluoximate, Triflumezopyrim and iodomethane; furthermore preparations based on Fungicides The active ingredients specified herein by their Common Name are known and described, for example, in The Pesticide Manual (16th Ed. British Crop Protection Council) or can be searched in the internet (e.g. www.alanwood.net/pesticides). All named fungicidal mixing partners of the classes (1) to (15) can, if their functional groups enable this, optionally form salts with suitable bases or acids. All named mixing partners of the classes (1) to (15) can include tautomeric forms, where applicable. 1) Inhibitors of the ergosterol biosynthesis, for example (1.01) aldimorph, (1.02) azaconazole, (1.03) bitertanol, (1.04) bromuconazole, (1.05) cyproconazole, (1.06) diclobutrazole, (1.07) difenoconazole, (1.08) diniconazole, (1.09) diniconazole-M, (1.10) dodemorph, (1.11) dodemorph acetate, (1.12) epoxiconazole, (1.13) etaconazole, (1.14) fenarimol, (1.15) fenbuconazole, (1.16) fenhexamid, (1.17) fenpropidin, (1.18) fenpropimorph, (1.19) fluquinconazole, (1.20) flurprimidol, (1.21) flusilazole, (1.22) flutriafol, (1.23) furconazole, (1.24) furconazole-cis, (1.25) hexaconazole, (1.26) imazalil, (1.27) imazalil sulfate, (1.28) imibenconazole, (1.29) ipconazole, (1.30) metconazole, (1.31) myclobutanil, (1.32) naftifine, (1.33) nuarimol, (1.34) oxpoconazole, (1.35) paclobutrazol, (1.36) pefurazoate, (1.37) penconazole, (1.38) piperalin, (1.39) prochloraz, (1.40) propiconazole, (1.41) prothioconazole, (1.42) pyributicarb, (1.43) pyrifenox, (1.44) quinconazole, (1.45) simeconazole, (1.46) spiroxamine, (1.47) tebuconazole, (1.48) terbinafine, (1.49) tetraconazole, (1.50) triadimefon, (1.51) triadimenol, (1.52) tridemorph, (1.53) triflumizole, (1.54) triforine, (1.55) triticonazole, (1.56) uniconazole, (1.57) uniconazole-p, (1.58) viniconazole, (1.59) voriconazole, (1.60) 1-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)cycloheptanol, (1.61) methyl 1-(2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)-1H-imidazole-5-carboxylate, (1.62) N′-({5-(difluoromethyl)-2-methyl-4-[3-(trimethylsilyl)propoxy]phenyl}-N-ethyl-N-methylimidoformamide, (1.63) N-ethyl-N-methyl-N′-{2-methyl-5-(trifluoromethyl)-4-[3-(trimethylsilyl)propoxy]phenyl}imidoformamide, (1.64) O-[1-(4-methoxyphenoxy)-3,3-dimethylbutan-2-yl] 1H-imidazole-1-carbothioate, (1.65) Pyrisoxazole, (1.66) 2-{[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.67) 1-{[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazol-5-yl thiocyanate, (1.68) 5-(allylsulfanyl)-1-{[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazole, (1.69) 2-[1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.70) 2-{[rel(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.71) 2-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.72) 1-{[rel(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazol-5-yl thiocyanate, (1.73) 1-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazol-5-yl thiocyanate, (1.74) 5-(allylsulfanyl)-1-{[rel(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazole, (1.75) 5-(allylsulfanyl)-1-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazole, (1.76) 2-[(2S,4S,5S)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.77) 2-[(2R,4S,5S)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.78) 2-[(2R,4R,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.79) 2-[(2S,4R,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.80) 2-[(2S,4S,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.81) 2-[(2R,4S,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.82) 2-[(2R,4R,5S)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.83) 2-[(2S,4R,5S)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.84) 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol, (1.85) 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (1.86) 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)pentan-2-ol, (1.87) 2-[2-chloro-4-(4-chlorophenoxy)phenyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (1.88) 2-[2-chloro-4-(2,4-dichlorophenoxy)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol, (1.89) (2R)-2-(1-chlorocyclopropyl)-4-[(1R)-2,2-dichlorocyclopropyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (1.90) (2R)-2-(1-chlorocyclopropyl)-4-[(1S)-2,2-dichlorocyclopropyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (1.91) (2S)-2-(1-chlorocyclopropyl)-4-[(1S)-2,2-dichlorocyclopropyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (1.92) (2S)-2-(1-chlorocyclopropyl)-4-[(1R)-2,2-dichlorocyclopropyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (1.93) (1S,2R,5R)-5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol, (1.94) (1R,2S,5S)-5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol, (1.95) 5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol. 2) Inhibitors of the respiratory chain at complex I or II, for example (2.01) bixafen, (2.02) boscalid, (2.03) carboxin, (2.04) diflumetorim, (2.05) fenfuram, (2.06) fluopyram, (2.07) flutolanil, (2.08) fluxapyroxad, (2.09) furametpyr, (2.10) furmecyclox, (2.11) isopyrazam (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric racemate 1RS,4SR,9SR), (2.12) isopyrazam (anti-epimeric racemate 1RS,4SR,9SR), (2.13) isopyrazam (anti-epimeric enantiomer 1R,4S,9S), (2.14) isopyrazam (anti-epimeric enantiomer 1S,4R,9R), (2.15) isopyrazam (syn-epimeric racemate 1RS,4SR,9RS), (2.16) isopyrazam (syn-epimeric enantiomer 1R,4S,9R), (2.17) isopyrazam (syn-epimeric enantiomer 1S,4R,9S), (2.18) mepronil, (2.19) oxycarboxin, (2.20) penflufen, (2.21) penthiopyrad, (2.22) sedaxane, (2.23) thifluzamide, (2.24) 1-methyl-N-[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide, (2.25) 3-(difluoromethyl)-1-methyl-N-[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-1H-pyrazole-4-carboxamide, (2.26) 3-(difluoromethyl)-N-[4-fluoro-2-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]-1-methyl-1H-pyrazole-4-carboxamide, (2.27) N-[1-(2,4-dichlorophenyl)-1-methoxypropan-2-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.28) 5,8-difluoro-N-[2-(2-fluoro-4-{[4-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)ethyl]quinazolin-4-amine, (2.29) benzovindiflupyr, (2.30) N-[(1S,4R)-9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.31) N-[(1R,4S)-9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.32) 3-(difluoromethyl)-1-methyl-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1H-pyrazole-4-carboxamide, (2.33) 1,3,5-trimethyl-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1H-pyrazole-4-carboxamide, (2.34) 1-methyl-3-(trifluoromethyl)-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1H-pyrazole-4-carboxamide, (2.35) 1-methyl-3-(trifluoromethyl)-N-[(3R)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (2.36) 1-methyl-3-(trifluoromethyl)-N-[(3S)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (2.37) 3-(difluoromethyl)-1-methyl-N-[(3S)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (2.38) 3-(difluoromethyl)-1-methyl-N-[(3R)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (2.39) 1,3,5-trimethyl-N-[(3R)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (2.40) 1,3,5-trimethyl-N-[(3S)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (2.41) benodanil, (2.42) 2-chloro-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)pyridine-3-carboxamide, (2.43) Isofetamid, (2.44) 1-methyl-3-(trifluoromethyl)-N-[2′-(trifluoromethyl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide, (2.45) N-(4′-chlorobiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.46) N-(2′,4′-dichlorobiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.47) 3-(difluoromethyl)-1-methyl-N-[4′-(trifluoromethyl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide, (2.48) N-(2′,5′-difluorobiphenyl-2-yl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide, (2.49) 3-(difluoromethyl)-1-methyl-N-[4′-(prop-1-yn-1-yl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide, (2.50) 5-fluoro-1,3-dimethyl-N-[4′-(prop-1-yn-1-yl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide, (2.51) 2-chloro-N-[4′-(prop-1-yn-1-yl)biphenyl-2-yl]nicotinamide, (2.52) 3-(difluoromethyl)-N-[4′-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]-1-methyl-1H-pyrazole-4-carboxamide, (2.53) N-[4′-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide, (2.54) 3-(difluoromethyl)-N-(4′-ethynylbiphenyl-2-yl)-1-methyl-1H-pyrazole-4-carboxamide, (2.55) N-(4′-ethynylbiphenyl-2-yl)-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide, (2.56) 2-chloro-N-(4′-ethynylbiphenyl-2-yl)nicotinamide, (2.57) 2-chloro-N-[4′-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]nicotinamide, (2.58) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-5-carboxamide, (2.59) 5-fluoro-N-[4′-(3-hydroxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide, (2.60) 2-chloro-N-[4′-(3-hydroxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]nicotinamide, (2.61) 3-(difluoromethyl)-N-[4′-(3-methoxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]-1-methyl-1H-pyrazole-4-carboxamide, (2.62) 5-fluoro-N-[4′-(3-methoxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide, (2.63) 2-chloro-N-[4′-(3-methoxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]nicotinamide, (2.64) 1,3-dimethyl-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1H-pyrazole-4-carboxamide, (2.65) 1,3-dimethyl-N-[(3R)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (2.66) 1,3-dimethyl-N-[(3S)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (2.67) 3-(difluoromethyl)-N-methoxy-1-methyl-N-[1-(2,4,6-trichlorophenyl)propan-2-yl]-1H-pyrazole-4-carboxamide, (2.68) 3-(difluoromethyl)-N-(7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1-methyl-1H-pyrazole-4-carboxamide, (2.69) 3-(difluoromethyl)-N-[(3R)-7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1-methyl-1H-pyrazole-4-carboxamide, (2.70) 3-(difluoromethyl)-N-[(3S)-7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1-methyl-1H-pyrazole-4-carboxamide. 3) Inhibitors of the respiratory chain at complex III, for example (3.01) ametoctradin, (3.02) amisulbrom, (3.03) azoxystrobin, (3.04) cyazofamid, (3.05) coumethoxystrobin, (3.06) coumoxystrobin, (3.07) dimoxystrobin, (3.08) enoxastrobin, (3.09) famoxadone, (3.10) fenamidone, (3.11) flufenoxystrobin, (3.12) fluoxastrobin, (3.13) kresoxim-methyl, (3.14) metominostrobin, (3.15) orysastrobin, (3.16) picoxystrobin, (3.17) pyraclostrobin, (3.18) pyrametostrobin, (3.19) pyraoxystrobin, (3.20) pyribencarb, (3.21) triclopyricarb, (3.22) trifloxystrobin, (3.23) (2E)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoropyrimidin-4-yl]oxy}phenyl)-2-(methoxyimino)-N-methylacetamide, (3.24) (2E)-2-(methoxyimino)-N-methyl-2-(2-{[({(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}amino)oxy]methyl}phenyl)acetamide, (3.25) (2E)-2-(methoxyimino)-N-methyl-2-{2-[(E)-({1-[3-(trifluoromethyl)phenyl]ethoxy}imino)methyl]phenyl}acetamide, (3.26) (2E)-2-{2-[({[(1E)-1-(3-{[(E)-1-fluoro-2-phenylvinyl]oxy}phenyl)ethylidene]amino}oxy)methyl]phenyl}-2-(methoxyimino)-N-methylacetamide, (3.27) Fenaminostrobin, (3.28) 5-methoxy-2-methyl-4-(2-{[({(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}amino)oxy]methyl}phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one, (3.29) methyl (2E)-2-{2-[({cyclopropyl[(4-methoxyphenyl)imino]methyl}sulfanyl)methyl]phenyl}-3-methoxyacrylate, (3.30) N-(3-ethyl-3,5,5-trimethylcyclohexyl)-3-formamido-2-hy droxybenzamide, (3.31) 2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide, (3.32) 2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide, (3.33) (2E,3Z)-5-{[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy}-2-(methoxyimino)-N,3-dimethylpent-3-enamide. 4) Inhibitors of the mitosis and cell division, for example (4.01) benomyl, (4.02) carbendazim, (4.03) chlorfenazole, (4.04) diethofencarb, (4.05) ethaboxam, (4.06) fluopicolide, (4.07) fuberidazole, (4.08) pencycuron, (4.09) thiabendazole, (4.10) thiophanate-methyl, (4.11) thiophanate, (4.12) zoxamide, (4.13) 5-chloro-7-(4-methylpiperidin-1-yl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine, (4.14) 3-chloro-5-(6-chloropyridin-3-yl)-6-methyl-4-(2,4,6-trifluorophenyl)pyridazine. 5) Compounds capable to have a multisite action, for example (5.01) bordeaux mixture, (5.02) captafol, (5.03) captan, (5.04) chlorothalonil, (5.05) copper hydroxide, (5.06) copper naphthenate, (5.07) copper oxide, (5.08) copper oxychloride, (5.09) copper(2+) sulfate, (5.10) dichlofluanid, (5.11) dithianon, (5.12) dodine, (5.13) dodine free base, (5.14) ferbam, (5.15) fluorofolpet, (5.16) folpet, (5.17) guazatine, (5.18) guazatine acetate, (5.19) iminoctadine, (5.20) iminoctadine albesilate, (5.21) iminoctadine triacetate, (5.22) mancopper, (5.23) mancozeb, (5.24) maneb, (5.25) metiram, (5.26) metiram zinc, (5.27) oxine-copper, (5.28) propamidine, (5.29) propineb, (5.30) sulfur and sulfur preparations including calcium polysulfide, (5.31) thiram, (5.32) tolylfluanid, (5.33) zineb, (5.34) ziram, (5.35) anilazine. 6) Compounds capable to induce a host defence, for example (6.01) acibenzolar-S-methyl, (6.02) isotianil, (6.03) probenazole, (6.04) tiadinil, (6.05) laminarin. 7) Inhibitors of the amino acid and/or protein biosynthesis, for example (7.01) andoprim, (7.02) blasticidin-S, (7.03) cyprodinil, (7.04) kasugamycin, (7.05) kasugamycin hydrochloride hydrate, (7.06) mepanipyrim, (7.07) pyrimethanil, (7.08) 3-(5-fluoro-3,3,4,4-tetramethyl-3,4-dihydroisoquinolin-1-yl)quinoline, (7.09) oxytetracycline, (7.10) streptomycin. 8) Inhibitors of the ATP production, for example (8.01) fentin acetate, (8.02) fentin chloride, (8.03) fentin hydroxide, (8.04) silthiofam. 9) Inhibitors of the cell wall synthesis, for example (9.01) benthiavalicarb, (9.02) dimethomorph, (9.03) flumorph, (9.04) iprovalicarb, (9.05) mandipropamid, (9.06) polyoxins, (9.07) polyoxorim, (9.08) validamycin A, (9.09) valifenalate, (9.10) polyoxin B, (9.11) (2E)-3-(4-tert-butylphenyl)-3-(2-chloropyridin-4-yl)-1-(morpholin-4-yl)prop-2-en-1-one, (9.12) (2Z)-3-(4-tert-butylphenyl)-3-(2-chloropyridin-4-yl)-1-(morpholin-4-yl)prop-2-en-1-one. 10) Inhibitors of the lipid and membrane synthesis, for example (10.01) biphenyl, (10.02) chloroneb, (10.03) dicloran, (10.04) edifenphos, (10.05) etridiazole, (10.06) iodocarb, (10.07) iprobenfos, (10.08) isoprothiolane, (10.09) propamocarb, (10.10) propamocarb hydrochloride, (10.11) prothiocarb, (10.12) pyrazophos, (10.13) quintozene, (10.14) tecnazene, (10.15) tolclofos-methyl. 11) Inhibitors of the melanin biosynthesis, for example (11.01) carpropamid, (11.02) diclocymet, (11.03) fenoxanil, (11.04) phthalide, (11.05) pyroquilon, (11.06) tricyclazole, (11.07) 2,2,2-trifluoroethyl {3-methyl-1-[(4-methylbenzoyl)amino]butan-2-yl}carbamate. 12) Inhibitors of the nucleic acid synthesis, for example (12.01) benalaxyl, (12.02) benalaxyl-M (kiralaxyl), (12.03) bupirimate, (12.04) clozylacon, (12.05) dimethirimol, (12.06) ethirimol, (12.07) furalaxyl, (12.08) hymexazol, (12.09) metalaxyl, (12.10) metalaxyl-M (mefenoxam), (12.11) ofurace, (12.12) oxadixyl, (12.13) oxolinic acid, (12.14) octhilinone. 13) Inhibitors of the signal transduction, for example (13.01) chlozolinate, (13.02) fenpiclonil, (13.03) fludioxonil, (13.04) iprodione, (13.05) procymidone, (13.06) quinoxyfen, (13.07) vinclozolin, (13.08) proquinazid. 14) Compounds capable to act as an uncoupler, for example (14.01) binapacryl, (14.02) dinocap, (14.03) ferimzone, (14.04) fluazinam, (14.05) meptyldinocap. 15) Further compounds, for example (15.001) benthiazole, (15.002) bethoxazin, (15.003) capsimycin, (15.004) carvone, (15.005) chinomethionat, (15.006) pyriofenone (chlazafenone), (15.007) cufraneb, (15.008) cyflufenamid, (15.009) cymoxanil, (15.010) cyprosulfamide, (15.011) dazomet, (15.012) debacarb, (15.013) dichlorophen, (15.014) diclomezine, (15.015) difenzoquat, (15.016) difenzoquat metilsulfate, (15.017) diphenylamine, (15.018) ecomate, (15.019) fenpyrazamine, (15.020) flumetover, (15.021) fluoroimide, (15.022) flusulfamide, (15.023) flutianil, (15.024) fosetyl-aluminium, (15.025) fosetyl-calcium, (15.026) fosetyl-sodium, (15.027) hexachlorobenzene, (15.028) irumamycin, (15.029) methasulfocarb, (15.030) methyl isothiocyanate, (15.031) metrafenone, (15.032) mildiomycin, (15.033) natamycin, (15.034) nickel dimethyldithiocarbamate, (15.035) nitrothal-isopropyl, (15.036) oxamocarb, (15.037) oxyfenthiin, (15.038) pentachlorophenol and salts, (15.039) phenothrin, (15.040) phosphorous acid and its salts, (15.041) propamocarb-fosetylate, (15.042) propanosine-sodium, (15.043) pyrimorph, (15.044) pyrrolnitrine, (15.045) tebufloquin, (15.046) tecloftalam, (15.047) tolnifanide, (15.048) triazoxide, (15.049) trichlamide, (15.050) zarilamid, (15.051) (3S,6S,7R,8R)-8-benzyl-3-[({3-[(isobutyryloxy)methoxy]-4-methoxypyridin-2-yl}carbonyl)amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl 2-methylpropanoate, (15.052) 1-(4-{4-[(5R)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone, (15.053) 1-(4-{4-[(5 S)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone, (15.054) Oxathiapiprolin, (15.055) 1-(4-methoxyphenoxy)-3,3-dimethylbutan-2-yl 1H-imidazole-1-carboxylate, (15.056) 2,3,5,6-tetrachloro-4-(methylsulfonyl)pyridine, (15.057) 2,3-dibutyl-6-chlorothieno[2,3-d]pyrimidin-4(3H)-one, (15.058) 2,6-dimethyl-1H,5H-[1,4]dithiino[2,3-c:5,6-c′]dipyrrole-1,3,5,7(2H,6H)-tetrone, (15.059) 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[(5R)-5-phenyl-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone, (15.060) 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[(5S)-5-phenyl-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone, (15.061) 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-{4-[4-(5-phenyl-4,5-dihydro-1,2-oxazol-3-yl)-1,3-thiazol-2-yl]piperidin-1-yl}ethanone, (15.062) 2-butoxy-6-iodo-3-propyl-4H-chromen-4-one, (15.063) 2-chloro-5-[2-chloro-1-(2,6-difluoro-4-methoxyphenyl)-4-methyl-1H-imidazol-5-yl]pyridine, (15.064) 2-phenylphenol and salts, (15.065) 3-(4,4,5-trifluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinoline, (15.066) 3,4,5-trichloropyridine-2,6-dicarbonitrile, (15.067) 3-chloro-5-(4-chlorophenyl)-4-(2,6-difluorophenyl)-6-methylpyridazine, (15.068) 4-(4-chlorophenyl)-5-(2,6-difluorophenyl)-3,6-dimethylpyridazine, (15.069) 5-amino-1,3,4-thiadiazole-2-thiol, (15.070) 5-chloro-N′-phenyl-N′-(prop-2-yn-1-yl)thiophene-2-sulfonohydrazide, (15.071) 5-fluoro-2-[(4-fluorobenzyl)oxy]pyrimidin-4-amine, (15.072) 5-fluoro-2-[(4-methylbenzyl)oxy]pyrimidin-4-amine, (15.073) 5-methyl-6-octyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine, (15.074) ethyl (2Z)-3-amino-2-cyano-3-phenylacrylate, (15.075) N′-(4-{[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]oxy}-2,5-dimethylphenyl)-N-ethyl-N-methylimidoformamide, (15.076) N-(4-chlorobenzyl)-3-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]propanamide, (15.077) N-[(4-chlorophenyl)(cyano)methyl]-3-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]propanamide, (15.078) N-[(5-bromo-3-chloropyridin-2-yl)methyl]-2,4-dichloronicotinamide, (15.079) N-[1-(5-bromo-3-chloropyridin-2-yl)ethyl]-2,4-dichloronicotinamide, (15.080) N-[1-(5-bromo-3-chloropyridin-2-yl)ethyl]-2-fluoro-4-iodonicotinamide, (15.081) N-{(E)-[(cyclopropylmethoxy)imino][6-(difluoromethoxy)-2,3-difluorophenyl]methyl}-2-phenylacetamide, (15.082) N-{(Z)-[(cyclopropylmethoxy)imino][6-(difluoromethoxy)-2,3-difluorophenyl]methyl}-2-phenylacetamide, (15.083) N′-{4-[(3-tert-butyl-4-cyano-1,2-thiazol-5-yl)oxy]-2-chloro-5-methylphenyl}-N-ethyl-N-methylimidoformamide, (15.084) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,3-thiazole-4-carboxamide, (15.085) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-thiazole-4-carboxamide, (15.086) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-thiazole-4-carboxamide, (15.087) pentyl {6-[({[(1-methyl-1H-tetrazol-5-yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl}carbamate, (15.088) phenazine-1-carboxylic acid, (15.089) quinolin-8-ol, (15.090) quinolin-8-ol sulfate (2:1), (15.091) tert-butyl {6-[({[(1-methyl-1H-tetrazol-5-yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl}carbamate, (15.092) (5-bromo-2-methoxy-4-methylpyridin-3-yl)(2,3,4-trimethoxy-6-methylphenyl)methanone, (15.093) N-[2-(4-{[3-(4-chlorophenyl)prop-2-yn-1-yl]oxy}-3-methoxyphenyl)ethyl]-N2-(methylsulfonyl)valinamide, (15.094) 4-oxo-4-[(2-phenylethyl)amino]butanoic acid, (15.095) but-3-yn-1-yl {6-[({[(Z)-(1-methyl-1H-tetrazol-5-yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl}carbamate, (15.096) 4-amino-5-fluoropyrimidin-2-ol (tautomeric form: 4-amino-5-fluoropyrimidin-2(1H)-one), (15.097) propyl 3,4,5-trihydroxybenzoate, (15.098) [3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4-yl](pyridin-3-yl)methanol, (15.099) (S)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4-yl](pyridin-3-yl)methanol, (15.100) (R)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4-yl](pyridin-3-yl)methanol, (15.101) 2-fluoro-6-(trifluoromethyl)-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)benzamide, (15.102) 2-(6-benzylpyridin-2-yl)quinazoline, (15.103) 2-[6-(3-fluoro-4-methoxyphenyl)-5-methylpyridin-2-yl]quinazoline, (15.104) 3-(4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinoline, (15.105) Abscisic acid, (15.106) N′-[5-bromo-6-(2,3-dihydro-1H-inden-2-yloxy)-2-methylpyridin-3-yl]-N-ethyl-N-methylimidoformamide, (15.107) N′-{5-bromo-6-[1-(3,5-difluorophenyl)ethoxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidoformamide, (15.108) N′-{5-bromo-6-[(1R)-1-(3,5-difluorophenyl)ethoxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidoformamide, (15.109) N′-{5-bromo-6-[(1S)-1-(3,5-difluorophenyl)ethoxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidoformamide, (15.110) N′-{5-bromo-6-[(cis-4-isopropylcyclohexyl)oxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidoformamide, (15.111) N′-{5-bromo-6-[(trans-4-isopropylcyclohexyl)oxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidoformamide, (15.112) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-isopropylbenzyl)-1-methyl-1H-pyrazole-4-carboxamide, (15.113) N-cyclopropyl-N-(2-cyclopropylbenzyl)-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (15.114) N-(2-tert-butylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (15.115) N-(5-chloro-2-ethylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (15.116) N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (15.117) N-cyclopropyl-3-(difluoromethyl)-N-(2-ethyl-5-fluorobenzyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (15.118) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(5-fluoro-2-isopropylbenzyl)-1-methyl-1H-pyrazole-4-carboxamide, (15.119) N-cyclopropyl-N-(2-cyclopropyl-5-fluorobenzyl)-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (15.120) N-(2-cyclopentyl-5-fluorobenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (15.121) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-fluoro-6-isopropylbenzyl)-1-methyl-1H-pyrazole-4-carboxamide, (15.122) N-cyclopropyl-3-(difluoromethyl)-N-(2-ethyl-5-methylbenzyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (15.123) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-isopropyl-5-methylbenzyl)-1-methyl-1H-pyrazole-4-carboxamide, (15.124) N-cyclopropyl-N-(2-cyclopropyl-5-methylbenzyl)-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (15.125) N-(2-tert-butyl-5-methylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (15.126) N-[5-chloro-2-(trifluoromethyl)benzyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (15.127) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-N-[5-methyl-2-(trifluoromethyl)benzyl]-1H-pyrazole-4-carboxamide, (15.128) N-[2-chloro-6-(trifluoromethyl)benzyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (15.129) N-[3-chloro-2-fluoro-6-(trifluoromethyl)benzyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (15.130) N-cyclopropyl-3-(difluoromethyl)-N-(2-ethyl-4,5-dimethylbenzyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (15.131) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-isopropylbenzyl)-1-methyl-1H-pyrazole-4-carbothioamide, (15.132) N′-(2,5-dimethyl-4-phenoxyphenyl)-N-ethyl-N-methylimidoformamide, (15.133) N′-{4-[(4,5-dichloro-1,3-thiazol-2-yl)oxy]-2,5-dimethylphenyl}-N-ethyl-N-methylimidoformamide, (15.134) N-(4-chloro-2,6-difluorophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (15.135) 9-fluoro-2,2-dimethyl-5-(quinolin-3-yl)-2,3-dihydro-1,4-benzoxazepine, (15.136) 2-{2-fluoro-6-[(8-fluoro-2-methylquinolin-3-yl)oxy]phenyl}propan-2-ol, (15.137) 2-{2-[(7,8-difluoro-2-methylquinolin-3-yl)oxy]-6-fluorophenyl}propan-2-ol, (15.138) 4-(2-chloro-4-fluorophenyl)-N-(2-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (15.139) 4-(2-chloro-4-fluorophenyl)-N-(2,6-difluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (15.140) 4-(2-chloro-4-fluorophenyl)-N-(2-chloro-6-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (15.141) 4-(2-bromo-4-fluorophenyl)-N-(2-chloro-6-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (15.142) N-(2-bromo-6-fluorophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (15.143) 4-(2-bromo-4-fluorophenyl)-N-(2-bromophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (15.144) 4-(2-bromo-4-fluorophenyl)-N-(2-bromo-6-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (15.145) 4-(2-bromo-4-fluorophenyl)-N-(2-chlorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (15.146) N-(2-bromophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (15.147) 4-(2-chloro-4-fluorophenyl)-N-(2-chlorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (15.148) 4-(2-bromo-4-fluorophenyl)-N-(2,6-difluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (15.149) 4-(2-bromo-4-fluorophenyl)-N-(2-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (15.150) N′-(4-{3-[(difluoromethyl)sulfanyl]phenoxy}-2,5-dimethylphenyl)-N-ethyl-N-methylimidoformamide, (15.151) N′-(2,5-dimethyl-4-{3-[(1,1,2,2-tetrafluoroethyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidoformamide, (15.152) N′-(2,5-dimethyl-4-{3-[(2,2,2-trifluoroethyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidoformamide, (15.153) N′-(2,5-dimethyl-4-{3-[(2,2,3,3-tetrafluoropropyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidoformamide, (15.154) N′-(2,5-dimethyl-4-{3-[(pentafluoroethyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidoformamide, (15.155) N′-(4-{[3-(difluoromethoxy)phenyl]sulfanyl}-2,5-dimethylphenyl)-N-ethyl-N-methylimidoformamide, (15.156) N′-(2,5-dimethyl-4-{[3-(1,1,2,2-tetrafluoroethoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-methylimidoformamide, (15.157) N′-(2,5-dimethyl-4-{[3-(2,2,2-trifluoroethoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-methylimidoformamide, (15.158) N′-(2,5-dimethyl-4-{[3-(2,2,3,3-tetrafluoropropoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-methylimidoformamide, (15.159) N′-(2,5-dimethyl-4-{[3-(pentafluoroethoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-methylimidoformamide, (15.160) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{5-[2-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (15.161) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{5-[2-fluoro-6-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (15.162) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{5-[2-chloro-6-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (15.163) 2-{3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}phenyl methanesulfonate, (15.164) 2-{3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydrro-,2-oxazol-5-yl}-3-chlorophenyl methanesulfonate, (15.165) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{(5S)-5-[2-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (15.166) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{(5R)-5-[2-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (15.167) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{(5S)-5-[2-fluoro-6-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (15.168) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{(5R)-5-[2-fluoro-6-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (15.169) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{(5S)-5-[2-chloro-6-(prop-2-yn-1-y-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-,3-thiazol-2-yl)piperidin-1-yl]ethanone, (15.170) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{(5R)-5-[2-chloro-6-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (15.171) 2-{(5S)-3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}phenyl methanesulfonate, (15.172) 2-{(5R)-3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}phenyl methanesulfonate, (15.173) 2-{(5S)-3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}-3-chlorophenyl methanesulfonate, (15.174) 2-{(5R)-3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}-3-chlorophenyl methanesulfonate. Biological Pesticides as Mixing Components The compounds of the formula (I) can be combined with biological pesticides. Biological pesticides comprise in particular bacteria, fungi, yeasts, plant extracts and products formed by microorganisms, including proteins and secondary metabolites. Biological pesticides comprise bacteria such as spore-forming bacteria, root-colonising bacteria and bacteria which act as biological insecticides, fungicides or nematicides. Examples of such bacteria which are employed or can be used as biological pesticides are: Examples of fungi and yeasts which are employed or can be used as biological pesticides are: Examples of viruses which are employed or can be used as biological pesticides are: Also included are bacteria and fungi which are added as ‘inoculant’ to plants or plant parts or plant organs and which, by virtue of their particular properties, promote plant growth and plant health. Examples which may be mentioned are: Examples of plant extracts and products formed by microorganisms including proteins and secondary metabolites which are employed or can be used as biological pesticides are: Safener as Mixing Components The compounds of the formula (I) can be combined with safeners such as, for example, benoxacor, cloquintocet (-mexyl), cyometrinil, cyprosulfamide, dichlormid, fenchlorazole (-ethyl), fenclorim, flurazole, fluxofenim, furilazole, isoxadifen (-ethyl), mefenpyr (-diethyl), naphthalic anhydride, oxabetrinil, 2-methoxy-N-({4-[(methylcarbamoyl)amino]phenyl}sulphonyl)benzamide (CAS 129531-12-0), 4-(dichloroacetyl)-1-oxa-4-azaspiro[4.5]decane (CAS 71526-07-3), 2,2,5-trimethyl-3-(dichloroacetyl)-1,3-oxazolidine (CAS 52836-31-4). Plants and Plant Parts All plants and plant parts can be treated in accordance with the invention. Here, plants are to be understood to mean all plants and plant parts such as wanted and unwanted wild plants or crop plants (including naturally occurring crop plants), for example cereals (wheat, rice, triticale, barley, rye, oats), maize, soya bean, potato, sugar beet, sugar cane, tomatoes, pepper, cucumber, melon, carrot, watermelon, onion, lettuce, spinach, leek, beans, Treatment according to the invention of the plants and plant parts with the compounds of the formula (I) is carried out directly or by allowing the compounds to act on the surroundings, environment or storage space by the customary treatment methods, for example by immersion, spraying, evaporation, fogging, scattering, painting on, injection and, in the case of propagation material, in particular in the case of seeds, also by applying one or more coats. As already mentioned above, it is possible to treat all plants and their parts according to the invention. In a preferred embodiment, wild plant species and plant cultivars, or those obtained by conventional biological breeding methods, such as crossing or protoplast fusion, and also parts thereof, are treated. In a further preferred embodiment, transgenic plants and plant cultivars obtained by genetic engineering methods, if appropriate in combination with conventional methods (genetically modified organisms), and parts thereof are treated. The term “parts” or “parts of plants” or “plant parts” has been explained above. The invention is used with particular preference to treat plants of the respective commercially customary cultivars or those that are in use. Plant cultivars are to be understood as meaning plants having new properties (“traits”) and which have been obtained by conventional breeding, by mutagenesis or by recombinant DNA techniques. They can be cultivars, varieties, bio- or genotypes. Transgenic Plant, Seed Treatment and Integration Events The transgenic plants or plant cultivars (those obtained by genetic engineering) which are to be treated with preference in accordance with the invention include all plants which, through the genetic modification, received genetic material which imparts particular advantageous useful properties (“traits”) to these plants. Examples of such properties are better plant growth, increased tolerance to high or low temperatures, increased tolerance to drought or to levels of water or soil salinity, enhanced flowering performance, easier harvesting, accelerated ripening, higher yields, higher quality and/or a higher nutritional value of the harvested products, better storage life and/or processability of the harvested products. Further and particularly emphasized examples of such properties are increased resistance of the plants against animal and microbial pests, such as against insects, arachnids, nematodes, mites, slugs and snails owing, for example, to toxins formed in the plants, in particular those formed in the plants by the genetic material from Crop Protection—Types of Treatment The treatment of the plants and plant parts with the compounds of the formula (I) is carried out directly or by action on their surroundings, habitat or storage space using customary treatment methods, for example by dipping, spraying, atomizing, irrigating, evaporating, dusting, fogging, broadcasting, foaming, painting, spreading-on, injecting, watering (drenching), drip irrigating and, in the case of propagation material, in particular in the case of seed, furthermore as a powder for dry seed treatment, a solution for liquid seed treatment, a water-soluble powder for slurry treatment, by incrusting, by coating with one or more coats, etc. It is furthermore possible to apply the compounds of the formula (I) by the ultra-low volume method or to inject the application form or the compound of the formula (I) itself into the soil. A preferred direct treatment of the plants is foliar application, i.e. the compounds of the formula (I) are applied to the foliage, where treatment frequency and the application rate should be adjusted according to the level of infestation with the pest in question. In the case of systemically active compounds, the compounds of the formula (I) also access the plants via the root system. The plants are then treated by the action of the compounds of the formula (I) on the habitat of the plant. This may be done, for example, by drenching, or by mixing into the soil or the nutrient solution, i.e. the locus of the plant (e.g. soil or hydroponic systems) is impregnated with a liquid form of the compounds of the formula (I), or by soil application, i.e. the compounds of the formula (I) according to the invention are introduced in solid form (e.g. in the form of granules) into the locus of the plants. In the case of paddy rice crops, this can also be done by metering the compound of the formula (I) in a solid application form (for example as granules) into a flooded paddy field. Treatment of Seed The control of animal pests by treating the seed of plants has been known for a long time and is the subject of continuous improvements. However, the treatment of seed entails a series of problems which cannot always be solved in a satisfactory manner. Thus, it is desirable to develop methods for protecting the seed and the germinating plant which dispense with, or at least reduce considerably, the additional application of pesticides during storage, after sowing or after emergence of the plants. It is furthermore desirable to optimize the amount of active compound employed in such a way as to provide optimum protection for the seed and the germinating plant from attack by animal pests, but without damaging the plant itself by the active compound employed. In particular, methods for the treatment of seed should also take into consideration the intrinsic insecticidal or nematicidal properties of pest-resistant or -tolerant transgenic plants in order to achieve optimum protection of the seed and also the germinating plant with a minimum of pesticides being employed. The present invention therefore in particular also relates to a method for the protection of seed and germinating plants, from attack by pests, by treating the seed with one of the compounds of the formula (I). The method according to the invention for protecting seed and germinating plants against attack by pests furthermore comprises a method where the seed is treated simultaneously in one operation or sequentially with a compound of the formula (I) and a mixing component. It also comprises a method where the seed is treated at different times with a compound of the formula (I) and a mixing component. The invention likewise relates to the use of the compounds of the formula (I) for the treatment of seed for protecting the seed and the resulting plant from animal pests. Furthermore, the invention relates to seed which has been treated with a compound of the formula (I) according to the invention so as to afford protection from animal pests. The invention also relates to seed which has been treated simultaneously with a compound of the formula (I) and a mixing component. The invention furthermore relates to seed which has been treated at different times with a compound of the formula (I) and a mixing component. In the case of seed which has been treated at different points in time with a compound of the formula (I) and a mixing component, the individual substances may be present on the seed in different layers. Here, the layers comprising a compound of the formula (I) and mixing components may optionally be separated by an intermediate layer. The invention also relates to seed where a compound of the formula (I) and a mixing component have been applied as component of a coating or as a further layer or further layers in addition to a coating. Furthermore, the invention relates to seed which, after the treatment with a compound of the formula (I), is subjected to a film-coating process to prevent dust abrasion on the seed. One of the advantages encountered with a systemically acting compound of the formula (I) is the fact that, by treating the seed, not only the seed itself but also the plants resulting therefrom are, after emergence, protected against animal pests. In this manner, the immediate treatment of the crop at the time of sowing or shortly thereafter can be dispensed with. It has to be considered a further advantage that by treatment of the seed with a compound of the formula (I), germination and emergence of the treated seed may be enhanced. It is likewise to be considered advantageous that compounds of the formula (I) can be used in particular also for transgenic seed. Furthermore, compounds of the formula (I) can be employed in combination with compositions or compounds of signalling technology, leading to better colonization by symbionts such as, for example, rhizobia, mycorrhizae and/or endophytic bacteria or fungi, and/or to optimized nitrogen fixation. The compounds of the formula (I) are suitable for protection of seed of any plant variety which is used in agriculture, in the greenhouse, in forests or in horticulture. In particular, this takes the form of seed of cereals (for example wheat, barley, rye, millet and oats), corn, cotton, soya beans, rice, potatoes, sunflowers, coffee, tobacco, canola, oilseed rape, beets (for example sugarbeets and fodder beets), peanuts, vegetables (for example tomatoes, cucumbers, bean, cruciferous vegetables, onions and lettuce), fruit plants, lawns and ornamental plants. The treatment of the seed of cereals (such as wheat, barley, rye and oats), maize, soya beans, cotton, canola, oilseed rape, vegetables and rice is of particular importance. As already mentioned above, the treatment of transgenic seed with a compound of the formula (I) is also of particular importance. This takes the form of seed of plants which, as a rule, comprise at least one heterologous gene which governs the expression of a polypeptide with in particular insecticidal and/or nematicidal properties. The heterologous genes in transgenic seed can originate from microorganisms such as In the context of the present invention, the compound of the formula (I) is applied to the seed. Preferably, the seed is treated in a state in which it is stable enough to avoid damage during treatment. In general, the seed may be treated at any point in time between harvest and sowing. The seed usually used has been separated from the plant and freed from cobs, shells, stalks, coats, hairs or the flesh of the fruits. For example, it is possible to use seed which has been harvested, cleaned and dried down to a moisture content which allows storage. Alternatively, it is also possible to use seed which, after drying, has been treated with, for example, water and then dried again, for example priming. In the case of rice seed, it is also possible to use seed which has been soaked, for example in water to a certain stage of the rice embryo (‘pigeon breast stage’), stimulating the germination and a more uniform emergence. When treating the seed, care must generally be taken that the amount of the compound of the formula (I) applied to the seed and/or the amount of further additives is chosen in such a way that the germination of the seed is not adversely affected, or that the resulting plant is not damaged. This must be ensured particularly in the case of active compounds which can exhibit phytotoxic effects at certain application rates. In general, the compounds of the formula (I) are applied to the seed in a suitable formulation. Suitable formulations and processes for seed treatment are known to the person skilled in the art. The compounds of the formula (I) can be converted to the customary seed dressing formulations, such as solutions, emulsions, suspensions, powders, foams, slurries or other coating compositions for seed, and also ULV formulations. These formulations are prepared in a known manner, by mixing the compounds of the formula (I) with customary additives such as, for example, customary extenders and also solvents or diluents, colorants, wetting agents, dispersants, emulsifiers, antifoams, preservatives, secondary thickeners, adhesives, gibberellins and also water. Colorants which may be present in the seed-dressing formulations which can be used in accordance with the invention are all colorants which are customary for such purposes. It is possible to use either pigments, which are sparingly soluble in water, or dyes, which are soluble in water. Examples include the dyes known by the names Rhodamine B, C.I. Pigment Red 112 and C.I. Solvent Red 1. Useful wetting agents which may be present in the seed dressing formulations usable in accordance with the invention are all substances which promote wetting and which are conventionally used for the formulation of agrochemically active compounds. Preference is given to using alkylnaphthalenesulphonates, such as diisopropyl- or diisobutylnaphthalenesulphonates. Useful dispersants and/or emulsifiers which may be present in the seed dressing formulations usable in accordance with the invention are all nonionic, anionic and cationic dispersants conventionally used for the formulation of active agrochemical ingredients. Preference is given to using nonionic or anionic dispersants or mixtures of nonionic or anionic dispersants. Suitable nonionic dispersants include in particular ethylene oxide/propylene oxide block polymers, alkylphenol polyglycol ethers and tristryrylphenol polyglycol ethers, and the phosphated or sulphated derivatives thereof. Suitable anionic dispersants are in particular lignosulphonates, polyacrylic acid salts and arylsulphonate/formaldehyde condensates. Antifoams which may be present in the seed dressing formulations usable in accordance with the invention are all foam-inhibiting substances conventionally used for the formulation of active agrochemical ingredients. Preference is given to using silicone antifoams and magnesium stearate. Preservatives which may be present in the seed dressing formulations usable in accordance with the invention are all substances usable for such purposes in agrochemical compositions. Examples include dichlorophene and benzyl alcohol hemiformal. Secondary thickeners which may be present in the seed dressing formulations usable in accordance with the invention are all substances which can be used for such purposes in agrochemical compositions. Cellulose derivatives, acrylic acid derivatives, xanthan, modified clays and finely divided silica are preferred. Adhesives which may be present in the seed dressing formulations usable in accordance with the invention are all customary binders usable in seed dressing products. Polyvinylpyrrolidone, polyvinyl acetate, polyvinyl alcohol and tylose may be mentioned as being preferred. Gibberellins which can be present in the seed-dressing formulations which can be used in accordance with the invention are preferably the gibberellins A1, A3 (=gibberellic acid), A4 and A7; gibberellic acid is especially preferably used. The gibberellins are known (cf. R. Wegler “Chemie der Pflanzenschutz- and Schädlingsbekämpfungsmittel”, vol. 2, Springer Verlag, 1970, pp. 401-412). The seed dressing formulations usable in accordance with the invention can be used to treat a wide variety of different kinds of seed either directly or after prior dilution with water. For instance, the concentrates or the preparations obtainable therefrom by dilution with water can be used to dress the seed of cereals, such as wheat, barley, rye, oats, and triticale, and also the seed of maize, rice, oilseed rape, peas, beans, cotton, sunflowers, soya beans and beets, or else a wide variety of different vegetable seed. The seed dressing formulations usable in accordance with the invention, or the dilute use forms thereof, can also be used to dress seed of transgenic plants. For treatment of seed with the seed dressing formulations usable in accordance with the invention, or the use forms prepared therefrom by adding water, all mixing units usable customarily for the seed dressing are useful. Specifically, the procedure in the seed dressing is to place the seed into a mixer, operated batch-wise or continously, to add the particular desired amount of seed dressing formulations, either as such or after prior dilution with water, and to mix everything until the formulation is distributed homogeneously on the seed. If appropriate, this is followed by a drying operation. The application rate of the seed dressing formulations usable in accordance with the invention can be varied within a relatively wide range. It is guided by the particular content of the compounds of the formula (I) in the formulations and by the seed. The application rates of the compound of the formula (I) are generally between 0.001 and 50 g per kilogram of seed, preferably between 0.01 and 15 g per kilogram of seed. Animal Health In the animal health field, i.e. in the field of veterinary medicine, the compounds of the formula (I) are active against animal parasites, in particular ectoparasites or endoparasites. The term endoparasites includes in particular helminths and protozoans, such as coccidia. Ectoparasites are typically and preferably arthropods, in particular insects and acarids. In the field of veterinary medicine the compounds of the formula (I) are suitable, with favourable homeotherm toxicity, for controlling parasites which occur in animal breeding and animal husbandry in livestock, breeding, zoo, laboratory, experimental and domestic animals. They are active against all or specific stages of development of the parasites. Agricultural livestock include, for example, mammals, such as sheep, goats, horses, donkeys, camels, buffaloes, rabbits, reindeers, fallow deers, and in particular cattle and pigs; or poultry such as turkeys, ducks, geese, and in particular chickens; fish and crustaceans, for example in aquaculture; and also insects such as bees. Domestic animals include, for example, mammals, such as hamsters, guinea pigs, rats, mice, chinchillas, ferrets and in particular dogs, cats, cage birds, reptiles, amphibians and aquarium fish. According to a preferred embodiment, the compounds of the formula (I) are administered to mammals. According to another preferred embodiment, the compounds of the formula (I) are administered to birds, namely cage birds and in particular poultry. By using the compounds of the formula (I) to control animal parasites, it is intended to reduce or prevent illness, cases of deaths and performance reductions (in the case of meat, milk, wool, hides, eggs, honey and the like), so that more economical and simpler animal keeping is made possible and better animal well-being is achievable. The term “control” or “controlling” as used herein with regard to the animal health field, means that the compounds of the formula (I) are effective in reducing the incidence of the respective parasite in an animal infected with such parasites to innocuous levels. More specifically, “controlling”, as used herein, means that the compound of the formula (I) is effective in killing the respective parasite, inhibiting its growth, or inhibiting its proliferation. Arthropods include: from the order of the Anoplurida, for example from the order of the Heteropterida, for example Arthropods furthermore include: from the subclass of the Acari (Acarina) and the order of the Metastigmata, for example from the family of argasidae like Parasitic Protozoa Include: Mastigophora ( Sarcomastigophora (Rhizopoda) such as Entamoebidae, for example, Apicomplexa (Sporozoa) such as Eimeridae, for example, Pathogenic endoparasites, which are helminths, include Platyhelmintha (e.g. Monogenea, cestodes and trematodes), nematodes, Acanthocephala, and Pentastoma, including: Monogenea: e.g.: Cestodes: from the order of the Pseudophyllidea for example: from the order of the Cyclophyllida for example: Trematodes: from the class of the Digenea for example: Nematodes: Trichinellida zum Beispiel: from the order of the Tylenchida for example: from the order of the Rhabditida for example: from the order of the Spirurida, for example: Acanthocephala: from the order of the Oligacanthorhynchida, for example: from the order of the Echinorhynchida, for example, Pentastoma: from the order of the Porocephalida, for example, In the veterinary field and in animal keeping, administration of the compounds of the formula (I) is carried out by methods generally known in the art, such as enterally, parenterally, dermally or nasally in the form of suitable preparations. Administration can be carried out prophylactically or therapeutically. Thus, one embodiment of the present invention refers to the use of a compound of the formula (I) as medicament. A further aspect refers to the use of a compound of the formula (I) as an antiendoparasitic agent, in particular a helminthicidal agent or antiprotozoic agent. Compounds of the formula (I) are suitable for use as an antiendoparasitic agent, in particular a helminthicidal agent or antiprotozoic agent, for example in animal husbandry, in animal breeding, in animal housing and in the hygiene sector. A further aspect in turn relates to the use of a compound of the formula (I) as an antiectoparasitic, in particular an arthropodicide such as an insecticide or an acaricide. A further aspect relates to the use of a compound of the formula (I) as an antiectoparasitic, in particular an arthropodicide such as an insecticide or an acaricide, for example in animal husbandry, in animal breeding, in stables or in the hygiene sector. Anthelmintic Mixing Components The following anthelmintic mixing components may be mentioned by way of example: Anthelmintically active compounds including trematicidally and cestocidally active compounds: from the class of the macrocyclic lactones, for example: abamectin, doramectin, emamectin, eprinomectin, ivermectin, milbemycin, moxidectin, nemadectin, selamectin; from the class of the benzimidazoles and probenzimidazoles, for example: albendazole, albendazole-sulphoxide, cambendazole, cyclobendazole, febantel, fenbendazole, flubendazole, mebendazole, netobimin, oxfendazole, oxibendazole, parbendazole, thiabendazole, thiophanate, triclabendazole; from the class of the cyclooctadepsipeptides, for example: emodepside, PF1022; from the class of the aminoacetonitrile derivatives, for example: monepantel; from the class of the tetrahydropyrimidines, for example: morantel, pyrantel, oxantel; from the class of the imidazothiazoles, for example: butamisole, levamisole, tetramisole; from the class of the salicylanilides, for example: bromoxanide, brotianide, clioxanide, closantel, niclosamide, oxyclozanide, rafoxanide, tribromsalan; from the class of the paraherquamides, for example: derquantel, paraherquamide; from the class of the aminophenylamidines, for example: amidantel, deacylated amidantel (dAMD), tribendimidine; from the class of the organophosphates, for example: coumaphos, crufomate, dichlorvos, haloxone, naphthalofos, trichlorfon; from the class of the substituted phenols, for example: bithionol, disophenol, hexachlorophene, niclofolan, meniclopholan, nitroxynil; from the class of the piperazinones, for example: praziquantel, epsiprantel; from various other classes, for example: amoscanate, bephenium, bunamidine, clonazepam, clorsulon, diamfenetid, dichlorophen, diethylcarbamazine, emetine, hetolin, hycanthone, lucanthone, Miracil, mirasan, niclosamide, niridazole, nitroxynil, nitroscanate, oltipraz, omphalotin, oxamniquin, paromomycin, piperazine, resorantel. Vector Control The compounds of the formula (I) can also be used in vector control. For the purpose of the present invention, a vector is an arthropod, in particular an insect or arachnid, capable of transmitting pathogens such as, for example, viruses, worms, single-cell organisms and bacteria from a reservoir (plant, animal, human, etc.) to a host. The pathogens can be transmitted either mechanically (for example trachoma by non-stinging flies) to a host, or by injection (for example malaria parasites by mosquitoes) into a host. Examples of vectors and the diseases or pathogens they transmit are: 1) Mosquitoes
2) Lice: skin infections, epidemic typhus; 3) Fleas: plague, endemic typhus; 4) Flies: sleeping sickness (trypanosomiasis); cholera, other bacterial diseases; 5) Mites: acariosis, epidemic typhus, rickettsialpox, tularaemia, Saint Louis encephalitis, tick-borne encephalitis (TBE), Crimean-Congo haemorrhagic fever, borreliosis; 6) Ticks: borellioses such as Examples of vectors in the sense of the present invention are insects, for example aphids, flies, leafhoppers or thrips, which are capable of transmitting plant viruses to plants. Other vectors capable of transmitting plant viruses are spider mites, lice, beetles and nematodes. Further examples of vectors in the sense of the present invention are insects and arachnids such as mosquitoes, in particular of the genera Vector control is also possible if the compounds of the formula (I) are resistance-breaking. Compounds of the formula (I) are suitable for use in the prevention of diseases and/or pathogens transmitted by vectors. Thus, a further aspect of the present invention is the use of compounds of the formula (I) for vector control, for example in agriculture, in horticulture, in gardens and in leisure facilities, and also in the protection of materials and stored products. Protection of Industrial Materials The compounds of the formula (I) are suitable for protecting industrial materials against attack or destruction by insects, for example from the orders Coleoptera, Hymenoptera, Isoptera, Lepidoptera, Psocoptera and Zygentoma. Industrial materials in the present context are understood to mean inanimate materials, such as preferably plastics, adhesives, sizes, papers and cards, leather, wood, processed wood products and coating compositions. The use of the invention for protecting wood is particularly preferred. In a further embodiment, the compounds of the formula (I) are used together with at least one further insecticide and/or at least one fungicide. In a further embodiment, the compounds of the formula (I) are present as a ready-to-use pesticide, i.e. they can be applied to the material in question without further modifications. Suitable further insecticides or fungicides are in particular those mentioned above. Surprisingly, it has also been found that the compounds of the formula (I) can be employed for protecting objects which come into contact with saltwater or brackish water, in particular hulls, screens, nets, buildings, moorings and signalling systems, against fouling. Likewise, the compounds of the formula (I), alone or in combinations with other active compounds, can be used as antifouling agents. Control of Animal Pests in the Hygiene Sector The compounds of the formula (I) are suitable for controlling animal pests in the hygiene sector. In particular, the invention can be applied in the domestic sector, in the hygiene sector and in the protection of stored products, especially for controlling insects, arachnids and mites encountered in enclosed spaces such as dwellings, factory halls, offices, vehicle cabins. For controlling animal pests, the compounds of the formula (I) are used alone or in combination with other active compounds and/or auxiliaries. They are preferably used in domestic insecticide products. The compounds of the formula (I) are effective against sensitive and resistant species, and against all developmental stages. These pests include, for example, pests from the class Arachnida, from the orders Scorpiones, Araneae and Opiliones, from the classes Chilopoda and Diplopoda, from the class Insecta the order Blattodea, from the orders Coleoptera, Dermaptera, Diptera, Heteroptera, Hymenoptera, Isoptera, Lepidoptera, Phthiraptera, Psocoptera, Saltatoria or Orthoptera, Siphonaptera and Zygentoma and from the class Malacostraca the order Isopoda. They are used, for example, in aerosols, pressure-free spray products, for example pump and atomizer sprays, automatic fogging systems, foggers, foams, gels, evaporator products with evaporator tablets made of cellulose or plastic, liquid evaporators, gel and membrane evaporators, propeller-driven evaporators, energy-free, or passive, evaporation systems, moth papers, moth bags and moth gels, as granules or dusts, in baits for spreading or in bait stations. The Preparation and Use Examples which follow illustrate the invention without limiting it. 3-(2,6-Difluorophenyl)-1,2,4-thiadiazol-5-amine (200 mg) was initially charged in acetonitrile. Diisopropylethylamine (303 mg) and 2,6-difluorobenzoyl chloride (215 mg) were added and the reaction mixture was heated at reflux for 15 hours. The reaction mixture was evaporated. Some ethyl acetate was added. The organic phase was washed with water, dried and evaporated. The residue was purified by column chromatography on silica gel using the mobile phase cyclohexane/ethyl acetate (gradient cyclohexane-ethyl acetate from 50%-50% to 0%-100%). This afforded 270 mg of the title compound. HPLC-MS: mass (m/z): 354.0 (M+H)+ 1H-NMR (400.0 MHz, d6-DMSO): see peak list for compound I-1-1 (Table 4) Synthesis scheme for 3-(2,6-difluorophenyl)-1,2,4-thiadiazol-5-amine To a solution of 2,6-difluorobenzonitrile (20 g) in diethyl ether (200 mL) was added lithium bis(trimethylsilyl)amide (240 mL, 1M in THF) at 0° C. The reaction mixture was stirred overnight at room temperature. After that, methyl tert-butyl ether (150 mL) was added and the reaction was stirred for 10 min. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (2×50 mL). The aqueous layer was basified (pH: 12-14) and extracted with ethyl acetate (2×50 mL). The combined organic layer was dried over sodium sulphate and concentrated under reduced pressure to afford the title compound (16 g) as a white solid. 1H-NMR (400.0 MHz, d6-DMSO): δ=7.46-7.38 (m, 1H), 7.13-7.08 (m, 2H), 6.51 (s large, 3H). To a solution of 2,6-difluorobenzenecarboximidamide (16 g) in carbon tetrachloride (160 mL), N-bromosuccinimide (18 g) was added at 0° C. and the reaction mixture was stirred for 1 hour. The reaction mixture was filtered through a pad of celite and the filtrate was concentrated under reduced pressure to afford the title compound (12 g) as a pale yellow solid. HPLC-MS: mass (m/z): 235.0 (M+H)+ To a solution of 2,6-difluorobenzenecarboximidamide (12 g) in methanol (120 mL) was added potassium thiocyanate (10 g) at 0° C. over a period of 10 minutes and the reaction mixture was stirred for 3 hours. Methanol was removed under reduced pressure. The residue was diluted with water (50 mL) and extracted with ethyl acetate (2×50 mL). The combined organic layer was dried over sodium sulphate and concentrated under reduced pressure. The crude compound was purified by column chromatography to afford the title compound (6.5 g) as a white solid. HPLC-MS: mass (m/z): 214.0 (M+H)+ 1H-NMR (400.0 MHz, d6-DMSO): δ=8.11 (s, 2H), 7.57-7.50 (m, 1H), 7.22-7.16 (m, 2H). 3-(2,6-Difluorophenyl)-1,2,4-thiadiazol-5-amine (100 mg) was initially placed in tetrahydrofuran. Sodium hydride (20.63 mg) was added in portion and the reaction mixture was stirred at room temperature for one hour. 2-Bromobenzoyl chloride in tetrahydrofuran (113 mg) was added dropwise and the reaction mixture was stirred overnight at room temperature. The reaction was quenched with 1 mL of methanol. The residue was purified first by column chromatography on silica gel using the mobile phase cyclohexane/ethyl acetate followed by preparative HPLC. This afforded 102 mg of the title compound. HPLC-MS: mass (m/z): 396.9 1H-NMR (400.0 MHz, d6-DMSO): see peak list for compound I-1-5 (Table 4) 3-(2-Chlorophenyl)-1,2,4-thiadiazol-5-amine (150 mg) was placed in 2 mL of dichloromethane. Trimethylamine (359 mg) and 2-bromobenzoyl chloride (156 mg) in 1 mL of dichloromethane were added at 0° C. The reaction mixture was stirred overnight at room temperature. The reaction mixture was diluted with dichloromethane and washed with water. The organic phase was dried over sodium sulphate and evaporated. The residue obtained was purified by column chromatography on silica gel using the mobile phase cyclohexane/ethyl acetate (100%-0% to 0%-100%). This afforded 182 mg of the title compound. HPLC-MS: mass (m/z): 393.9 (M+H)+ 1H-NMR (400.0 MHz, CD3CN): see peak list for compound I-1-21 (Table 4) 3-(2,6-Difluorophenyl)-1,2,4-thiadiazol-5-amine (100 mg) was placed in chloroform. Diisopropylethylamine (182 mg) was added. 2-Chloronicotinoyl chloride (99 mg) was added as well as 4-(N,N-dimethylamino)pyridine (0.6 mg). The reaction mixture was stirred at room temperature overnight. Some water was added. After extraction with dichloromethane the organic phase was dried over sodium sulfate and evaporated. The residue obtained was purified by silica gel chromatography with cyclohexane-ethylacetate as eluents. This afforded 118 mg of the title compound. HPLC-MS: mass (m/z): 352.9 (M+H)+ 1H-NMR (400.0 MHz, d6-DMSO): see peak list for compound I-1-29 (Table 4) N-[3-(2,6-Difluorophenyl)-1,2,4-thiadiazol-5-yl]-2-(trifluoromethyl)nicotinamide (48 mg) was solubilized in 2 mL of methanol. One equivalent of sodium methoxide was added. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was then evaporated leading to the title compound (50 mg). HPLC-MS: mass (m/z): 386.0 ([M-Na++H+]+H)+ 1H-NMR (400.0 MHz, d6-DMSO): see peak list for compound I-1-30 (Table 4) 3-(2,6-Difluorophenyl)-1,2,4-thiadiazol-5-amine (1 equiv) was placed in chloroform. Diisopropylethylamine (3 equiv) was added. 2-(Trifluoromethyl)nicotinoyl chloride (1.2 equiv) and dimethylaminopyridine (0.01 equiv) were added at room temperature. The reaction mixture was stirred overnight at room temperature. Some water was added. After extraction with chloroform the organic phase was evaporated. The residue obtained was purified by silica gel chromatography and then by HPLC. This afforded the title compound (5.5% yield) as well as N-[3-(2,6-difluorophenyl)-1,2,4-thiadiazol-5-yl]-2-(trifluoromethyl)nicotinamide (compound I-1-6, 36% yield). HPLC-MS: mass (m/z): 560.0 (M+H)+ 1H-NMR (400.0 MHz, d6-DMSO): see peak list for compound I-1-31 (Table 4) Compound I-1-6 was also be obtained by cleavage of compound I-1-31 in methanol using 10% sodium hydroxide with stirring at room temperature for 1 hour, followed by purification by preparative HPLC. Analytical data for compound I-1-6 are provided in Table 4. N-[3-(2,6-Difluorophenyl)-1,2,4-thiadiazol-5-yl]-2-(trifluoromethyl)nicotinamide (Compound I-1-6, 100 mg) was placed in 2 mL of dimethylformamide under argon. Sodium hydride (9 mg) was added and the reaction mixture was stirred at room temperature for 10 minutes. Ethyliodide (0.031 mL) was added and the reaction mixture was stirred overnight at room temperature. Purification by preparative HPC afforded 35.8 mg of the title compound. HPLC-MS: mass (m/z): 415.1 (M+H)+ 1H-NMR (400.0 MHz, d6-DMSO): see peak list for compound I-1-34 (Table 4) To 2-ethylnicotinic acid (227 mg) in dimethylformamide was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) (HATU) (571 mg) and diisopropylethylamine (364 mg). The reaction mixture was stirred at room temperature for 15 minutes. 3-(2,6-difluorophenyl)-1,2,4-thiadiazol-5-amine (200 mg) and 4-(N,N-dimethylamino)pyridine (11 mg) were added. The reaction was heated at 80° C. and stirred overnight. HPLC purification afforded 188 mg of the title compound. HPLC-MS: mass (m/z): 347.1 (M+H)+ 1H-NMR (400.0 MHz, d6-DMSO): see peak list for compound I-1-36 (Table 4) N-(3-Bromo-1,2,4-thiadiazol-5-yl)-2-(trifluoromethyl)nicotinamide (100 mg), [2-(trifluoromethoxy)phenyl]boronic acid (175 mg), potassium phosphate (112 mg) and X-Phos aminobiphenyl palladium chloride precatalyst (22 mg) were placed in a mixture of degassed tetrahydrofuran/water (2 mL/0.2 mL). The reaction mixture was heated at 60° C. overnight. After cooling down and purification by preparative HPLC, 73.5 mg of the title compound were obtained. HPLC-MS: mass (m/z): 435.0 (M+H)+ 1H-NMR (400.0 MHz, d6-DMSO): see peak list for compound I-1-55 (Table 4) To a solution of 3-bromo-5-chloro-1,2,4-thiadiazole (5 g) in ethanol (15 mL) was added an aqueous ammonia solution (26%, 2 equiv). The reaction mixture was heated at 70° C. for 3 hours. It was then cooled down and an aqueous solution of sodium hydrogenecarbonate was added. The precipitate was filtered off, washed with water and dried. This afforded 2.88 g of the title compound. HPLC-MS: mass (m/z): 182.0 1H-NMR (400.0 MHz, d6-DMSO): 8.37 (br s, 2H) To 2-(trifluoromethyl)nicotinamide (11.9 g) in dimethylformamide (97 mL) was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) (HATU) (23.7 g) and diisopropylethylamine (20.3 mL). The reaction mixture was stirred at room temperature for 15 minutes. 3-bromo-1,2,4-thiadiazol-5-amine (7 g) and 4-(N,N-dimethyl)aminopyridine (475 mg) were added. The reaction was heated at 80° C. and stirred overnight. A solution of aqueous monosodium phosphate (5%) was added. The reaction mixture was extracted 4 times with chloroform. The organic phases were combined, dried and evaporated. The residue obtained was purified by column chromatography on silica gel using the mobile phase cyclohexane/acetone. This afforded 5.12 g of the title compound. HPLC-MS: mass (m/z): 352.9; 354.9 1H-NMR (400.0 MHz, d6-DMSO): δ=14.20 (s, 1H), 8.96 (d, 1H), 8.41 (d, 1H), 7.96 (dd, 1H) N-{3-[2-(Trifluoromethoxy)phenyl]-1,2,4-thiadiazol-5-yl}-2-(trifluoromethyl)benzamide was obtained analogously to synthesis example 9 starting with N-(3-bromo-1,2,4-thiadiazol-5-yl)-2-(trifluoromethyl)benzamide. HPLC-MS: mass (m/z): 434.0 (M+H)+ 1H-NMR (400.0 MHz, d6-DMSO): see peak list for compound I-1-70 (Table 4) N-(3-Bromo-1,2,4-thiadiazol-5-yl)-2-(trifluoromethyl)benzamide (4.3 g) was obtained analogously to synthesis example 9 starting with 2-(trifluoromethyl)benzoic acid (6.1 g) and 3-bromo-1,2,4-thiadiazol-5-amine (3.6 g). HPLC-MS: mass (m/z): 353.9 1H-NMR (400.0 MHz, d6-DMSO): δ=14.06 (s, 1H), 7.95 (d, 1H), 7.89 (m, 3H) To the mixture of N-[3-(2-chlorophenyl)-1,2,4-thiadiazol-5-yl]-2-(trifluoromethyl)nicotinamide (Compound I-1-43, 100 mg), sodium trifluoromethanesulfinate (487 mg) and copper (II) triflate (38 mg), under argon, was added acetonitrile (5 mL). To the resulting mixture, at vigorous stirring, was added tert-butylhydroperoxide (0.75 mL, 70 wt. % in H2O) over 1 hour by a syringe pump. After stirring for additional 12 hours the reaction mixture was filtered. The resulting filtrate was concentrated to ca. 2 mL. Preparative HPLC separation afforded 11 mg of the title compound. HPLC-MS: mass (m/z): 453.0 (M+H)+ 1H-NMR (400.0 MHz, d6-DMSO): 14.1 (bs, 1H), 9.0 (dd, 4.8, 1H), 8.4 (dd, 8.0, 1H), 8.1 (dd, 1H), 8.0 (dd, 1H), 7.9 (dd, 1H), 7.7 (m, 1H). To the mixture of 2-(trifluoromethyl)-N-{3-[2-(trifluoromethyl)phenyl]-1,2,4-thiadiazol-5-yl}nicotinamide (Compound I-1-20, 70 mg), sodium trifluoromethanesulfinate (313 mg) and copper (II) triflate (18 mg), under argon, was added acetonitrile (2 mL). To the resulting mixture, at vigorous stirring, was added tert-butylhydroperoxide (0.28 mL, 70 wt. % in H2O) over 30 minutes by a syringe pump. The reaction mixture was stirred for 18 hours and then additional sodium trifluoromethanesulfinate (313 mg) and tert-butylhydroperoxide (0.28 mL, 70 wt. % in H2O) were added. After stirring for additional 15 hours the reaction mixture was filtered. The resulting filtrate was concentrated to ca. 1 mL. Preparative HPLC separation afforded 1 mg of the title compound. HPLC-MS: mass (m/z): 487.1 (M+H)+ 1H-NMR (400.0 MHz, d6-DMSO): 14.07 (bs, 1H), 8.96 (d, 1H), 8.49 (d, 1H), 8.28 (d, 2H), 8.03 (t, 1H), 7.93 (dd, 1H). This compound (2 mg) was also isolated from the previous reaction transforming compound Compound I-1-20 into compound I-1-65 and compound I-1-66. HPLC-MS: mass (m/z): 487.1 (M+H)+ 1H-NMR (400.0 MHz, d6-DMSO): 14.09 (bs, 1H), 8.97 (d, 4.8 Hz, 1H), 8.45 (d, 7.9 Hz, 1H), 8.24-8.27 (m, 2H), 8.15 (d, 8.4 Hz, 1H), 7.94 (dd, 7.9, 4.8 Hz, 1H). To a mixture of N-(3-phenyl-1,2,4-thiadiazol-5-yl)-2-(trifluoromethyl)nicotinamide (100 mg, compound obtained by amide coupling with the corresponding amine) in a 5 ml crimp sealable flask, N-iodosuccinimide (141 mg), Pd(OAc)2, (24 mg) and acetonitrile (2 ml) were added. The mixture was heated in a sealed flask (5 mL) at 110° C. overnight. At room temperature a 10% aqueous solution of Na2SO3 (25 mL) was added, the resulting suspension was extracted with dichloromethane (3×50 mL), the organic phases combined, filtered through a water repellant filter and the solvent removed under reduced pressure. The crude material was taken up in dimethylsulfoxide (2 ml) and transferred to a 5 ml crimp sealable flask. Copper (I) cyanide (32 mg) was added and the mixture heated at 140° C. for 1 hour. Water (20 ml) was added, and the resulting precipitate collected by filtration. Further purification was performed using preparative HPLC, affording the title compound as a white solid (10.1 mg). HPLC-MS: mass (m/z): 376.0 (M+H)+ 1H-NMR (400.0 MHz, CD3OD): 9.0 (d, 1H), 8.4 (d, 1H), 8.3 (dd, 1H), 8.0 (dd, 1H), 7.9 (dd, 1H), 7.9 (dt, 1H), 7.7 (dt, 1H). Compound I-1-78 was obtained as a second product in the previous reaction transforming N-(3-phenyl-1,2,4-thiadiazol-5-yl)-2-(trifluoromethyl)nicotinamide (100 mg) into compound I-1-67 (mono-nitrile) and compound I-1-78 (bis-nitrile). It was obtained after purification by preparative HPLC (4 mg). HPLC-MS: mass (m/z): 401.1 (M+H)+ 1H-NMR (400.0 MHz, CD3OD): 8.9 (dd, 1H), 8.3 (dd, 1H), 8.2 (d, 2H), 7.8 (m, 2H) 2-(Trifluoromethyl)nicotinic acid (168 mg), bromo-tris-pyrrolidino phosphoniumhexafluorophosphate (513 mg) and 3-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-1,2,4-thiadiazol-5-amine (206 mg) and diisopropylethylamine (189 mg) were placed in dichloromethane (7 mL). The reaction mixture was stirred overnight at room temperature. Some water was added. After extraction with dichloromethane the organic phase was dried and evaporated. The residue obtained was purified first by silica gel chromatography and then by preparative HPLC. This afforded 65 mg of the title compound. HPLC-MS: mass (m/z): 353.9 (M+H)+ 1H-NMR (400.0 MHz, d6-DMSO): see peak list for compound I-2-3 (Table 2) Compound I-2-6 (66 mg) was obtained analogously to compound I-1-21 using diisopropylethylamine as a base and the appropriate starting thiadiazol-amine adduct. HPLC-MS: mass (m/z): 351.0, 352.9 1H-NMR (400.0 MHz, d6-DMSO): 13.82 (s, 1H), 8.67 (d, 1H), 8.15 (d, 1H), 7.79 (d, 1H), 7.65-7.59 (m, 3H), 7.52 (t, 1H). To a solution of ammonium chloride (7.70 g) in toluene (200 mL) a solution of trimethylaluminium in 2M in hexane (20.8 g, 144 mmol) was added dropwise at 0° C. and the mixture was stirred for 30 minutes. 3-chloropyridine-2-carbonitrile (10.0 g) was then added. The reaction was heated to 80° C. and stirred at this temperature until gas evolution stopped. After completion of the reaction, the reaction mixture was cooled to 0° C., quenched with methanol (10 mL), and filtered through a pad of silica gel. The filtrate was evaporated under reduced pressure. This afforded 8.43 g of the title compound. At 0° C. trimethylamine (10.7 g) was added to a solution of 3-chloropyridine-2-carboximidamide (5.50 g) in methanol (100 mL) followed by dropwise addition of bromine (5.64 g). The reaction mixture was stirred for 30 minutes at 0° C. before potassium thiocyanate (3.77 g) was added. The reaction was stirred overnight at room temperature and then evaporated under reduced pressure. The residue was washed with water, dried in air, and re-crystallized from acetonitrile to obtain 3.15 g of the title compound. Compound I-3-1 (17 mg) was obtained analogously to compound compound I-1-36 (Synthetic Example 8) using the appropriate starting thiadiazol-amine (100 mg). HPLC-MS: mass (m/z): 385.0 (M+H)+ 1H-NMR (400.0 MHz, d6-DMSO): see peak list for compound I-3-1 (Table 3) The appropriate thiadiazol-amine adduct was obtained analogously to 3-(3-chloropyridin-2-yl)-1,2,4-thiadiazol-5-amine using the 2 steps protocole previously described in Synthetic Example 15, starting with 2-chloronicotinonitrile. The compounds of formulae (I-1), (1-2) and (1-3) described in Tables 1, 2 and 3 are likewise preferred compounds which were obtained according to or analogously to the Synthesis Examples described above. NMR-Peak Lists 1H-NMR data of selected examples are written in form of 1H-NMR-peak lists. To each signal peak are listed the 6-value in ppm and the signal intensity in round brackets. Between the 6-value—signal intensity pairs are semicolons as delimiters. The peak list of an example has therefore the form: Intensity of sharp signals correlates with the height of the signals in a printed example of a NMR spectrum in cm and shows the real relations of signal intensities. From broad signals several peaks or the middle of the signal and their relative intensity in comparison to the most intensive signal in the spectrum can be shown. For calibrating chemical shift for 1H spectra, we use tetramethylsilane and/or the chemical shift of the solvent used, especially in the case of spectra measured in DMSO. Therefore in NMR peak lists, tetramethylsilane peak can occur but not necessarily. The 1H-NMR peak lists are similar to classical 1H-NMR prints and contains therefore usually all peaks, which are listed at classical NMR-interpretation. Additionally they can show like classical 1H-NMR prints signals of solvents, stereoisomers of the target compounds, which are also object of the invention, and/or peaks of impurities. To show compound signals in the delta-range of solvents and/or water the usual peaks of solvents, for example peaks of DMSO in DMSO-D6 and the peak of water are shown in our 1H-NMR peak lists and have usually on average a high intensity. The peaks of stereoisomers of the target compounds and/or peaks of impurities have usually on average a lower intensity than the peaks of target compounds (for example with a purity >90%). Such stereoisomers and/or impurities can be typical for the specific preparation process. Therefore their peaks can help to recognize the reproduction of our preparation process via “side-products-fingerprints”. An expert, who calculates the peaks of the target compounds with known methods (MestreC, ACD-simulation, but also with empirically evaluated expectation values) can isolate the peaks of the target compounds as needed optionally using additional intensity filters. This isolation would be similar to relevant peak picking at classical 1H-NMR interpretation. Further details of NMR-data description with peak lists you find in the publication “Citation of NMR Peaklist Data within Patent Applications” of the Research Disclosure Database Number 564025. 9 mg compound is solved in 1 ml acetone and diluted with acetone to the desired concentration. 250 μl of the test solution is filled in 25 ml glass test tubes and homogeneously distributed on the inner walls by rotation and tilting on a shaking device (2 h at 30 rpm). With a compound concentration of 900 ppm, an inner surface of 44.7 cm2 and a homogeneous distribution, a dose of 5 gg/cm2 is achieved. After the solvent has evaporated, each test tube is filled with 5-10 adult cat fleas ( A compound shows a good efficacy against In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 5 μg/cm2 (=500 g/ha): I-1-4, I-1-6, I-1-7, I-1-31. In this test, for example, the following compounds from the preparation examples showed good activity of 90% at an application rate of 5 μg/cm2 (=500 g/ha): I-1-30. Solvent: dimethyl sulfoxide To produce a suitable preparation of active compound, 10 mg of active compound are dissolved in 0.5 ml solvent, and the concentrate is diluted with solvent to the desired concentration. Five adult engorged female ticks ( After 7 days egg deposition of fertile eggs is monitored. Eggs where fertility is not visible are stored in a climate chamber till hatching after about 42 days. An efficacy of 100% means all eggs are infertile; 0% means all eggs are fertile. In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 20 μg/animal: I-1-1, I-1-3, I-1-4, I-1-5, I-1-6, I-1-7, I-1-8, I-1-9, I-1-11, I-1-12, I-1-14, I-1-20, I-1-22, I-1-30, I-1-31, I-1-44, I-1-55, I-1-57. Solvent: dimethyl sulfoxide To produce a suitable preparation of active compound, 10 mg of active compound are dissolved in 0.5 ml solvent, and the concentrate is diluted with cattle blood to the desired concentration. Approximately 20 adult unfed cat fleas ( After 2 days mortality in % is determined. 100% means all the fleas have been killed; 0% means none of the fleas have been killed. In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 100 ppm: I-1-6, I-1-14, I-1-20, I-1-30, I-1-31, I-1-44, I-1-55, I-1-57. In this test, for example, the following compounds from the preparation examples showed good activity of 98% at an application rate of 100 ppm: I-1-12. In this test, for example, the following compounds from the preparation examples showed good activity of 95% at an application rate of 100 ppm: I-1-1. In this test, for example, the following compounds from the preparation examples showed good activity of 90% at an application rate of 100 ppm: I-1-4, I-1-7, I-1-8. In this test, for example, the following compounds from the preparation examples showed good activity of 70% at an application rate of 100 ppm: I-1-9, I-1-25, I-1-28. Solvent: dimethyl sulfoxide 10 mg active compound are dissolved in 0.5 ml Dimethylsulfoxid. Serial dilutions are made to obtain the desired rates. Approximately 20 1st instar larvae of the Australian sheep blowfly ( After 2 days mortality in % is determined. 100% means all the larvae have been killed; 0% means none of the larvae have been killed. In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 100 ppm: I-1-6, I-1-7, I-1-8, I-1-14, I-1-20, I-1-30, I-1-31, I-1-44, I-1-55, I-1-57. In this test, for example, the following compounds from the preparation examples showed good activity of ≥70% and <100% at an application rate of 100 ppm: I-1-4, I-1-5, I-1-12, I-1-19. Solvent: dimethyl sulfoxide To produce a suitable preparation of active compound, 10 mg of active compound are dissolved in 0.5 ml solvent, and the concentrate is diluted with water to the desired concentration. 10 adult house flies ( After 2 days mortality in % is determined. 100% means all the flies have been killed; 0% means none of the flies have been killed. In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 100 ppm: I-1-57. In this test, for example, the following compounds from the preparation examples showed good activity of 80% at an application rate of 100 ppm: I-1-31. Solvent: dimethyl sulfoxide To produce a suitable preparation of active compound, 10 mg of active compound are dissolved in 0.5 ml solvent, and the concentrate is diluted with “Ringer's solution” to the desired concentration. Approximately 40 larvae of the red stomach worm ( After 5 days the percentage of larval mortality is recorded. 100% efficacy means all larvae are killed, 0% efficacy means no larvae are killed. In this test for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 20 ppm: I-1-2. In this test for example, the following compounds from the preparation examples showed good activity of 80% at an application rate of 20 ppm: I-1-1, I-1-56. Solvent: 78.0 parts by weight of acetone
Emulsifier: alkylarylpolyglycol ether To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvent, and the concentrate is diluted with water, containing an emulsifier concentration of 1000 ppm, to the desired concentration. Further test concentrations are prepared by dilution with emulsifier containing water. Soaked wheat seeds ( After 7 days efficacy in % is determined. 100% means all the seedlings have grown up like in the untreated, uninfected control; 0% means none of the seedlings have grown. In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 160 μg/well: I-1-7, I-1-19, I-1-20, I-1-44, I-1-55, I-1-57, I-1-64, I-1-70, I-1-73. In this test, for example, the following compounds from the preparation examples showed good activity of 80% at an application rate of 160 μg/well: I-1-6, I-1-29, I-1-38, I-1-53, I-1-61, I-1-77. Solvent: 125.0 parts by weight of acetone To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvent, and the concentrate is diluted with water to the desired concentration. Vessels are filled with sand, a solution of the active ingredient, a suspension containing eggs and larvae of the southern root-knot nematode ( After 14 days the nematicidal activity is determined on the basis of the percentage of gall formation. 100% means no galls were found and 0% means the number of galls found on the roots of the treated plants was equal to that in untreated control plants. In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 20 ppm: I-1-2, I-1-6, I-1-10, I-1-12, I-1-14, I-1-20, I-1-29, I-1-30, I-1-36. In this test, for example, the following compounds from the preparation examples showed good activity of 90% at an application rate of 20 ppm: I-1-1, I-1-3, I-1-4, I-1-5, I-1-13, I-1-16, I-1-19, I-1-28, I-1-48. In this test, for example, the following compounds from the preparation examples showed good activity of 70% at an application rate of 20 ppm: I-1-9, I-1-39. Solvent: 78.0 parts by weight acetone
Emulsifier: alkylarylpolyglycol ether To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvents and is diluted with water, containing an emulsifier concentration of 1000 ppm, to the desired concentration. Further test concentrations are prepared by dilution with emulsifier containing water. Chinese cabbage ( After 5-6 days mortality in % is determined. 100% means all aphids have been killed and 0% means none of the aphids have been killed. In this test, for example, the following compounds from the preparation examples showed good activity of ≥70% at an application rate of 500 g/ha: I-1-6, I-1-12, I-1-20, I-1-30, I-1-32, I-1-35, I-1-39, I-1-54, I-1-55, I-1-56, I-1-57, I-1-61, I-1-62, I-1-64, I-2-1, I-2-3, I-3-2. Solvent: 78.0 parts by weight of acetone
Emulsifier: alkylarylpolyglycol ether To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvent, and the concentrate is diluted with water, containing an emulsifier concentration of 1000 ppm, to the desired concentration. Further test concentrations are prepared by dilution with emulsifier containing water. Barley plants ( After 4 days mortality in % is determined. 100% means all the stink bugs have been killed; 0% means none of the stink bugs have been killed. In this test, for example, the following compounds from the preparation examples showed good activity of ≥90 at an application rate of 500 g/ha: I-1-18, I-1-20, I-1-21, I-1-22, I-1-23, I-1-25, I-1-26, I-1-29, I-1-33, I-1-35, I-1-37, I-1-42, I-1-43, I-1-44, I-1-50, I-1-51, I-1-55, I-1-56, I-1-57, I-1-58, I-1-59, I-1-60, I-1-61, I-1-62, I-1-63, I-1-64, I-1-69, I-1-76. Solvent: 78.0 parts by weight of acetone
Emulsifier: alkylarylpolyglycol ether To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvents and is diluted with water, containing an emulsifier concentration of 1000 ppm, to the desired concentration. Further test concentrations are prepared by dilution with emulsifier containing water. Rice plants ( After 4 days mortality in % is determined. 100% means all planthoppers have been killed and 0% means none of the planthoppers have been killed. In this test, for example, the following compounds from the preparation examples showed good activity of ≥70% at an application rate of 500 g/ha: I-1-20, I-1-42, I-1-50, I-1-51, I-1-61, I-1-75. Solvent: 78.0 parts by weight of acetone
Emulsifier: alkylarylpolyglycol ether To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvents and is diluted with water, containing an emulsifier concentration of 1000 ppm, to the desired concentration. Further test concentrations are prepared by dilution with emulsifier containing water. Chinese cabbage ( After 7 days mortality in % is determined. 100% means all beetle larvae have been killed and 0% means none of the beetle larvae have been killed. In this test, for example, the following compounds from the preparation examples showed good activity of ≥80 at an application rate of 500 g/ha: I-1-1, I-1-2, I-1-3, I-1-4, I-1-5, I-1-6, I-1-7, I-1-8, I-1-9, I-1-10, I-1-11, I-1-12, I-1-13, I-1-14, I-1-18, I-1-19, I-1-20, I-1-21, I-1-22, I-1-23, I-1-24, I-1-25, I-1-26, I-1-27, I-1-28, I-1-30, I-1-31, I-1-32, I-1-35, I-1-36, I-1-37, I-1-38, I-1-39, I-1-40, I-1-41, I-1-43, I-1-44, I-1-46, I-1-47, I-1-48, I-1-50, I-1-52, I-1-53, I-1-54, I-1-55, I-1-56, I-1-57, I-1-58, I-1-59, I-1-60, I-1-61, I-1-62, I-1-64, I-1-68, I-1-69, I-1-70, I-1-71, I-1-72, I-1-73, I-1-76, I-1-78, I-2-1, I-2-2, I-2- 3, I-2-4, I-2-5, I-2-6, I-3-1, I-3-2. Solvent: 78.0 parts by weight acetone
Emulsifier: alkylarylpolyglycol ether To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvents and is diluted with water, containing an emulsifier concentration of 1000 ppm, to the desired concentration. Further test concentrations are prepared by dilution with emulsifier containing water. Maize ( After 7 days mortality in % is determined. 100% means all caterpillars have been killed and 0% means none of the caterpillars have been killed. In this test, for example, the following compounds from the preparation examples showed good activity of ≥80% at an application rate of 500 g/ha: I-1-27, I-1-28, I-1-55, I-1-57, I-1-61, I-1-62, I-1-64, I-1-69, I-1-76. Solvent: 78.0 parts by weight acetone
Emulsifier: alkylarylpolyglycol ether To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvents and is diluted with water, containing an emulsifier concentration of 1000 ppm, to the desired concentration. Further test concentrations are prepared by dilution with emulsifier containing water. French bean ( After 6 days mortality in % is determined. 100% means all spider mites have been killed and 0% means none of the spider mites have been killed. In this test, for example, the following compounds from the preparation examples showed good activity of ≥70% at an application rate of 500 g/ha: I-1-1, I-1-3, I-1-4, I-1-5, I-1-6, I-1-8, I-1-15, I-1-16, I-1-17, I-1-19, I-1-20, I-1-30, I-1-31, I-1-32, I-1-34, I-1-43, I-1-49, I-1-51, I-1-55, I-1-56, I-1-57, I-1-59, I-1-60, I-1-61, I-1-62, I-1-64, I-1-69, I-1-74, I-1-76, I-2-1, I-2-6. Solvent: 14 parts by weight of dimethylformamide Emulsifier: alkylaryl polyglycol ether To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvent and is diluted with water, containing an emulsifier concentration of 1000 ppm, to the desired concentration. Further test concentrations are prepared by dilution with emulsifier containing water. Cabbage leaves ( After 7 days, mortality in % is determined. 100% means all the caterpillars have been killed and 0% means none of the caterpillars have been killed. In this test, for example, the following compounds from the preparation examples showed good activity of 100% at an application rate of 100 ppm: I-1-10, I-1-11, I-1-12. Solvent: 52.5 parts by weight of acetone
Emulsifier: alkylaryl polyglycolether To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvent, and the concentrate is diluted with water, containing an emulsifier concentration of 1000 ppm, to the desired concentration. Ammonium salt and/or penetration enhancer in a dosage of 1000 ppm are added to the desired concentration if necessary. Barley plants ( After 4 days mortality in % is determined. 100% means all the stink bugs have been killed; 0% means none of the stink bugs have been killed. In this test, for example, the following compounds from the preparation examples showed good activity of of ≥90% at an application rate of 500 g/ha: I-1-1, I-1-3, I-1-4, I-1-6, I-1-7, I-1-8, I-1-10, I-1-11, I-1-12, I-1-14, I-1-15, I-1-20, I-1-25, I-1-27, I-1-29, I-1-30, I-1-31, I-1-35, I-1-42, I-1-43, I- 1-44, I-1-50, I-1-51, I-1-55, I-1-56, I-1-57, I-1-58, I-1-59, I-1-60, I-1-61, I-1-62, I-1-64, I-1-65, I-1-66, I- 1-67, I-1-69, I-1-73, I-2-5, I-3-1, I-3-2, I-3-3, I-3-4. Solvent: 52.5 parts by weight of acetone
Emulsifier: alkylaryl polyglycolether To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvents and is diluted with water, containing an emulsifier concentration of 1000 ppm, to the desired concentration. Further test concentrations are prepared by dilution with emulsifier containing water. Ammonium salt and/or penetration enhancer in a dosage of 1000 ppm are added to the desired concentration if necessary. Rice plants ( After 4 days mortality in % is determined. 100% means all planthoppers have been killed and 0% means none of the planthoppers have been killed. In this test, for example, the following compounds from the preparation examples showed good activity of ≥80% at an application rate of 500 g/ha: I-1-6, I-1-20, I-1-30, I-1-42, I-1-59, I-1-61, I-1-62, I-1-65, I-2-6, I-3-5. Solvent: 7 parts by weight of dimethylformamide Emulsifier: alkylaryl polyglycolether To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvent and is diluted with water, containing an emulsifier concentration of 1000 ppm, to the desired concentration. Further test concentrations are prepared by dilution with emulsifier containing water. Ammonium salt and/or penetration enhancer (rapeseed oil methyl esters) in a dosage of 1000 ppm are added to the desired concentration if necessary. Kidney bean plants ( After 7 days feeding control in % is determined. 100% means there is no feeding damage visible and 0% means the plant damage corresponds to that of the untreated control plants. In this test, for example, the following compounds from the preparation examples showed good activity of ≥75% at an application rate of 100 ppm: I-1-4, I-1-6, I-1-7, I-1-14, I-1-20. Solvent: 7 parts by weight of dimethylformamide Emulsifier: alkylaryl polyglycolether To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amount of solvent and is diluted with water, containing an emulsifier concentration of 1000 ppm, to the desired concentration. Further test concentrations are prepared by dilution with emulsifier containing water. Ammonium salt and/or penetration enhancer (rapeseed oil methyl esters) in a dosage of 1000 ppm are added to the desired concentration if necessary. Cotton plants ( After 2 days feeding control in % is determined. 100% means there is no feeding damage visible and 0% means the plant damage corresponds to that of the untreated control plants. In this test, for example, the following compounds from the preparation examples showed good activity of ≥70% at an application rate of 100 ppm: I-1-4, I-1-6, I-1-7, I-1-14, I-1-20, I-1-43. The present application relates to thiadiazole compounds, compositions containing such compounds, their use for controlling animal pests including arthropods, insects and nematodes, and to processes and intermediates for the preparation of the thiadiazole compounds. 1. Compound of formula (I) in which
A represents a radical from the group consisting of in which the broken line represents the bond to the thiadiazole ring, D represents a radical from the group consisting of in which the broken line represents the bond to the carbon atom in C=Q, E represents hydrogen, C1-C6-alkyl, C3-C6-cycloalkyl, C2-C6-haloalkyl, C3-C6-alkenyl, C3-C6-alkynyl, C3-C6-cycloalkyl-C1-C6-alkyl, cyano-C1-C6-alkyl, C1-C6-alkylcarbonyl, C1-C6-alkoxy-C1-C6-alkyl, C1-C6-alkoxycarbonyl, a metal ion, an ammonium ion or represents C(═O)-D, Q represents oxygen or sulfur, R1 represents halogen, cyano, nitro, C1-C6-alkyl, C1-C6-haloalkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C1-C6-alkylthio, C1-C6-haloalkylthio C3-C6-alkenylthio, C3-C6-alkynylthio, C1-C6-alkylsulphinyl, C1-C6-haloalkylsulphinyl, C1-C6-alkylsulphonyl, C1-C6-haloalkylsulphonyl, R2 represents hydrogen, halogen, cyano, nitro, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C1-C6-alkylthio, C1-C6-haloalkylthio, C1-C6-alkylsulphinyl, C1-C6-haloalkylsulphinyl, C1-C6-alkylsulphonyl, C1-C6-haloalkylsulphonyl, provided that if R1 is fluorine in A-2, R2 must be not represent hydrogen in A-2, R3 represents halogen, cyano, nitro, C1-C6-alkyl, C1-C6-haloalkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C3-C6-alkenoxy, C3-C6-haloalkenoxy, C3-C6-alkynoxy, C3-C6-cycloalkoxy C1-C6-alkylthio, C1-C6-haloalkylthio, C1-C6-alkylsulphinyl, C1-C6-haloalkylsulphinyl, C1-C6-alkylsulphonyl, C1-C6-haloalkylsulphonyl and R4 represents hydrogen, halogen, nitro, cyano, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C1-C6-alkylthio, C1-C6-haloalkylthio, C1-C6-alkylsulphinyl, C1-C6-haloalkylsulphinyl C1-C6-alkylsulphonyl, C1-C6-haloalkylsulphonyl. 2. Compound of formula (I) according to A represents a radical from the group consisting of in which the broken line represents the bond to the thiadiazole ring, D represents a radical from the group consisting of in which the broken line represents the bond to the carbon atom in C=Q, E represents hydrogen, C1-C4-alkyl, C3-C6-cycloalkyl, C2-C4-haloalkyl, C3-C4-alkenyl, C3-C4-alkynyl, C3-C6-cycloalkyl-C1-C4-alkyl, cyano-C1-C4-alkyl, C1-C4-alkylcarbonyl, C1-C4-alkoxy-C1-C4-alkyl, C1-C4-alkoxycarbonyl, an alkali metal ion, an earth alkali metal ion, an ammonium ion or represents C(═O)-D, Q represents oxygen or sulfur, R1 represents halogen, cyano, nitro, C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C1-C6-alkylthio, C1-C6-haloalkylthio C3-C6-alkenylthio, C3-C6-alkynylthio, C1-C6-alkylsulphinyl, C1-C6-haloalkylsulphinyl, C1-C6-alkylsulphonyl, C1-C6-haloalkylsulphonyl, R2 represents hydrogen, halogen, cyano, nitro, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C1-C6-alkylthio, C1-C6-haloalkylthio, C1-C6-alkylsulphinyl, C1-C6-haloalkylsulphinyl, C1-C6-alkylsulphonyl, C1-C6-haloalkylsulphonyl, provided that if R1 is fluorine in A-2, R2 must be not represent hydrogen in A-2, R3 represents halogen, cyano, nitro, C1-C6-alkyl, C1-C6-haloalkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C3-C6-alkenoxy, C3-C6-haloalkenoxy, C3-C6-alkynoxy, C3-C6-cycloalkoxy, C1-C6-alkylthio, C1-C6-haloalkylthio, C1i-C6-alkylsulphinyl, C1-C6-haloalkylsulphinyl, C1-C6-alkylsulphonyl, C1-C6-haloalkylsulphonyl R4 represents hydrogen, halogen, nitro, cyano, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C1-C6-alkylthio, C1-C6-haloalkylthio, C1-C6-alkylsulphinyl, C1-C6-haloalkylsulphinyl, C1-C6-alkyl sulphonyl, C1-C6-haloalkyl sulphonyl. 3. Compound of formula (I) according to A represents a radical from the group consisting of in which the broken line represents the bond to the thiadiazole ring, D represents a radical from the group consisting of in which the broken line represents the bond to the carbon atom in C=Q, E represents hydrogen, C1-C4-alkyl, C2-C4-haloalkyl, cyano-C1-C4-alkyl, C1-C4-alkylcarbonyl, C1-C4-alkoxy-C1-C4-alkyl, C1-C4-alkoxycarbonyl, an alkali metal ion, an earth alkali metal ion, an ammonium ion or represents C(═O)-D, Q represents oxygen or sulfur, R1 represents halogen, cyano, nitro, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-haloalkylthio, C1-C4-alkylsulphinyl, C1-C4-haloalkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-haloalkylsulphonyl, R2 represents hydrogen, halogen, cyano, nitro, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4alkylthio, C1-C4-haloalkylthio, C1-C4-alkylsulphinyl, C1-C4-haloalkylsulphinyl, C1-C4alkylsulphonyl, C1-C4-haloalkylsulphonyl, provided that if R1 is fluorine in A-2, R2 must be not represent hydrogen in A-2, R3 represents halogen, cyano, nitro, C1-C4-alkyl, C1-C4-haloalkyl, C2-C4-alkenyl, C2-C4-alkynyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C3-C4-alkenoxy, C3-C4-haloalkenoxy, C3-C4-alkynoxy, C3-C6-cycloalkoxy, C1-C4-alkylthio, C1-C4-haloalkylthio, C1-C4-alkylsulphinyl, C1-C4-haloalkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-haloalkylsulphonyl, R4 represents hydrogen, halogen, nitro, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-haloalkylthio, C1-C4-alkylsulphinyl, C1-C4-haloalkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-haloalkylsulphonyl. 4. Compound of the formula (I) according to A represents a radical from the group consisting of in which the broken line represents the bond to the thiadiazole ring, D represents a radical from the group consisting of in which the broken line represents the bond to the carbon atom in C=Q, E represents hydrogen, methyl, ethyl, difluormethyl, trifluormethyl, cyanomethyl, a Li-, Na-, K-, Mg-, Ca-ion, an ammonium ion of formula wherein R5, R6, R7 and R8 independently represent hydrogen, C1-C4-alkyl or benzyl, or E represents C(═O)-D, Q represents oxygen or sulfur, R1 represents fluorine, chlorine, bromine, iodine, cyano, nitro, methyl, ethyl, difluoromethyl, trifluoromethyl, chloro-difluoromethyl, pentafluoroethyl, cyclopropyl, methoxy, ethoxy difluoromethoxy, trifluoromethoxy, chloro-difluoro-methoxy, difluoroethoxy, trifluoroethoxy, methylthio, ethylthio, trifluoromethylthio, difluoromethylthio, difluoroethylthio, trifluoroethylthio, methylsulphinyl, ethylsulphinyl, trifluoromethylsulphinyl, difluoromethylsulphinyl, difluoroethylsulphinyl, trifluoroethylsulphinyl, methylsulphonyl, ethylsulphonyl, trifluoromethylsulphonyl, difluoromethylsulphonyl, difluoroethylsulphonyl, trifluoroethylsulphonyl, R2 represents hydrogen, fluorine, chlorine, bromine, iodine, cyano, nitro, methyl, ethyl, difluoromethyl, trifluoromethyl, chloro-difluoromethyl, pentafluoroethyl, methoxy, ethoxy, -difluoromethoxy, trifluoromethoxy, chloro-difluoro-methoxy, difluoroethoxy, trifluoroethoxy methylthio, ethylthio, trifluoromethylthio, difluoromethylthio, difluoroethylthio, trifluoroethylthio, trifluoromethylsulphinyl, difluoromethylsulphinyl, difluoroethylsulphinyl, trifluoroethylsulphinyl, methylsulphonyl, ethylsulphonyl, trifluoromethylsulphonyl, difluoromethylsulphonyl, difluoroethylsulphonyl, trifluoroethylsulphonyl, provided that if R1 is fluorine in A-2, R2 must be not represent hydrogen in A-2, R3 represents fluorine, chlorine, bromine, iodine, cyano, nitro, methyl, ethyl, difluoromethyl, trifluoromethyl, chloro-difluoromethyl, pentafluoroethyl, cyclopropyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, chloro-difluoro-methoxy, difluoroethoxy, trifluoroethoxy, methylthio, ethylthio, trifluoromethylthio, difluoromethylthio, difluoroethylthio, trifluoroethylthio, methylsulphinyl, ethylsulphinyl, trifluoromethylsulphinyl, difluoromethylsulphinyl, difluoroethylsulphinyl, trifluoroethylsulphinyl, methylsulphonyl, ethylsulphonyl, trifluoromethylsulphonyl, difluoromethylsulphonyl, difluoroethylsulphonyl, trifluoroethylsulphonyl and R4 represents hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano, methyl, ethyl, difluoromethyl, trifluoromethyl, chloro-difluoromethyl, pentafluoroethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, chloro-difluoro-methoxy, difluoroethoxy, trifluoroethoxy methylthio, ethylthio, trifluoromethylthio, difluoromethylthio, difluoroethylthio, trifluoroethylthio, trifluoromethylsulphinyl, difluoromethylsulphinyl, difluoroethylsulphinyl, trifluoroethylsulphinyl, methylsulphonyl, ethylsulphonyl, trifluoromethylsulphonyl, difluoromethylsulphonyl, difluoroethylsulphonyl, trifluoroethylsulphonyl. 5. Compound of formula (I-1) in which
D represents a radical from the group consisting of in which the broken line represents the bond to the carbon atom in C=Q, E represents hydrogen; a Li-, Na-, K-, Mg-, Ca-ion, an ammonium ion of formula wherein R5, R6, R7 and R8 independently represent hydrogen, methyl, ethyl or benzyl, Q represents oxygen, R1 represents fluorine, chlorine, bromine, iodine, cyano, nitro, methyl, ethyl, difluoromethyl, trifluoromethyl, chloro-difluoromethyl, pentafluoroethyl, cyclopropyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, chloro-difluoro-methoxy, difluoroethoxy, trifluoroethoxy, methylthio, ethylthio, trifluoromethylthio, difluoromethylthio, difluoroethylthio, trifluoroethylthio, methylsulphinyl, ethylsulphinyl, trifluoromethylsulphinyl, difluoromethylsulphinyl, difluoroethylsulphinyl, trifluoroethylsulphinyl, methylsulphonyl, ethylsulphonyl, trifluoromethylsulphonyl, difluoromethylsulphonyl, difluoroethylsulphonyl, trifluoroethylsulphonyl, R2 represents hydrogen, fluorine, chlorine, bromine, iodine, cyano, nitro, methyl, ethyl, difluoromethyl, trifluoromethyl, chloro-difluoromethyl, pentafluoroethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, chloro-difluoro-methoxy, difluoroethoxy, trifluoroethoxy methylthio, ethylthio, trifluoromethylthio, difluoromethylthio, difluoroethylthio, trifluoroethylthio, trifluoromethylsulphinyl, difluoromethylsulphinyl, difluoroethylsulphinyl, trifluoroethylsulphinyl, methylsulphonyl, ethylsulphonyl, trifluoromethylsulphonyl, difluoromethylsulphonyl, difluoroethylsulphonyl, trifluoroethylsulphonyl, R3 represents fluorine, chlorine, bromine, iodine, cyano, nitro, methyl, ethyl, difluoromethyl, trifluoromethyl, chloro-difluoromethyl, pentafluoroethyl, cyclopropyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, chloro-difluoro-methoxy, difluoroethoxy, trifluoroethoxy, methylthio, ethylthio, trifluoromethylthio, difluoromethylthio, difluoroethylthio, trifluoroethylthio, methylsulphinyl, ethylsulphinyl, trifluoromethylsulphinyl, difluoromethylsulphinyl, difluoroethylsulphinyl, trifluoroethylsulphinyl, methylsulphonyl, ethylsulphonyl, trifluoromethylsulphonyl, difluoromethylsulphonyl, difluoroethylsulphonyl, trifluoroethylsulphonyl, R4 represents hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano, methyl, ethyl, difluoromethyl, trifluoromethyl, chloro-difluoromethyl, pentafluoroethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, chloro-difluoro-methoxy, difluoroethoxy, trifluoroethoxy methylthio, ethylthio, trifluoromethylthio, difluoromethylthio, difluoroethylthio, trifluoroethylthio, trifluoromethylsulphinyl, difluoromethylsulphinyl, difluoroethylsulphinyl, trifluoroethylsulphinyl, methylsulphonyl, ethylsulphonyl, trifluoromethyl sulphonyl, difluoromethylsulphonyl, difluoroethylsulphonyl, trifluoroethylsulphonyl 6. Compound of formula (I-2) in which
D represents a radical from the group consisting of in which the broken line represents the bond to the carbon atom in C=Q, E represents hydrogen, a Li-, Na-, K-, Mg-, Ca-ion, an ammonium ion of formula wherein R5, R6, R7 and R8 independently represent hydrogen, methyl, ethyl or benzyl, Q represents oxygen, R1 represents fluorine, chlorine, bromine, iodine, cyano, nitro, methyl, ethyl, difluoromethyl, trifluoromethyl, chloro-difluoromethyl, pentafluoroethyl, cyclopropyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, chloro-difluoro-methoxy, difluoroethoxy, trifluoroethoxy, methylthio, ethylthio, trifluoromethylthio, difluoromethylthio, difluoroethylthio, trifluoroethylthio, ethylsulphinyl, trifluoromethylsulphinyl, difluoromethylsulphinyl, difluoroethylsulphinyl, trifluoroethylsulphinyl, methylsulphonyl, ethylsulphonyl, trifluoromethyl sulphonyl, difluoromethylsulphonyl, difluoroethylsulphonyl, trifluoroethylsulphonyl, R2 represents hydrogen, fluorine, chlorine, bromine, iodine, cyano, nitro, methyl, ethyl, difluoromethyl, trifluoromethyl, chloro-difluoromethyl, pentafluoroethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, chloro-difluoro-methoxy, difluoroethoxy, trifluoroethoxy methylthio, ethylthio, trifluoromethylthio, difluoromethylthio, difluoroethylthio, trifluoroethylthio, trifluoromethylsulphinyl, difluoromethylsulphinyl, difluoroethylsulphinyl, trifluoroethylsulphinyl, methylsulphonyl, ethylsulphonyl, trifluoromethylsulphonyl, difluoromethylsulphonyl, difluoroethylsulphonyl, trifluoroethylsulphonyl, R3 represents fluorine, chlorine, bromine, iodine, cyano, nitro, methyl, ethyl, difluoromethyl, trifluoromethyl, chloro-difluoromethyl, pentafluoroethyl, cyclopropyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, chloro-difluoro-methoxy, difluoroethoxy, trifluoroethoxy, methylthio, ethylthio, trifluoromethylthio, difluoromethylthio, difluoroethylthio, trifluoroethylthio, methylsulphinyl, ethylsulphinyl, trifluoromethylsulphinyl, difluoromethylsulphinyl, difluoroethylsulphinyl, trifluoroethylsulphinyl, methylsulphonyl, ethylsulphonyl, trifluoromethylsulphonyl, difluoromethylsulphonyl, difluoroethylsulphonyl, trifluoroethylsulphonyl R4 represents hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano, methyl, ethyl, difluoromethyl, trifluoromethyl, chloro-difluoromethyl, pentafluoroethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, chloro-difluoro-methoxy, difluoroethoxy, trifluoroethoxy, methylthio, ethylthio, trifluoromethylthio, difluoromethylthio, difluoroethylthio, trifluoroethylthio, trifluoromethylsulphinyl, difluoromethylsulphinyl, difluoroethylsulphinyl, trifluoroethylsulphinyl, methylsulphonyl, ethylsulphonyl, trifluoromethylsulphonyl, difluoromethylsulphonyl, difluoroethylsulphonyl, trifluoroethylsulphonyl. 7. Compound of formula (I-3) in which D represents a radical from the group consisting of in which the broken line represents the bond to the carbon atom in C=Q, E represents hydrogen, Q represents oxygen, R1 represents fluorine, chlorine, bromine, iodine, R2 represents hydrogen, R3 represents fluorine, chlorine, bromine, iodine, difluoromethyl, trifluoromethyl, chloro-difluoromethyl, pentafluoroethyl, and R4 represents hydrogen. 8. Composition comprising, at least one compound according to 9. Method for controlling one or more pests, comprising allowing a compound of the formula (I) according to 10. A compound according to 11. 3-(2,6-Difluorophenyl)-1,2,4-thiadiazol-5-amine. 12. 3-(2-Chloropyridin-3-yl)-1,2,4-thiadiazol-5-amine.PREPARATION EXAMPLES
Synthesis Example 1
N-[3-(2,6-difluorophenyl)-1,2,4-thiadiazol-5-yl]-2,6-difluorobenzamide (Compound I-1-1 in Table 1)
Step 1: Preparation of 2,6-difluorobenzenecarboximidamide
Step 2: Preparation of N-bromo-2,6-difluorobenzenecarboximidamide
Step 3: Preparation of 3-(2,6-difluorophenyl)-1,2,4-thiadiazol-5-amine
Synthesis Example 2
2-Bromo-N-[3-(2,6-difluorophenyl)-1,2,4-thiadiazol-5-yl]benzamide (Compound I-1-5 in Table 1)
Synthesis Example 3
2-Bromo-N-[3-(2-chlorophenyl)-1,2,4-thiadiazol-5-yl]benzamide (Compound I-1-21 in Table 1)
Synthesis Example 4
2-Chloro-N-[3-(2,6-difluorophenyl)-1,2,4-thiadiazol-5-yl]nicotinamide (Compound I-1-29 in Table 1)
Synthesis Example 5
Sodium [3-(2,6-difluorophenyl)-1,2,4-thiadiazol-5-yl]{[2-(trifluoromethyl)pyridin-3-yl]carbonyl}azanide (Compound I-1-30 in Table 1)
Synthesis Example 6
N-[3-(2,6-Difluorophenyl)-1,2,4-thiadiazol-5-yl]-2-(trifluoromethyl)-N-{[2-(trifluoromethyl)pyridin-3-yl]carbonyl}nicotinamide (Compound I-1-31 in Table 1)
Synthesis Example 7
N-[3-(2,6-Difluorophenyl)-1,2,4-thiadiazol-5-yl]-N-ethyl-2-(trifluoromethyl)nicotinamide (Compound I-1-34 in Table 1)
Synthesis Example 8
N-[3-(2,6-Difluorophenyl)-1,2,4-thiadiazol-5-yl]-2-ethylnicotinamide (Compound I-1-36 in Table 1)
Synthesis Example 9
N-{3-[2-(Trifluoromethoxy)phenyl]-1,2,4-thiadiazol-5-yl}-2-(trifluoromethyl)nicotinamide (Compound I-1-55 in Table 1)
Synthesis scheme for N-(3-bromo-1,2,4-thiadiazol-5-yl)-2-(trifluoromethyl)nicotinamide
Step 1: Preparation of 3-bromo-1,2,4-thiadiazol-5-amine
Preparation of N-(3-bromo-1,2,4-thiadiazol-5-yl)-2-(trifluoromethyl)nicotinamide
Synthesis Example 10
N-{3-[2-(trifluoromethoxy)phenyl]-1,2,4-thiadiazol-5-yl}-2-(trifluoromethyl)benzamide
Preparation of N-{3-[2-(trifluoromethoxy)phenyl]-1,2,4-thiadiazol-5-yl}-2-(trifluoromethyl)benzamide
Synthesis Example 11
N-{3-[2-Chloro-3-(trifluoromethyl)phenyl]-1,2,4-thiadiazol-5-yl}-2-(trifluoromethyl)nicotinamide (Compound I-1-62 in Table 1)
Synthesis Example 12
N-{3-[2,6-Bis(trifluoromethyl)phenyl]-1,2,4-thiadiazol-5-yl}-2-(trifluoromethyl)nicotinamide (Compound I-1-65 in Table 1)
N-{3-[2,4-Bis(trifluoromethyl)phenyl]-1,2,4-thiadiazol-5-yl}-2-(trifluoromethyl)nicotinamide (Compound I-1-66 in Table 1)
Synthesis Example 13
N-[3-(2-Cyanophenyl)-1,2,4-thiadiazol-5-yl]-2-(trifluoromethyl)nicotinamide (Compound I-1-67 in Table 1)
N-[3-(2,6-Dicyanophenyl)-1,2,4-thiadiazol-5-yl]-2-(trifluoromethyl)nicotinamide (Compound I-1-78 in Table 1)
Synthesis Example 14
N-{3-[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]-1,2,4-thiadiazol-5-yl}-2-(trifluoromethyl)nicotinamide (Compound I-2-3 in Table 2)
Synthesis Example 15
2-Chloro-N-[3-(3-chloropyridin-2-yl)-1,2,4-thiadiazol-5-yl]benzamide (Compound I-2-6 in Table 2)
Synthesis scheme for 3-(3-chloropyridin-2-yl)-1,2,4-thiadiazol-5-amine
Step 1: Preparation of 3-chloropyridine-2-carboximidamide
Step 2: Preparation of 3-(3-chloropyridin-2-yl)-1,2,4-thiadiazol-5-amine
Synthesis Example 16
N-[3-(2-Chloropyridin-3-yl)-1,2,4-thiadiazol-5-yl]-2-(trifluoromethyl)benzamide (Compound I-3-1 in Table 3)
(I-1) Compound No. D E R1 R2 Q I-1-1 2,6-difluorophenyl H F 6-F O Synthesis Example 1 I-1-2 2-fluorophenyl H F 6-F O I-1-3 2-chlorophenyl H F 6-F O I-1-4 2-trifluoromethyl phenyl H F 6-F O I-1-5 2-bromophenyl H F 6-F O Synthesis Example 2 I-1-6 3-(2-trifluoromethyl) H F 6-F O pyridinyl I-1-7 3-(2-trifluoromethyl) H F 6-F O pyrazinyl I-1-8 2-iodophenyl H F 6-F O I-1-9 2-difluoromethyl phenyl H F 6-F O I-1-10 2-nitrophenyl H F 6-F O I-1-11 2-trifluoromethy1-3- H F 6-F O fluorophenyl I-1-12 2-trifluoromethy1-6- H F 6-F O fluorophenyl I-1-13 2-(3-trifluoromethyl) H F 6-F O pyridinyl I-1-14 3-(2-difluoromethyl) H F 6-F O pyridinyl I-1-15 2,6-difluorophenyl H CF3 H O I-1-16 2-bromophenyl H CF3 H O I-1-17 2-chlorophenyl H CF3 H O I-1-18 2-trifluoromethyl phenyl H CF3 H O I-1-19 2-(3-trifluoromethyl) H CF3 H O pyridinyl I-1-20 3-(2-trifluoromethyl) H CF3 H O pyridinyl I-1-21 2-bromophenyl H Cl H O Synthesis Example 3 I-1-22 2-chlorophenyl H Cl H O I-1-23 2-trifluoromethyl phenyl H Cl H O I-1-24 2-(3-chloro)pyridinyl H Cl H O I-1-25 2-fluorophenyl H Cl H O I-1-26 2-iodophenyl H Cl H O I-1-27 2-trifluoromethyl-6- H Cl H O fluorophenyl I-1-28 2-fluorophenyl H CN H O I-1-29 3-(2-chloro) pyridinyl H F 6-F O Synthesis Example 4 I-1-30 3-(2-trifluoromethyl) Na F 6-F O Synthesis Example 5 pyridinyl I-1-31 3-(2-trifluoromethyl) CO-3-(2-CF3) F 6-F O Synthesis Example 6 pyridinyl pyridinyl I-1-32 3,5-(2-trifluoromethyl) H F 6-F O pyrimidinyl I-1-33 3-(2-methoxy) pyridinyl H F 6-F O I-1-34 3-(2-trifluoromethyl) Et F 6-F O Synthesis Example 7 pyridinyl I-1-35 2-(trifluoromethyl)-4,5- H F 6-F O dihydro-3,6-oxathiinyl I-1-36 3-(2-ethyl) pyridinyl H F 6-F O Synthesis Example 8 I-1-37 3-(2-pentafluoroethyl) H F 6-F O pyridinyl I-1-38 2-(2,2,2-trifluoroethyl)- H F 6-F O 3-pyridinyl I-1-39 2-(difluoromethyl)-4,5- H F 6-F O dihydro-3,6-oxathiinyl I-1-40 3-(2-methyl) pyrazinyl H F 6-F O I-1-41 2-methylphenyl H Cl H O I-1-42 3-(2-chloro) pyridinyl H Cl H O I-1-43 3-(2-trifluoromethyl) H Cl H O pyridinyl I-1-44 3-(2-trifluoromethyl) H Cl H O pyrazinyl I-1-45 3-(2-methoxy) pyridinyl H Cl H O I-1-46 3-(2-pentafluoroethyl) H Cl H O pyridinyl I-1-47 2-(2,2,2-trifluoroethyl)- H Cl H O 3-pyridinyl I-1-48 3-(2-ethyl) pyridinyl H Cl H O I-1-49 2-(methyl)-4,5-dihydro- H CF3 H O 3,6-oxathiinyl I-1-50 3,6-(2-trifluoromethyl) H CF3 H O pyrazinyl I-1-51 3-(2-chloro) pyridinyl H CF3 H O I-1-52 3-(2-pentafluoroethyl) H CF3 H O pyridinyl I-1-53 3-(2-trifluoromethyl) H CH3 H O pyridinyl I-1-54 3-(2-trifluoromethyl) H OCH3 H O pyridinyl I-1-55 3-(2-trifluoromethyl) H OCF3 H O Synthesis Example 9 pyridinyl I-1-56 3-(2-trifluoromethyl) H F 4-F O pyridinyl I-1-57 3-(2-trifluoromethyl) H F H O pyridinyl I-1-58 3-(2-trifluoromethyl) H C2H5 H O pyridinyl I-1-58 3-(2-trifluoromethyl) H C2H5 H O pyridinyl I-1-59 3-(2-trifluoromethyl) H CH(CH3)2 H O pyridinyl I-1-60 3-(2-trifluoromethyl) H CF3 4-F O pyridinyl I-1-61 3-(2-trifluoromethyl) H CF3 3-F O pyridinyl I-1-62 3-(2-trifluoromethyl) H Cl 3-CF3 O Synthesis Example 11 pyridinyl I-1-63 3-(2-trifluoromethyl) H Cl 6-Cl O pyridinyl I-1-64 3-(2-trifluoromethyl) H CF3 5-F O pyridinyl I-1-65 3-(2-trifluoromethyl) H CF3 6-CF3 O Synthesis Example 12 pyridinyl I-1-66 3-(2-trifluoromethyl) H CF3 4-CF3 O Synthesis Example 12 pyridinyl I-1-67 3-(2-trifluoromethyl) H CN H O Synthesis Example 13 pyridinyl I-1-68 2-trifluoromethyl phenyl H CH3 H O I-1-69 2-trifluoromethyl phenyl H CF3 5-F O I-1-70 2-trifluoromethyl phenyl H OCF3 H O Synthesis Example 10 I-1-71 2-trifluoromethyl phenyl H F 4-F O I-1-72 2-trifluoromethyl phenyl H OCH3 H O I-1-73 2-trifluoromethyl phenyl H F H O I-1-74 2-trifluoromethyl phenyl H CH(CH3)2 H O I-1-75 2-trifluoromethyl phenyl H CF3 4-F O I-1-76 2-trifluoromethyl phenyl H CF3 3-F O I-1-77 2-trifluoromethyl- H F 6-F O 3-chloro phenyl I-1-78 3-(2-trifluoromethyl) H CN 6-CN O Synthesis Example 13 pyridinyl (I-2) Compound No. D E R1 R2 Q I-2-1 2-fluorophenyl H Cl 5-CF3 O I-2-2 2-trifluoromethyl phenyl H Cl 5-CF3 O I-2-3 3-(2-trifluoromethyl) H Cl 5-CF3 O Synthesis Example 14 pyridinyl I-2-4 2-trifluoromethyl phenyl H Cl H O I-2-5 3-(2-trifluoromethyl) H Cl H O pyridinyl I-2-6 2-chloro phenyl H Cl H O Synthesis Example 15 I-2-7 3-(2-trifluoromethyl) H F 5-F O pyridinyl (1-3) Compound No. D E R1 R2 Q I-3-1 2-trifluoromethyl phenyl H Cl H O I-3-2 3-(2-trifluoromethyl) pyridinyl H Cl H O I-3-3 3-(2-chloro) pyridinyl H Cl H O I-3-4 H Cl H O I-3-5 2-iodo phenyl H Cl H O
δ1(intensity1);δ2(intensity2); . . . ;δi(intensityi); . . . ;Sn(intensityn)Example I-1-1: HPLC-MS: mass (m/z): 354.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.136(5.3); 8.316(0.4); 7.758(0.7); 7.738(2.0); 7.721(3.1); 7.701(2.1); 7.682(2.0); 7.666(2.8); 7.661(2.6); 7.645(5.2); 7.628(2.9); 7.624(3.1); 7.607(1.5); 7.358(5.9); 7.337(10.9); 7.320(11.6); 7.307(3.3); 7.300(16.0); 7.279(7.7); 7.270(1.9); 7.249(1.0); 7.228(0.5); 4.038(0.5); 4.021(0.4); 3.329(329.8); 2.681(0.6); 2.676(1.3); 2.672(1.7); 2.667(1.3); 2.663(0.6); 2.525(5.9); 2.512(100.3); 2.507(197.4); 2.503(257.0); 2.498(183.8); 2.494(87.3); 2.339(0.6); 2.334(1.3); 2.330(1.7); 2.325(1.2); 2.321(0.6); 1.989(1.7); 1.398(6.1); 1.253(0.7); 1.193(0.5); 1.175(1.0); 1.158(0.5); 1.122(0.4); 0.146(0.6); 0.008(4.8); 0.000(129.8); −0.009(4.3); −0.150(0.5) Example I-1-2: HPLC-MS: mass (m/z): 336.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.744(4.1); 7.894(2.7); 7.889(3.0); 7.875(5.4); 7.871(5.7); 7.856(3.1); 7.852(3.1); 7.736(1.3); 7.731(1.3); 7.723(1.5); 7.717(3.0); 7.714(2.7); 7.697(3.2); 7.692(1.8); 7.683(1.8); 7.678(2.7); 7.662(2.8); 7.657(2.6); 7.645(1.9); 7.641(5.3); 7.636(1.9); 7.624(2.7); 7.620(3.1); 7.603(1.5); 7.455(4.1); 7.434(3.9); 7.429(4.7); 7.419(5.1); 7.408(4.0); 7.400(8.4); 7.381(3.8); 7.324(1.6); 7.317(9.5); 7.303(2.0); 7.296(16.0); 7.289(2.2); 7.276(7.8); 7.268(1.6); 3.333(268.7); 2.676(0.9); 2.672(1.2); 2.667(0.9); 2.525(3.8); 2.512(72.5); 2.507(142.4); 2.503(185.4); 2.498(133.3); 2.494(64.0); 2.334(0.9); 2.330(1.2); 2.325(0.9); 1.397(0.5); 1.176(0.4); 0.146(0.4); 0.008(3.0); 0.000(77.8); −0.009(2.6); −0.150(0.4) Example I-1-3: HPLC-MS: mass (m/z): 352.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.845(1.1); 7.788(1.1); 7.785(1.1); 7.769(1.4); 7.765(1.4); 7.660(0.6); 7.654(0.8); 7.634(1.9); 7.630(2.0); 7.617(0.7); 7.608(0.9); 7.587(0.4); 7.537(0.7); 7.533(0.7); 7.518(1.0); 7.515(1.0); 7.501(0.5); 7.497(0.5); 7.321(0.3); 7.314(1.8); 7.300(0.5); 7.293(3.0); 7.273(1.5); 3.331(115.1); 3.328(118.2); 2.676(0.5); 2.671(0.7); 2.667(0.5); 2.524(2.4); 2.519(3.8); 2.511(41.7); 2.507(83.0); 2.502(108.5); 2.497(77.0); 2.493(35.9); 2.333(0.5); 2.329(0.7); 2.324(0.5); 1.989(0.8); 1.398(16.0); 1.175(0.5); 0.008(2.1); 0.000(58.1); −0.009(1.7) Example I-1-4: HPLC-MS: mass (m/z): 386.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.953(8.1); 7.948(4.9); 7.931(10.7); 7.913(7.3); 7.879(2.8); 7.863(6.1); 7.840(6.0); 7.818(4.7); 7.799(1.5); 7.679(1.3); 7.663(2.7); 7.658(2.6); 7.642(5.2); 7.626(2.8); 7.621(3.1); 7.605(1.4); 7.325(1.7); 7.318(9.4); 7.297(16.0); 7.277(7.9); 7.269(1.6); 3.324(37.2); 2.676(0.7); 2.672(1.0); 2.667(0.8); 2.542(1.7); 2.507(115.8); 2.502(151.6); 2.498(112.5); 2.334(0.7); 2.329(1.0); 2.325(0.7); 2.087(6.1); 0.008(2.4); 0.000(60.5); −0.009(2.7) Example I-1-5: HPLC-MS: mass (m/z): 396.9 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.832(7.0); 7.806(6.2); 7.803(5.2); 7.787(7.7); 7.783(7.0); 7.756(5.6); 7.751(6.6); 7.737(5.7); 7.732(7.0); 7.679(1.4); 7.663(2.9); 7.658(2.6); 7.646(2.0); 7.642(5.5); 7.637(2.0); 7.625(2.7); 7.620(3.2); 7.604(1.5); 7.581(2.3); 7.578(2.8); 7.562(6.9); 7.559(6.9); 7.544(7.4); 7.542(8.1); 7.537(6.7); 7.523(6.2); 7.518(6.0); 7.504(2.4); 7.499(1.9); 7.327(1.2); 7.324(1.6); 7.316(9.8); 7.303(2.1); 7.296(16.0); 7.289(2.2); 7.275(8.0); 7.267(1.4); 3.326(14.3); 3.176(1.5); 3.165(1.4); 2.677(0.4); 2.672(0.5); 2.668(0.3); 2.525(1.4); 2.512(28.2); 2.508(56.1); 2.503(73.1); 2.499(52.2); 2.494(24.7); 2.334(0.4); 2.330(0.5); 2.326(0.3); 0.146(0.3); 0.008(2.9); 0.000(75.0); −0.009(2.6); −0.150(0.3) Example I-1-6: HPLC-MS: mass (m/z): 387.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.085(6.7); 8.959(6.2); 8.947(6.1); 8.450(5.8); 8.430(6.2); 7.952(5.0); 7.940(5.1); 7.932(4.9); 7.920(4.6); 7.684(1.3); 7.668(2.8); 7.663(2.7); 7.652(2.1); 7.647(5.4); 7.631(2.8); 7.626(3.2); 7.610(1.4); 7.329(1.9); 7.322(9.4); 7.301(16.0); 7.281(7.8); 7.273(1.7); 3.326(21.4); 2.678(0.4); 2.674(0.5); 2.669(0.4); 2.509(60.9); 2.504(79.3); 2.500(59.6); 2.336(0.4); 2.331(0.5); 2.327(0.4); 2.076(1.0); 0.008(0.5); 0.000(10.0); −0.008(0.5) Example I-1-7: HPLC-MS: mass (m/z): 388.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 19.989(0.4); 14.289(2.5); 9.200(0.6); 9.171(9.3); 9.128(7.8); 8.313(2.6); 7.682(1.1); 7.666(2.8); 7.661(2.7); 7.645(5.2); 7.625(3.1); 7.608(1.4); 7.320(9.1); 7.300(16.0); 7.279(7.7); 7.199(0.5); 7.071(0.5); 6.944(0.5); 5.754(0.5); 3.432(0.5); 3.407(0.6); 3.391(0.8); 3.318(842.9); 3.185(0.4); 2.675(5.7); 2.670(7.6); 2.666(5.7); 2.574(0.8); 2.506(974.5); 2.501(1267.3); 2.497(924.6); 2.333(5.5); 2.328(7.4); 2.324(5.5); 1.235(0.8); 0.146(0.6); 0.008(5.1); 0.000(126.9); −0.008(5.0); −0.150(0.7) Example I-1-8: HPLC-MS: mass (m/z): 443.8 (M + H)+ 1H-NMR(601.6 MHz, d6-DMSO): δ = 13.769(3.4); 8.314(0.4); 8.012(2.5); 8.000(2.6); 7.674(2.0); 7.671(2.1); 7.661(2.6); 7.659(2.6); 7.654(1.0); 7.651(0.9); 7.640(1.5); 7.629(0.9); 7.626(1.0); 7.615(0.4); 7.573(1.4); 7.560(2.6); 7.558(2.5); 7.546(1.3); 7.339(1.2); 7.336(1.2); 7.326(1.9); 7.324(1.9); 7.313(1.5); 7.308(3.0); 7.294(4.9); 7.280(2.5); 4.035(0.5); 4.023(0.4); 3.325(59.5); 3.323(54.0); 3.322(54.4); 3.320(79.6); 2.613(0.9); 2.610(0.7); 2.523(1.3); 2.520(1.7); 2.517(1.6); 2.508(47.0); 2.505(104.3); 2.502(148.2); 2.499(108.3); 2.496(50.8); 2.386(1.0); 1.989(1.9); 1.398(16.0); 1.187(0.5); 1.175(1.1); 1.163(0.6); 0.005(0.6); 0.000(20.5); −0.006(0.7) Example I-1-9: HPLC-MS: mass (m/z): 368.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.919(6.7); 8.316(1.2); 7.981(5.0); 7.962(5.8); 7.844(3.1); 7.827(7.5); 7.811(3.8); 7.795(5.9); 7.776(2.9); 7.753(3.7); 7.736(4.7); 7.718(2.0); 7.680(1.8); 7.663(3.4); 7.659(2.8); 7.647(2.1); 7.642(5.6); 7.637(2.1); 7.626(2.8); 7.621(3.4); 7.605(2.0); 7.588(0.8); 7.582(0.9); 7.564(0.5); 7.521(2.3); 7.384(5.2); 7.327(1.9); 7.319(9.9); 7.298(16.0); 7.278(8.1); 7.270(1.6); 7.247(2.5); 7.045(0.3); 6.906(0.7); 6.769(0.3); 6.286(0.3); 3.557(0.4); 3.540(0.3); 3.323(386.7); 2.680(1.3); 2.675(2.7); 2.671(3.7); 2.666(2.7); 2.662(1.3); 2.541(2.8); 2.524(13.3); 2.511(216.9); 2.506(432.4); 2.502(567.6); 2.497(405.6); 2.493(192.0); 2.337(1.3); 2.333(2.7); 2.328(3.7); 2.324(2.6); 2.319(1.2); 2.189(1.0); 1.989(1.1); 1.459(0.4); 1.442(0.4); 1.398(3.3); 1.268(1.5); 1.251(1.4); 1.204(1.1); 1.187(2.4); 1.175(1.1); 1.170(1.2); 1.159(1.9); 1.142(1.7); 1.104(0.7); 1.091(0.6); 1.047(0.6); 0.931(0.6); 0.146(2.7); 0.008(26.8); 0.000(645.6); −0.009(22.4); −0.025(0.8); −0.031(0.5); −0.150(2.8) Example I-1-10: HPLC-MS: mass (m/z): 363.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.971(6.2); 8.316(0.7); 8.263(5.3); 8.243(6.0); 7.974(1.3); 7.957(5.0); 7.954(5.0); 7.941(15.0); 7.936(13.4); 7.923(3.0); 7.917(1.0); 7.907(0.4); 7.889(4.2); 7.883(3.2); 7.872(3.3); 7.868(4.6); 7.862(2.9); 7.852(2.7); 7.846(2.3); 7.679(1.3); 7.663(2.9); 7.658(2.6); 7.646(2.1); 7.641(5.3); 7.637(2.1); 7.625(2.7); 7.620(3.1); 7.604(1.4); 7.326(1.8); 7.318(9.5); 7.298(16.0); 7.277(7.8); 7.269(1.6); 3.322(125.2); 2.676(1.4); 2.671(1.8); 2.666(1.4); 2.541(38.9); 2.524(4.8); 2.511(112.5); 2.506(220.1); 2.502(284.4); 2.497(204.0); 2.493(98.2); 2.333(1.4); 2.329(1.9); 2.324(1.4); 2.074(0.4); 1.175(0.5); 1.158(0.5); 0.146(1.4); 0.008(15.4); 0.000(322.2); −0.009(12.4); −0.034(0.4); −0.150(1.4) Example I-1-11: HPLC-MS: mass (m/z): 404.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.036(7.0); 8.316(0.7); 7.958(1.5); 7.944(2.0); 7.937(3.4); 7.924(3.4); 7.917(2.5); 7.904(2.2); 7.775(3.0); 7.747(3.5); 7.724(7.7); 7.704(5.0); 7.681(1.4); 7.665(2.9); 7.660(2.5); 7.648(2.1); 7.643(5.3); 7.639(2.0); 7.627(2.7); 7.622(3.1); 7.606(1.4); 7.329(1.4); 7.326(2.0); 7.318(9.6); 7.304(2.7); 7.298(16.0); 7.277(7.8); 7.269(1.5); 3.322(102.6); 2.676(1.3); 2.671(1.7); 2.667(1.2); 2.662(0.6); 2.542(62.1); 2.511(104.2); 2.507(198.0); 2.502(253.2); 2.498(179.5); 2.493(85.0); 2.338(0.6); 2.333(1.2); 2.329(1.6); 2.324(1.2); 0.146(1.3); 0.008(17.2); 0.000(304.2); −0.009(11.2); −0.029(0.4); −0.150(1.3) Example I-1-12: HPLC-MS: mass (m/z): 403.9 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.253(8.3); 7.923(0.9); 7.903(2.7); 7.892(1.8); 7.884(4.2); 7.869(3.1); 7.857(4.4); 7.833(13.6); 7.812(5.2); 7.689(1.4); 7.672(2.8); 7.668(2.6); 7.656(1.9); 7.651(5.2); 7.647(1.9); 7.635(2.7); 7.630(3.1); 7.614(1.4); 7.334(1.7); 7.327(9.4); 7.313(2.1); 7.306(16.0); 7.285(7.6); 7.278(1.5); 5.760(3.2); 3.336(6.5); 3.024(0.5); 2.781(0.4); 2.676(0.4); 2.529(1.2); 2.516(20.1); 2.511(40.3); 2.507(52.9); 2.502(38.1); 2.498(18.2); 1.232(0.3); 0.000(4.8) Example I-1-13: HPLC-MS: mass (m/z): 387.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.077(4.4); 9.018(5.5); 9.007(5.4); 8.493(4.6); 8.473(4.9); 8.316(2.4); 7.934(3.0); 7.922(3.2); 7.915(3.1); 7.903(2.6); 7.683(1.3); 7.667(2.8); 7.662(2.5); 7.645(5.2); 7.629(2.8); 7.624(3.0); 7.608(1.3); 7.328(1.9); 7.321(9.4); 7.300(16.0); 7.280(7.8); 7.272(1.5); 3.382(0.5); 3.322(663.8); 2.675(5.5); 2.671(7.4); 2.666(5.3); 2.662(2.6); 2.603(0.5); 2.541(9.3); 2.524(20.1); 2.511(433.8); 2.506(860.9); 2.502(1118.2); 2.497(788.5); 2.493(366.9); 2.453(0.9); 2.333(5.3); 2.328(7.1); 2.324(5.1); 2.319(2.4); 2.074(0.7); 0.146(0.4); 0.008(3.9); 0.000(104.4); −0.008(3.5); −0.150(0.5) Example I-1-14: HPLC-MS: mass (m/z): 369.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.022(4.5); 8.909(5.8); 8.905(6.2); 8.897(6.2); 8.893(6.1); 8.388(5.5); 8.368(5.8); 8.316(1.0); 7.796(4.3); 7.784(4.3); 7.777(4.2); 7.764(4.0); 7.682(1.3); 7.666(2.8); 7.661(2.6); 7.649(1.9); 7.644(5.3); 7.628(2.7); 7.623(3.1); 7.607(1.4); 7.385(3.0); 7.328(1.6); 7.321(9.5); 7.300(16.0); 7.280(7.9); 7.272(1.5); 7.250(6.6); 7.116(3.3); 3.325(125.0); 2.995(0.9); 2.675(1.7); 2.671(2.3); 2.667(1.7); 2.541(22.1); 2.524(5.6); 2.511(131.5); 2.506(261.9); 2.502(342.7); 2.498(247.9); 2.493(120.4); 2.333(1.6); 2.329(2.2); 2.324(1.7); 1.469(0.4); 0.146(1.9); 0.008(15.4); 0.000(399.5); −0.008(14.8); −0.150(2.0) Example I-1-15: HPLC-MS: mass (m/z): 385.9 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.060(11.4); 8.316(1.6); 7.928(7.7); 7.908(9.5); 7.857(3.6); 7.842(11.2); 7.837(15.6); 7.818(8.7); 7.799(3.5); 7.773(4.8); 7.753(6.3); 7.737(4.8); 7.721(4.9); 7.703(3.0); 7.700(3.0); 7.683(1.3); 7.668(0.4); 7.650(0.4); 7.401(0.6); 7.359(8.9); 7.338(16.0); 7.317(7.7); 7.299(0.5); 7.278(0.5); 4.038(0.6); 4.020(0.6); 3.395(0.4); 3.377(0.5); 3.324(420.5); 2.680(1.3); 2.676(2.6); 2.671(3.6); 2.667(2.6); 2.541(2.2); 2.524(9.7); 2.520(15.7); 2.511(205.4); 2.507(417.9); 2.502(550.4); 2.498(392.5); 2.493(184.3); 2.338(1.2); 2.333(2.5); 2.329(3.5); 2.324(2.5); 2.320(1.2); 1.989(2.5); 1.398(8.4); 1.244(0.6); 1.227(0.6); 1.193(0.8); 1.179(1.0); 1.175(1.8); 1.157(0.9); 1.138(0.4); 1.121(1.3); 1.104(1.2); 0.146(1.3); 0.008(10.9); 0.000(313.4); −0.009(9.7); −0.150(1.3) Example I-1-16: HPLC-MS: mass (m/z): 428.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.767(10.4); 8.316(1.8); 7.923(6.9); 7.904(8.2); 7.842(2.3); 7.829(16.0); 7.823(11.0); 7.813(8.6); 7.801(6.5); 7.797(6.1); 7.782(7.4); 7.778(7.3); 7.766(3.9); 7.751(10.3); 7.746(12.0); 7.732(8.8); 7.728(9.8); 7.656(0.5); 7.636(0.5); 7.575(2.3); 7.572(2.8); 7.556(6.8); 7.553(6.8); 7.538(8.2); 7.517(4.9); 7.512(4.6); 7.498(1.8); 7.494(1.5); 7.430(0.4); 7.324(0.4); 7.305(0.4); 7.279(0.4); 3.464(0.3); 3.449(0.4); 3.432(0.3); 3.358(1.1); 3.324(929.0); 3.285(0.6); 3.076(0.4); 2.680(2.1); 2.675(4.4); 2.671(5.8); 2.666(4.2); 2.662(2.0); 2.541(3.8); 2.524(17.7); 2.511(333.2); 2.506(660.5); 2.502(861.2); 2.497(613.5); 2.493(289.0); 2.337(2.0); 2.333(4.1); 2.328(5.7); 2.324(4.1); 2.319(1.9); 1.989(0.4); 1.466(2.7); 1.449(2.7); 1.398(6.1); 1.199(0.5); 1.190(0.5); 1.176(1.5); 1.160(1.3); 1.106(1.2); 1.040(1.3); 1.024(1.2); 0.146(5.2); 0.043(0.4); 0.034(0.7); 0.008(51.6); 0.000(1193.8); −0.009(43.1); −0.039(0.8); −0.066(0.4); −0.150(5.3) Example I-1-17: HPLC-MS: mass (m/z): 383.9 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.786(8.5); 7.926(6.9); 7.906(8.2); 7.850(0.9); 7.844(2.2); 7.832(16.0); 7.825(10.4); 7.816(8.3); 7.796(2.6); 7.789(6.7); 7.786(7.0); 7.770(11.3); 7.766(10.6); 7.751(3.8); 7.749(4.1); 7.734(2.2); 7.728(1.6); 7.657(2.5); 7.654(3.8); 7.637(11.3); 7.633(14.2); 7.628(7.1); 7.615(8.2); 7.611(7.5); 7.595(3.2); 7.591(3.0); 7.562(0.4); 7.539(5.8); 7.535(5.5); 7.521(6.7); 7.517(6.3); 7.511(1.2); 7.503(4.1); 7.499(3.8); 7.495(0.8); 7.488(1.0); 7.420(0.5); 7.412(0.4); 7.402(2.0); 7.395(1.1); 7.393(0.9); 7.389(0.9); 7.386(1.1); 7.379(1.8); 7.301(0.9); 7.294(0.5); 7.291(0.5); 7.287(0.6); 7.278(0.6); 3.599(0.5); 3.582(0.7); 3.565(0.5); 3.475(0.5); 3.458(0.7); 3.441(0.5); 3.329(98.1); 3.077(2.4); 2.677(0.5); 2.672(0.7); 2.668(0.5); 2.543(0.4); 2.526(2.1); 2.512(38.2); 2.508(75.9); 2.503(99.1); 2.499(70.2); 2.494(32.7); 2.335(0.5); 2.330(0.6); 2.326(0.4); 1.469(4.0); 1.459(4.2); 1.452(4.0); 1.442(3.9); 1.427(0.6); 1.259(0.4); 1.234(0.4); 1.212(0.4); 1.194(0.9); 1.177(0.6); 1.166(0.8); 1.151(3.9); 1.134(3.6); 1.106(7.7); 1.050(0.8); 1.044(3.6); 1.033(0.9); 1.027(3.5); 0.146(0.7); 0.008(6.4); 0.000(150.5); −0.009(5.0); −0.150(0.7) Example I-1-18: HPLC-MS: mass (m/z): 418.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.883(7.2); 8.315(0.6); 8.053(0.6); 7.946(4.4); 7.925(14.3); 7.906(12.8); 7.874(2.7); 7.857(6.7); 7.832(16.0); 7.814(10.1); 7.795(3.9); 7.767(3.7); 7.748(4.3); 7.731(2.3); 7.698(0.4); 7.650(0.5); 7.628(0.6); 7.608(0.5); 7.458(0.3); 3.431(0.3); 3.324(277.7); 3.286(0.4); 3.268(0.3); 3.076(1.8); 2.670(2.2); 2.666(1.7); 2.540(1.4); 2.505(262.3); 2.501(334.4); 2.497(255.4); 2.328(2.2); 2.324(1.7); 1.467(1.2); 1.450(1.2); 1.426(0.5); 1.414(1.2); 1.397(1.2); 1.304(0.7); 1.287(0.7); 1.260(1.1); 1.242(1.0); 1.236(0.8); 1.221(0.3); 1.181(0.7); 1.164(1.4); 1.146(0.8); 1.105(5.7); 1.087(1.3); 1.080(1.4); 1.069(1.8); 1.051(2.0); 1.036(1.1); 0.936(0.4); 0.145(1.7); 0.007(14.7); −0.0005(324.0); −0.0010(326.9); −0.150(1.8) Example I-1-19: HPLC-MS: mass (m/z): 419.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.978(7.0); 9.023(9.2); 9.012(9.1); 9.011(9.1); 8.496(8.6); 8.494(8.8); 8.476(9.3); 8.474(9.2); 8.314(0.7); 7.940(6.8); 7.929(14.6); 7.920(7.2); 7.909(16.0); 7.864(4.4); 7.848(12.2); 7.845(12.6); 7.822(9.7); 7.803(4.1); 7.775(5.7); 7.773(5.7); 7.755(7.2); 7.738(2.8); 7.721(0.4); 5.754(4.5); 3.318(78.2); 3.182(0.6); 3.065(0.6); 2.681(0.6); 2.676(1.1); 2.672(1.5); 2.667(1.1); 2.512(82.2); 2.507(162.7); 2.503(219.5); 2.498(167.6); 2.494(85.1); 2.334(1.0); 2.329(1.4); 2.325(1.0); 1.234(0.7); 0.146(1.2); 0.008(12.5); 0.000(270.7); −0.008(11.7); −0.150(1.2) Example I-1-20: HPLC-MS: mass (m/z): 418.9 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.999(11.2); 8.948(8.3); 8.937(8.3); 8.444(7.6); 8.425(8.1); 8.314(1.3); 7.939(6.7); 7.927(14.9); 7.907(16.0); 7.880(0.4); 7.856(4.3); 7.836(14.8); 7.815(9.6); 7.796(3.9); 7.769(5.8); 7.750(6.9); 7.732(2.8); 3.316(102.3); 3.015(0.7); 2.675(2.5); 2.671(3.3); 2.666(2.6); 2.506(372.2); 2.501(493.7); 2.497(382.0); 2.332(2.3); 2.328(3.2); 2.324(2.5); 1.398(2.2); 0.146(2.7); 0.008(29.6); 0.000(559.3); −0.008(30.7); −0.044(0.3); −0.150(2.8) Example I-1-21: HPLC-MS: mass (m/z): 393.9 (M + H)+ 1H-NMR(400.0 MHz, CD3CN): δ = 11.163(0.5); 7.857(7.8); 7.853(6.2); 7.851(6.0); 7.839(10.2); 7.834(8.4); 7.768(7.6); 7.765(7.1); 7.749(9.8); 7.746(8.9); 7.673(6.8); 7.668(7.9); 7.655(7.8); 7.653(7.8); 7.649(9.3); 7.568(5.9); 7.564(7.5); 7.551(10.1); 7.548(11.3); 7.545(10.9); 7.532(10.2); 7.529(10.2); 7.514(8.0); 7.510(8.1); 7.507(9.0); 7.502(8.1); 7.493(4.4); 7.488(12.1); 7.483(8.7); 7.475(10.0); 7.469(11.4); 7.464(3.8); 7.456(16.0); 7.451(11.4); 7.438(9.9); 7.434(8.2); 7.419(3.3); 7.415(2.7); 5.448(1.2); 2.159(7.7); 2.115(1.7); 2.108(1.5); 2.102(1.2); 1.972(0.6); 1.965(3.0); 1.959(4.2); 1.953(26.8); 1.947(49.3); 1.941(67.0); 1.935(45.5); 1.929(23.1); 1.769(0.4); 1.436(1.1); 1.377(0.4); 1.372(0.7); 1.338(0.5); 1.283(0.6); 1.276(0.9); 1.268(0.5); 0.008(1.9); 0.000(43.5); −0.009(1.6) Example I-1-22: HPLC-MS: mass (m/z): 349.9 (M + H)+ 1H-NMR(400.0 MHz, CD3CN): δ = 11.219(0.4); 7.856(5.2); 7.851(4.3); 7.849(4.0); 7.837(6.9); 7.832(5.8); 7.720(4.3); 7.718(6.4); 7.715(4.5); 7.701(5.2); 7.699(6.5); 7.698(6.2); 7.696(5.3); 7.592(1.1); 7.584(11.0); 7.581(13.7); 7.574(11.4); 7.572(16.0); 7.569(8.9); 7.566(5.5); 7.561(5.6); 7.552(1.4); 7.547(5.1); 7.545(5.5); 7.542(6.7); 7.524(0.3); 7.515(1.0); 7.504(4.8); 7.494(5.4); 7.493(5.3); 7.490(3.6); 7.485(7.3); 7.483(4.3); 7.476(4.3); 7.472(8.7); 7.467(6.5); 7.464(3.7); 7.454(10.9); 7.448(8.2); 7.435(6.7); 7.431(5.6); 7.416(2.2); 7.413(1.8); 5.448(0.7); 2.169(6.7); 2.115(0.8); 2.109(0.7); 2.103(0.6); 2.096(0.4); 1.965(1.5); 1.959(2.1); 1.954(13.1); 1.947(24.3); 1.941(33.2); 1.935(22.8); 1.929(11.6); 1.371(0.5); 1.283(0.4); 1.275(0.6); 1.267(0.5); 0.008(1.0); 0.000(21.1); −0.009(0.7) Example I-1-23: HPLC-MS: mass (m/z): 384.0 (M + H)+ 1H-NMR(400.0 MHz, CD3CN): δ = 11.145(0.5); 7.903(2.5); 7.895(1.1); 7.888(3.5); 7.883(2.4); 7.855(3.9); 7.850(3.3); 7.837(4.8); 7.831(4.4); 7.807(2.6); 7.796(16.0); 7.793(15.3); 7.779(2.8); 7.769(1.7); 7.755(0.6); 7.569(2.9); 7.565(3.6); 7.551(3.7); 7.549(3.8); 7.546(5.0); 7.494(1.7); 7.489(2.2); 7.476(4.6); 7.471(4.2); 7.457(6.9); 7.452(6.6); 7.438(4.8); 7.434(4.1); 7.419(1.6); 7.416(1.5); 5.447(1.4); 2.145(6.7); 2.107(0.8); 2.101(0.6); 1.964(2.2); 1.958(2.7); 1.952(16.3); 1.946(29.6); 1.940(39.9); 1.934(27.2); 1.927(13.9); 1.679(0.7); 1.663(0.6); 1.268(0.3); 0.008(0.7); 0.000(16.8); −0.009(0.5) Example I-1-24: HPLC-MS: mass (m/z): 350.9 (M + H)+ 1H-NMR(400.0 MHz, CD3CN): δ = 11.728(2.0); 8.655(14.4); 8.652(14.5); 8.644(14.8); 8.640(14.2); 8.057(14.1); 8.054(13.9); 8.036(16.0); 8.033(15.0); 7.903(0.4); 7.889(11.2); 7.888(11.2); 7.884(9.0); 7.881(8.1); 7.871(14.6); 7.865(12.2); 7.855(0.4); 7.849(0.4); 7.657(15.5); 7.646(15.0); 7.637(14.1); 7.625(13.7); 7.568(8.3); 7.564(10.8); 7.551(9.5); 7.549(10.6); 7.546(13.9); 7.530(0.7); 7.491(4.7); 7.486(5.9); 7.473(14.3); 7.468(13.1); 7.457(15.9); 7.455(15.6); 7.452(15.1); 7.448(11.0); 7.439(14.8); 7.435(12.0); 7.420(4.8); 7.416(3.6); 5.448(3.6); 4.068(0.5); 4.050(0.6); 3.602(0.4); 2.158(50.4); 2.121(1.2); 2.114(1.1); 2.108(1.1); 2.102(0.8); 2.096(0.5); 1.972(2.9); 1.965(5.0); 1.959(5.9); 1.953(39.2); 1.947(72.2); 1.941(99.0); 1.935(67.9); 1.928(34.6); 1.775(0.5); 1.769(0.6); 1.763(0.4); 1.436(2.3); 1.371(3.3); 1.339(0.8); 1.284(1.2); 1.276(4.0); 1.265(1.4); 1.222(0.8); 1.204(1.4); 1.186(0.8); 0.008(1.8); 0.000(46.2); −0.009(1.6) Example I-1-25: HPLC-MS: mass (m/z): 351.9 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.075(8.2); 13.921(0.5); 8.316(2.5); 7.927(0.4); 7.875(8.2); 7.870(7.5); 7.856(10.3); 7.851(9.2); 7.756(1.3); 7.739(2.8); 7.735(2.9); 7.718(4.8); 7.698(3.0); 7.681(1.3); 7.658(0.5); 7.649(0.7); 7.638(6.9); 7.635(7.7); 7.618(9.6); 7.615(10.8); 7.607(1.1); 7.585(1.4); 7.559(4.1); 7.555(4.7); 7.541(9.2); 7.536(8.4); 7.522(6.9); 7.516(7.1); 7.514(9.0); 7.509(8.1); 7.495(9.9); 7.491(9.2); 7.476(3.7); 7.473(3.0); 7.426(0.4); 7.356(9.0); 7.335(16.0); 7.314(7.7); 7.274(0.3); 7.225(2.6); 7.204(4.6); 7.183(2.2); 3.687(0.6); 3.505(0.7); 3.487(0.5); 3.469(0.6); 3.396(0.3); 3.323(444.0); 3.163(0.5); 3.145(0.5); 3.024(0.6); 2.945(0.3); 2.857(0.5); 2.680(2.4); 2.676(5.0); 2.671(6.9); 2.666(4.9); 2.662(2.3); 2.572(0.9); 2.524(22.5); 2.511(404.6); 2.506(803.5); 2.502(1045.5); 2.497(740.9); 2.493(346.7); 2.338(2.4); 2.333(5.0); 2.329(6.8); 2.324(4.7); 2.320(2.2); 1.258(0.4); 1.235(1.6); 1.162(0.6); 1.145(1.2); 1.127(0.5); 1.023(0.5); 1.005(0.9); 0.987(0.4); 0.146(0.7); 0.008(6.3); 0.000(175.2); −0.009(5.6); −0.150(0.6) Example I-1-26: HPLC-MS: mass (m/z): 441.9 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 8.316(1.0); 7.988(2.3); 7.969(2.7); 7.954(0.8); 7.850(2.6); 7.845(2.2); 7.832(3.3); 7.827(3.0); 7.690(0.4); 7.673(3.1); 7.669(3.4); 7.654(3.8); 7.650(3.8); 7.609(1.8); 7.590(2.6); 7.545(1.2); 7.526(2.8); 7.506(2.8); 7.492(3.6); 7.487(3.3); 7.473(2.6); 7.469(2.4); 7.455(1.1); 7.273(1.2); 7.234(0.4); 7.214(0.5); 4.055(1.2); 4.038(3.5); 4.020(3.6); 4.002(1.2); 3.322(144.1); 2.680(1.0); 2.675(2.0); 2.671(2.8); 2.666(2.0); 2.661(0.9); 2.524(8.4); 2.519(12.8); 2.511(154.9); 2.506(312.0); 2.501(410.2); 2.497(290.9); 2.492(135.5); 2.337(0.9); 2.333(1.9); 2.328(2.6); 2.324(1.8); 2.319(0.9); 1.989(16.0); 1.234(0.9); 1.193(4.4); 1.175(8.6); 1.157(4.3); 0.008(0.9); 0.000(25.5); −0.009(0.7) Example I-1-27: HPLC-MS: mass (m/z): 401.9 (M + H)+ 1H-NMR(601.6 MHz, CD3CN): δ = 7.845(5.3); 7.842(4.6); 7.841(4.9); 7.832(6.9); 7.829(5.9); 7.765(1.3); 7.752(2.7); 7.742(2.4); 7.739(1.8); 7.729(1.7); 7.692(6.1); 7.679(3.9); 7.626(0.4); 7.624(0.3); 7.615(0.4); 7.612(0.8); 7.611(0.8); 7.606(0.6); 7.603(0.8); 7.602(0.8); 7.599(0.7); 7.598(0.8); 7.590(0.8); 7.589(0.8); 7.580(2.5); 7.576(2.9); 7.561(4.7); 7.557(5.2); 7.555(6.2); 7.545(6.3); 7.544(5.9); 7.542(6.3); 7.517(0.4); 7.509(0.6); 7.507(0.7); 7.497(0.5); 7.496(0.5); 7.494(0.6); 7.474(2.8); 7.471(3.9); 7.461(6.5); 7.458(6.3); 7.449(5.1); 7.445(4.7); 7.441(6.4); 7.438(6.2); 7.435(0.5); 7.428(7.3); 7.426(7.0); 7.418(0.8); 7.416(3.0); 7.414(2.8); 7.405(0.5); 7.402(0.4); 7.396(0.5); 7.394(0.5); 7.384(0.6); 7.381(0.6); 7.369(0.4); 4.077(2.0); 4.065(6.1); 4.053(6.0); 4.041(2.1); 3.049(2.7); 2.993(2.2); 2.985(2.2); 2.800(1.8); 2.054(0.5); 2.050(0.8); 2.046(0.5); 1.971(28.0); 1.963(5.5); 1.955(9.1); 1.951(9.6); 1.947(53.3); 1.943(93.0); 1.939(132.5); 1.935(87.4); 1.931(46.6); 1.926(1.8); 1.922(0.9); 1.832(0.3); 1.828(0.6); 1.824(0.9); 1.820(0.6); 1.360(0.3); 1.340(0.9); 1.307(0.4); 1.285(1.5); 1.269(2.9); 1.263(1.1); 1.215(8.0); 1.204(16.0); 1.192(8.3); 0.893(0.3); 0.881(0.7); 0.869(0.5); 0.846(0.3); 0.096(0.5); 0.005(3.7); 0.000(142.5); −0.006(4.2); −0.100(0.5) Example I-1-28: HPLC-MS: mass (m/z): 343.1 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.168(7.1); 8.314(1.3); 8.275(9.0); 8.273(9.6); 8.255(10.5); 8.253(10.2); 8.027(8.7); 8.010(9.2); 8.008(9.6); 7.900(4.7); 7.897(4.9); 7.881(9.3); 7.878(9.3); 7.862(5.5); 7.858(5.5); 7.759(1.1); 7.745(7.4); 7.742(8.6); 7.726(11.6); 7.723(13.6); 7.707(6.2); 7.704(7.0); 7.684(1.2); 7.359(8.9); 7.338(16.0); 7.317(7.7); 3.317(425.8); 2.680(1.3); 2.675(2.7); 2.671(3.8); 2.666(2.8); 2.662(1.4); 2.524(8.4); 2.519(13.2); 2.511(220.4); 2.506(471.4); 2.502(640.6); 2.497(463.4); 2.493(222.3); 2.425(0.3); 2.338(1.3); 2.333(2.7); 2.328(3.8); 2.324(2.8); 2.074(1.4); 0.008(2.0); 0.000(71.6); −0.009(2.4) Example I-1-29: HPLC-MS: mass (m/z): 352.9 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.979(8.2); 8.631(6.0); 8.627(6.5); 8.619(6.5); 8.614(6.4); 8.313(0.5); 8.284(6.3); 8.279(6.5); 8.265(6.9); 8.260(6.7); 7.680(1.2); 7.664(2.8); 7.659(2.9); 7.649(7.7); 7.643(6.2); 7.637(8.3); 7.630(7.4); 7.618(6.9); 7.606(1.5); 7.324(1.7); 7.317(9.1); 7.297(16.0); 7.276(7.7); 3.316(93.5); 2.671(1.4); 2.506(158.6); 2.502(209.0); 2.498(166.2); 2.329(1.4); 0.000(10.2) Example I-1-30: HPLC-MS: mass (m/z): 386.0 ([M − Na+ + H+] + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 8.694(2.7); 8.685(2.7); 8.683(2.7); 8.529(0.5); 8.315(3.9); 8.144(2.5); 8.126(2.7); 8.124(2.7); 7.721(2.5); 7.709(2.5); 7.702(2.4); 7.690(2.2); 7.542(0.7); 7.525(1.4); 7.520(1.3); 7.509(1.0); 7.504(2.7); 7.500(1.0); 7.488(1.3); 7.483(1.6); 7.467(0.7); 7.209(0.4); 7.205(0.6); 7.195(4.2); 7.188(0.7); 7.184(0.8); 7.175(6.2); 7.166(0.9); 7.155(3.5); 7.144(0.5); 4.100(0.6); 4.088(0.5); 3.722(0.4); 3.327(32.2); 3.300(23.3); 3.206(0.4); 3.159(16.0); 2.675(0.9); 2.671(1.3); 2.667(0.9); 2.524(4.6); 2.519(7.0); 2.511(74.8); 2.506(151.2); 2.502(198.3); 2.497(143.0); 2.493(69.4); 2.333(0.8); 2.329(1.2); 2.324(0.8); 0.008(1.0); 0.000(28.1); −0.008(1.0) Example I-1-31: HPLC-MS: mass (m/z): 560.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.074(0.7); 8.953(2.2); 8.938(13.6); 8.926(12.5); 8.855(1.7); 8.843(1.8); 8.627(10.7); 8.607(11.2); 8.444(1.6); 8.424(1.7); 8.315(0.7); 8.273(1.6); 8.253(1.7); 7.948(1.3); 7.935(1.3); 7.928(1.4); 7.916(1.2); 7.894(9.6); 7.882(9.8); 7.874(9.6); 7.862(9.1); 7.841(1.4); 7.829(1.4); 7.821(1.3); 7.809(1.2); 7.681(0.4); 7.661(0.9); 7.644(1.5); 7.623(1.0); 7.606(0.5); 7.597(1.3); 7.581(2.6); 7.576(2.6); 7.560(5.0); 7.543(2.7); 7.539(3.0); 7.523(1.3); 7.319(2.7); 7.298(4.7); 7.278(2.2); 7.184(8.8); 7.163(16.0); 7.142(7.5); 3.322(104.2); 2.672(1.7); 2.508(225.2); 2.504(296.0); 2.499(220.6); 2.334(1.3); 2.330(1.8); 2.326(1.3); 2.075(13.9); 0.146(1.4); 0.008(12.4); 0.000(283.6); −0.008(12.1); −0.150(1.4) Example I-1-32: HPLC-MS: mass (m/z): 388.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.252(0.5); 9.670(7.1); 9.572(8.0); 7.693(0.5); 7.677(1.1); 7.672(1.0); 7.660(0.8); 7.655(2.2); 7.651(0.8); 7.639(1.1); 7.634(1.3); 7.618(0.6); 7.341(0.5); 7.337(0.7); 7.330(3.9); 7.309(6.6); 7.288(3.2); 7.281(0.6); 3.343(8.6); 2.513(14.3); 2.508(18.8); 2.504(13.6); 2.499(6.6); 2.079(16.0); 0.000(0.5) Example I-1-33: HPLC-MS: mass (m/z): 349.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.223(1.2); 8.438(1.4); 8.434(1.6); 8.426(1.5); 8.421(1.5); 8.313(0.4); 8.185(1.5); 8.180(1.5); 8.166(1.6); 8.161(1.5); 7.661(0.7); 7.656(0.7); 7.640(1.4); 7.623(0.8); 7.618(0.9); 7.602(0.4); 7.320(0.4); 7.313(2.2); 7.292(3.8); 7.272(1.9); 7.218(1.5); 7.206(1.5); 7.199(1.5); 7.187(1.5); 3.995(16.0); 3.318(137.2); 2.675(0.8); 2.670(1.1); 2.666(0.8); 2.510(65.1); 2.506(133.9); 2.501(179.5); 2.497(133.1); 2.333(0.7); 2.328(1.0); 2.324(0.8); 0.000(6.1) Example I-1-34: HPLC-MS: mass (m/z): 415.1 (M + H)+ 1H-NMR(600.1 MHz, d6-DMSO): δ = 9.022(3.8); 9.014(3.9); 8.538(3.7); 8.525(3.9); 8.011(3.0); 8.003(3.1); 7.997(3.1); 7.989(2.9); 7.687(0.7); 7.676(1.6); 7.673(1.6); 7.662(3.0); 7.651(1.7); 7.648(1.8); 7.637(0.8); 7.332(1.0); 7.327(5.3); 7.314(9.1); 7.300(4.7); 4.006(1.5); 3.332(296.9); 2.617(0.4); 2.614(0.3); 2.526(0.7); 2.522(0.9); 2.519(0.9); 2.508(48.1); 2.505(65.9); 2.502(49.9); 2.388(0.4); 2.076(1.2); 1.234(7.5); 1.223(16.0); 1.211(7.4); 0.000(0.8) Example I-1-35: HPLC-MS: mass (m/z): 410.1 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 19.971(0.3); 14.034(10.3); 12.734(0.3); 8.313(1.1); 8.129(0.9); 7.671(1.3); 7.651(3.8); 7.633(5.8); 7.615(4.4); 7.597(1.7); 7.580(0.3); 7.308(9.0); 7.287(16.0); 7.266(8.3); 4.464(14.4); 4.278(0.3); 3.408(0.4); 3.318(414.6); 3.199(0.4); 2.995(0.5); 2.890(0.7); 2.852(0.4); 2.730(0.7); 2.671(4.2); 2.640(0.4); 2.502(712.7); 2.498(712.8); 2.329(4.3); 2.074(1.0); 1.258(0.7); 1.244(0.6); 0.145(0.4); 0.000(43.0); −0.003(34.2) Example I-1-36: HPLC-MS: mass (m/z): 347.1 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.801(3.7); 8.702(2.9); 8.698(3.2); 8.690(3.1); 8.686(3.0); 8.112(2.8); 8.108(2.9); 8.092(3.1); 8.088(2.9); 7.678(0.6); 7.662(1.3); 7.657(1.2); 7.646(1.0); 7.641(2.5); 7.624(1.3); 7.620(1.5); 7.604(0.7); 7.431(2.7); 7.419(2.7); 7.412(2.6); 7.399(2.5); 7.324(0.8); 7.317(4.4); 7.296(7.4); 7.275(3.6); 7.268(0.7); 3.340(79.0); 2.963(1.9); 2.944(6.1); 2.925(6.2); 2.907(2.0); 2.676(0.4); 2.671(0.5); 2.667(0.4); 2.511(31.3); 2.507(61.3); 2.502(82.1); 2.498(61.9); 2.333(0.4); 2.329(0.5); 2.074(2.8); 1.258(7.6); 1.239(16.0); 1.220(7.3); 0.008(1.4); 0.000(30.3); −0.008(1.2) Example I-1-37: HPLC-MS: mass (m/z): 437.1 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.026(7.7); 8.982(5.7); 8.970(5.8); 8.469(5.5); 8.465(5.8); 8.449(6.1); 8.445(6.0); 7.963(4.6); 7.951(4.6); 7.943(4.4); 7.931(4.2); 7.684(1.3); 7.668(2.7); 7.663(2.5); 7.652(1.8); 7.647(5.2); 7.630(2.7); 7.626(3.1); 7.610(1.3); 7.330(1.6); 7.323(9.4); 7.302(16.0); 7.281(7.7); 7.273(1.5); 3.322(130.9); 2.672(0.9); 2.667(0.6); 2.512(48.3); 2.508(101.7); 2.503(142.7); 2.499(108.4); 2.494(53.3); 2.330(0.8); 0.146(0.4); 0.008(3.1); 0.000(86.5); −0.008(3.2); −0.149(0.3) Example I-1-38: HPLC-MS: mass (m/z): 401.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.967(5.7); 8.812(4.0); 8.808(4.9); 8.800(4.5); 8.796(4.9); 8.309(3.8); 8.306(4.6); 8.289(4.2); 8.286(4.8); 7.684(0.8); 7.667(1.8); 7.663(2.0); 7.642(5.7); 7.630(5.5); 7.623(4.9); 7.610(4.3); 7.330(1.2); 7.323(5.8); 7.303(10.2); 7.282(4.9); 4.193(2.2); 4.165(6.9); 4.137(7.1); 4.109(2.4); 3.326(42.1); 2.673(0.4); 2.508(47.1); 2.504(66.5); 2.500(57.5); 2.331(0.4); 2.076(16.0); 0.008(1.8); 0.000(40.2) Example I-1-39: HPLC-MS: mass (m/z): 392.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.638(1.1); 8.314(0.8); 7.670(1.3); 7.653(2.8); 7.649(2.6); 7.637(1.9); 7.632(5.3); 7.628(2.0); 7.616(2.7); 7.611(3.1); 7.595(1.4); 7.312(1.6); 7.304(9.6); 7.284(16.0); 7.263(8.0); 7.255(1.5); 6.891(1.0); 6.761(2.2); 6.630(1.1); 4.466(8.0); 4.455(9.4); 4.444(8.3); 3.330(27.5); 3.237(8.1); 3.226(9.4); 3.215(7.8); 2.675(1.7); 2.671(2.4); 2.666(1.7); 2.524(5.5); 2.510(132.8); 2.506(279.6); 2.501(391.5); 2.497(291.6); 2.493(141.2); 2.333(1.7); 2.328(2.4); 2.324(1.7); 2.073(1.8); 0.146(1.3); 0.008(10.4); 0.000(291.3); −0.008(10.6); −0.150(1.3) Example I-1-40: HPLC-MS: mass (m/z): 334.2 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.741(1.6); 8.824(3.1); 8.819(3.2); 8.691(3.1); 8.314(0.4); 7.680(0.4); 7.661(0.9); 7.643(1.5); 7.626(1.0); 7.607(0.4); 7.318(2.5); 7.297(4.3); 7.277(2.1); 3.320(322.5); 2.827(16.0); 2.670(3.0); 2.611(0.4); 2.540(10.9); 2.501(501.2); 2.328(2.8); 1.258(0.3); 1.238(0.6); 0.000(44.6) Example I-1-41: HPLC-MS: mass (m/z): 330.1 (M + H)+ 1H-NMR(400.0 MHz, CD3CN): δ = 7.853(1.7); 7.848(1.3); 7.846(1.2); 7.835(2.1); 7.829(1.9); 7.674(1.8); 7.657(1.8); 7.654(1.9); 7.564(1.3); 7.559(1.6); 7.546(1.4); 7.544(1.5); 7.541(2.2); 7.516(0.7); 7.513(0.8); 7.497(1.7); 7.494(1.8); 7.487(0.8); 7.481(1.2); 7.479(1.4); 7.475(1.3); 7.468(2.2); 7.463(2.1); 7.452(2.5); 7.451(2.5); 7.447(2.4); 7.444(1.9); 7.434(2.1); 7.430(1.8); 7.415(0.7); 7.411(0.5); 7.383(2.1); 7.370(1.5); 7.365(1.7); 7.364(1.7); 7.351(2.0); 7.332(0.9); 7.307(0.3); 7.305(0.3); 2.553(2.7); 2.508(16.0); 2.154(4.8); 1.964(0.6); 1.958(0.7); 1.952(5.1); 1.946(9.5); 1.940(13.1); 1.933(8.9); 1.927(4.6); 1.477(0.9); 1.371(0.4); 1.338(0.7); 1.283(0.9); 1.275(0.5); 1.268(1.7); 0.000(6.2) Example I-1-42: HPLC-MS: mass (m/z): 351.0, 352.9 1H-NMR(400.0MHz, d6-DMSO): δ = 20.010(0.4); 19.941(0.4); 13.924(8.7); 8.624(8.4); 8.613(9.4); 8.314(1.9); 8.272(8.9); 8.253(9.3); 7.867(8.7); 7.863(7.2); 7.849(10.3); 7.844(8.0); 7.644(7.3); 7.632(13.5); 7.624(9.1); 7.613(16.0); 7.594(0.5); 7.556(4.0); 7.538(9.0); 7.513(11.6); 7.493(9.6); 7.476(3.2); 3.477(0.5); 3.454(0.6); 3.319(975.8); 2.670(7.6); 2.611(0.8); 2.505(1061.9); 2.501(1229.8); 2.328(7.3); 1.988(0.5); 1.234(0.6); 0.147(0.6); 0.000(78.7); −0.007(10.4); −0.150(0.5) Example I-1-43: HPLC-MS: mass (m/z): 385.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.023(11.0); 8.952(11.2); 8.940(11.2); 8.431(10.5); 8.411(11.2); 8.314(1.4); 7.944(9.2); 7.932(9.2); 7.924(8.9); 7.912(8.5); 7.875(10.8); 7.870(10.7); 7.856(13.1); 7.851(12.6); 7.638(9.5); 7.635(11.2); 7.619(13.7); 7.616(16.0); 7.559(5.1); 7.554(6.1); 7.541(12.3); 7.536(11.5); 7.522(9.2); 7.514(12.6); 7.510(10.8); 7.495(12.5); 7.492(12.3); 7.477(4.6); 7.473(4.1); 3.317(184.7); 3.188(0.4); 2.675(2.2); 2.671(3.1); 2.666(2.3); 2.524(7.6); 2.511(194.1); 2.506(402.4); 2.502(539.8); 2.497(396.0); 2.493(196.2); 2.333(2.2); 2.329(3.1); 2.324(2.4); 2.074(6.3); 0.000(16.8) Example I-1-44: HPLC-MS: mass (m/z): 386.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.210(4.2); 9.187(12.5); 9.181(16.0); 9.144(16.0); 9.138(12.6); 8.314(0.7); 7.897(8.0); 7.892(8.0); 7.878(9.3); 7.873(9.2); 7.644(7.2); 7.641(8.2); 7.625(10.7); 7.622(12.0); 7.566(3.7); 7.562(4.5); 7.548(9.1); 7.543(8.7); 7.529(6.7); 7.521(9.5); 7.517(8.0); 7.502(9.4); 7.499(9.1); 7.483(3.4); 7.480(3.1); 3.862(0.4); 3.322(180.2); 2.676(1.2); 2.672(1.7); 2.667(1.3); 2.507(211.4); 2.503(278.3); 2.498(207.3); 2.329(1.7); 2.325(1.2); 2.074(1.2); 0.000(8.8) Example I-1-45: HPLC-MS: mass (m/z): 347.1 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.160(1.7); 8.437(1.6); 8.432(1.7); 8.425(1.7); 8.420(1.7); 8.179(1.6); 8.174(1.6); 8.161(1.7); 8.156(1.6); 7.870(1.4); 7.865(1.3); 7.851(1.6); 7.846(1.5); 7.634(1.2); 7.631(1.4); 7.615(1.7); 7.611(1.9); 7.554(0.6); 7.549(0.8); 7.536(1.6); 7.531(1.5); 7.517(1.3); 7.511(2.3); 7.507(1.4); 7.492(1.6); 7.489(1.5); 7.474(0.6); 7.217(1.6); 7.205(1.6); 7.199(1.6); 7.186(1.6); 3.998(16.0); 3.961(0.6); 3.562(0.6); 3.321(161.3); 2.675(0.6); 2.671(0.9); 2.666(0.6); 2.541(6.1); 2.524(2.1); 2.510(51.7); 2.506(106.3); 2.501(146.4); 2.497(108.5); 2.493(51.9); 2.333(0.6); 2.328(0.8); 2.324(0.7); 0.000(6.3) Example I-1-46: HPLC-MS: mass (m/z): 435.1 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.977(10.4); 8.985(12.2); 8.973(12.3); 8.455(11.6); 8.436(12.4); 8.216(0.4); 8.197(0.4); 7.963(8.9); 7.951(9.1); 7.943(8.8); 7.931(8.2); 7.881(9.9); 7.876(10.5); 7.862(11.3); 7.858(11.5); 7.643(10.1); 7.640(11.0); 7.623(15.1); 7.620(16.0); 7.595(0.5); 7.563(5.0); 7.558(5.8); 7.544(12.2); 7.540(11.4); 7.525(9.3); 7.519(14.2); 7.514(10.8); 7.499(12.7); 7.496(12.0); 7.481(4.6); 7.478(4.0); 3.339(22.1); 2.678(0.5); 2.547(20.0); 2.512(59.8); 2.508(79.9); 2.335(0.5); 0.000(11.1) Example I-1-47: HPLC-MS: mass (m/z): 399.1 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.924(4.7); 8.814(8.3); 8.810(8.8); 8.802(9.0); 8.798(8.6); 8.306(8.0); 8.302(8.1); 8.287(8.9); 8.283(8.3); 7.880(7.5); 7.876(7.0); 7.862(9.2); 7.857(8.6); 7.644(13.1); 7.632(7.9); 7.624(16.0); 7.612(7.2); 7.561(2.9); 7.557(3.5); 7.543(7.4); 7.538(7.2); 7.524(6.1); 7.519(10.8); 7.500(7.7); 7.497(7.4); 7.482(2.7); 7.479(2.5); 4.198(4.1); 4.170(12.7); 4.143(13.2); 4.115(4.5); 3.342(11.8); 2.715(0.5); 2.675(0.4); 2.545(119.1); 2.528(1.2); 2.510(44.5); 2.506(60.4); 2.501(45.4); 2.372(0.5); 2.333(0.3); 0.000(6.4) Example I-1-48: HPLC-MS: mass (m/z): 345.2 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.759(3.5); 8.705(3.0); 8.701(3.1); 8.693(3.2); 8.688(3.0); 8.111(2.8); 8.107(2.7); 8.092(3.0); 8.088(2.8); 7.866(2.7); 7.861(2.5); 7.848(3.3); 7.843(3.1); 7.637(2.4); 7.634(2.7); 7.617(3.3); 7.614(3.8); 7.556(1.3); 7.551(1.5); 7.537(3.2); 7.532(2.9); 7.518(2.5); 7.513(4.3); 7.509(2.8); 7.495(3.2); 7.491(2.8); 7.476(1.1); 7.473(0.9); 7.439(2.6); 7.426(2.6); 7.419(2.5); 7.407(2.4); 3.483(0.3); 3.361(73.5); 2.962(1.9); 2.944(6.0); 2.925(6.2); 2.906(2.1); 2.676(0.8); 2.671(1.1); 2.666(0.9); 2.541(40.7); 2.524(3.0); 2.506(145.6); 2.502(199.2); 2.497(147.4); 2.328(1.1); 2.324(0.9); 1.258(7.7); 1.239(16.0); 1.220(7.3); 0.000(5.1) Example I-1-49: HPLC-MS: mass (m/z): 388.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 7.903(0.8); 7.889(1.1); 7.880(1.3); 7.823(1.3); 7.819(1.6); 7.810(3.4); 7.801(2.2); 7.797(1.5); 7.788(0.5); 7.777(1.6); 7.768(1.2); 7.755(0.7); 5.754(2.3); 4.716(0.9); 4.702(2.0); 4.689(1.0); 4.271(0.3); 4.259(0.4); 4.248(0.4); 3.418(0.6); 3.414(0.7); 3.401(1.6); 3.384(1.8); 3.371(0.8); 3.367(0.7); 3.318(88.1); 2.957(0.4); 2.945(0.4); 2.934(0.4); 2.735(2.3); 2.718(3.7); 2.702(1.9); 2.675(0.6); 2.670(0.9); 2.666(0.6); 2.592(16.0); 2.524(2.2); 2.510(48.8); 2.506(101.5); 2.501(135.8); 2.497(98.1); 2.492(46.9); 2.333(0.6); 2.328(0.8); 2.324(0.6); 2.222(2.4); 1.710(0.9); 1.234(0.7); 0.008(0.6); 0.000(16.4); −0.009(0.5) Example I-1-50: HPLC-MS: mass (m/z): 420.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.187(6.5); 9.181(16.0); 9.143(14.8); 8.314(1.2); 7.933(9.1); 7.913(11.5); 7.874(5.0); 7.855(13.2); 7.842(7.0); 7.824(10.2); 7.805(4.5); 7.778(6.3); 7.759(8.1); 7.740(3.1); 3.392(0.5); 3.318(369.4); 2.717(0.3); 2.671(4.7); 2.628(0.4); 2.502(774.4); 2.328(4.5); 2.073(1.8); 0.146(2.2); 0.051(0.3); 0.008(17.6); 0.000(459.4); −0.150(2.2) Example I-1-51: HPLC-MS: mass (m/z): 385.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.909(10.8); 8.631(7.8); 8.626(8.5); 8.619(8.4); 8.614(8.3); 8.314(0.7); 8.289(7.7); 8.285(8.0); 8.270(8.6); 8.266(8.2); 8.048(0.5); 7.928(7.3); 7.909(8.8); 7.854(1.1); 7.849(2.3); 7.835(16.0); 7.819(8.6); 7.800(2.4); 7.773(3.9); 7.753(4.7); 7.737(2.3); 7.720(0.8); 7.648(8.1); 7.635(8.0); 7.629(7.8); 7.616(7.5); 3.354(113.6); 2.892(0.3); 2.732(0.4); 2.690(2.6); 2.676(1.4); 2.671(1.9); 2.667(1.5); 2.541(7.3); 2.524(5.6); 2.507(220.5); 2.502(304.9); 2.498(230.5); 2.333(1.2); 2.329(1.7); 2.325(1.2); 2.074(0.6); 1.299(0.5); 1.259(0.8); 1.235(3.2); 1.179(0.4); 0.854(0.5); 0.146(1.1); 0.008(9.4); 0.000(224.8); −0.008(8.7); −0.150(1.0) Example I-1-52: HPLC-MS: mass (m/z): 469.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 19.853(0.4); 13.944(4.2); 12.777(0.5); 12.741(0.8); 8.965(6.6); 8.957(6.6); 8.451(4.8); 8.434(4.9); 8.313(2.2); 8.199(0.6); 8.177(0.6); 8.132(6.1); 8.046(0.9); 7.945(4.4); 7.924(12.1); 7.905(10.4); 7.852(3.7); 7.832(16.0); 7.813(8.9); 7.794(3.6); 7.766(5.0); 7.747(6.5); 7.728(3.0); 7.623(0.5); 7.609(0.6); 3.576(0.4); 3.570(0.4); 3.505(0.5); 3.435(0.8); 3.407(0.9); 3.319(939.6); 3.219(1.0); 2.891(1.3); 2.767(0.4); 2.732(1.5); 2.670(7.0); 2.628(0.8); 2.506(892.2); 2.501(1141.4); 2.497(892.8); 2.328(6.5); 2.220(0.7); 2.205(0.6); 2.073(13.1); 1.235(0.4); 0.145(0.4); 0.000(81.9) Example I-1-53: HPLC-MS: mass (m/z): 365.1 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.915(1.2); 8.948(1.7); 8.935(1.7); 8.420(1.5); 8.401(1.6); 7.948(2.0); 7.940(1.5); 7.929(3.0); 7.920(1.3); 7.908(1.2); 7.413(0.4); 7.396(1.4); 7.380(2.1); 7.377(2.1); 7.366(2.8); 7.352(2.1); 7.333(1.5); 7.317(0.6); 7.312(0.6); 3.321(432.2); 2.675(1.1); 2.670(1.6); 2.666(1.2); 2.615(16.0); 2.510(87.6); 2.506(182.6); 2.501(256.5); 2.497(197.5); 2.493(99.0); 2.332(1.1); 2.328(1.5); 2.323(1.1); 2.073(0.6); 0.146(0.4); 0.008(3.8); 0.000(101.6); −0.008(4.0); −0.150(0.5) Example I-1-54: HPLC-MS: mass (m/z): 381.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.934(1.2); 8.944(1.4); 8.934(1.4); 8.412(1.3); 8.394(1.4); 8.392(1.4); 7.934(1.2); 7.922(1.2); 7.915(1.1); 7.903(1.1); 7.742(1.5); 7.738(1.6); 7.723(1.7); 7.719(1.6); 7.510(0.8); 7.506(0.7); 7.492(1.0); 7.489(1.2); 7.485(1.0); 7.471(1.0); 7.466(0.9); 7.196(2.0); 7.176(1.7); 7.083(1.1); 7.081(1.0); 7.064(1.9); 7.062(1.9); 7.046(0.9); 7.044(0.9); 3.818(16.0); 3.320(33.7); 2.524(0.7); 2.511(15.4); 2.507(31.2); 2.502(42.6); 2.498(31.4); 2.493(14.9) Example I-1-55: HPLC-MS: mass (m/z): 435.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.003(10.5); 11.225(1.1); 8.955(10.9); 8.945(10.6); 8.943(10.7); 8.439(10.1); 8.421(10.6); 8.420(10.6); 8.314(1.3); 8.113(13.4); 8.108(12.6); 8.093(15.2); 8.089(13.1); 7.946(9.3); 7.934(9.2); 7.926(8.8); 7.914(8.5); 7.694(4.7); 7.690(5.0); 7.675(9.8); 7.670(10.1); 7.655(10.3); 7.651(9.7); 7.602(8.1); 7.599(10.4); 7.583(11.9); 7.580(15.7); 7.563(16.0); 7.561(14.1); 7.542(8.0); 7.487(3.1); 7.467(4.6); 7.395(2.1); 7.392(2.2); 7.378(2.6); 7.375(3.7); 7.357(1.8); 7.354(1.8); 7.169(2.1); 7.167(2.2); 7.149(3.7); 7.132(1.7); 7.130(1.8); 3.321(308.9); 2.676(1.7); 2.672(2.4); 2.667(1.7); 2.525(6.3); 2.512(133.7); 2.507(277.5); 2.503(383.4); 2.498(285.0); 2.494(136.5); 2.339(0.8); 2.334(1.6); 2.330(2.3); 2.325(1.6); 2.074(1.7); 1.233(0.4); 0.000(2.5) Example I-1-56: HPLC-MS: mass (m/z): 387.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.037(1.0); 8.953(3.9); 8.943(3.9); 8.941(3.9); 8.425(3.5); 8.423(3.6); 8.406(3.9); 8.404(3.9); 8.188(1.8); 8.171(2.1); 8.166(3.7); 8.149(3.7); 8.144(2.2); 8.127(1.8); 7.945(3.4); 7.933(3.4); 7.926(3.2); 7.914(3.1); 7.475(1.9); 7.468(1.9); 7.451(2.2); 7.446(3.3); 7.440(2.1); 7.423(1.9); 7.417(2.0); 7.294(1.6); 7.289(1.5); 7.274(3.0); 7.268(2.8); 7.252(1.5); 7.246(1.4); 3.324(39.4); 2.678(0.4); 2.673(0.5); 2.669(0.3); 2.527(1.4); 2.513(28.4); 2.509(57.9); 2.504(79.3); 2.500(58.6); 2.495(27.9); 2.336(0.4); 2.331(0.5); 2.326(0.3); 2.076(16.0); 0.000(0.5) Example I-1-57: HPLC-MS: mass (m/z): 369.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.038(7.5); 8.952(11.4); 8.942(11.3); 8.940(11.1); 8.428(10.2); 8.426(10.5); 8.408(11.3); 8.406(11.1); 8.314(1.2); 8.134(0.4); 8.116(5.7); 8.111(6.1); 8.096(11.5); 8.092(12.2); 8.083(1.6); 8.076(6.5); 8.072(6.3); 7.944(9.7); 7.932(9.7); 7.925(9.3); 7.913(8.8); 7.610(2.8); 7.605(3.1); 7.597(3.4); 7.592(5.9); 7.587(5.4); 7.585(4.8); 7.578(6.0); 7.575(5.4); 7.571(6.7); 7.566(4.3); 7.558(4.0); 7.554(3.7); 7.411(8.3); 7.389(15.2); 7.385(11.0); 7.382(8.1); 7.371(16.0); 7.364(7.8); 7.361(6.6); 7.352(8.3); 7.350(6.8); 6.521(0.4); 5.755(0.9); 3.321(155.6); 2.677(1.5); 2.672(2.0); 2.668(1.5); 2.526(6.0); 2.512(121.8); 2.508(244.2); 2.503(330.5); 2.499(243.4); 2.494(115.6); 2.335(1.4); 2.330(1.9); 2.325(1.4); 0.000(1.9) Example I-1-58: HPLC-MS: mass (m/z): 379.1 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.898(2.9); 8.953(2.6); 8.941(2.6); 8.434(2.4); 8.416(2.6); 8.314(0.5); 7.945(2.2); 7.933(2.2); 7.925(2.1); 7.913(2.0); 7.865(2.6); 7.862(2.8); 7.845(2.9); 7.843(2.9); 7.452(0.9); 7.448(0.9); 7.433(2.4); 7.430(2.4); 7.415(2.6); 7.412(2.6); 7.389(4.0); 7.373(1.7); 7.348(1.9); 7.345(1.7); 7.330(2.6); 7.326(2.3); 7.311(1.2); 7.308(1.1); 3.318(148.7); 3.046(1.6); 3.027(5.2); 3.009(5.3); 2.990(1.7); 2.675(0.8); 2.671(1.1); 2.666(0.8); 2.524(2.8); 2.511(62.4); 2.506(129.1); 2.502(178.4); 2.497(133.0); 2.493(63.9); 2.333(0.8); 2.329(1.1); 2.324(0.8); 2.073(0.8); 1.165(7.2); 1.146(16.0); 1.127(7.1); 0.000(1.4) Example I-1-59: HPLC-MS: mass (m/z): 393.1 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.897(1.2); 8.947(1.5); 8.936(1.5); 8.431(1.3); 8.411(1.4); 7.939(1.2); 7.927(1.2); 7.919(1.2); 7.907(1.1); 7.696(1.6); 7.694(1.7); 7.677(1.9); 7.674(1.8); 7.514(0.9); 7.498(2.3); 7.494(2.3); 7.485(1.4); 7.482(1.3); 7.468(1.5); 7.465(1.6); 7.448(0.6); 7.445(0.6); 7.322(1.1); 7.318(1.1); 7.303(1.5); 7.285(0.8); 7.281(0.8); 5.753(3.3); 3.767(0.3); 3.749(0.9); 3.732(1.2); 3.715(0.9); 3.698(0.4); 3.318(83.1); 2.675(0.5); 2.671(0.7); 2.666(0.5); 2.524(1.6); 2.511(35.9); 2.506(75.5); 2.501(105.2); 2.497(77.7); 2.493(36.7); 2.333(0.5); 2.328(0.6); 2.324(0.4); 1.207(16.0); 1.190(15.9); 0.000(5.9) Example I-1-60: HPLC-MS: mass (m/z): 437.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.067(0.5); 14.013(6.2); 8.944(10.5); 8.932(10.7); 8.434(9.3); 8.414(10.0); 8.313(1.8); 7.954(7.8); 7.933(13.8); 7.917(16.0); 7.904(7.3); 7.849(8.4); 7.843(9.5); 7.826(8.6); 7.820(9.4); 7.801(0.4); 7.793(0.4); 7.724(5.3); 7.717(5.0); 7.703(9.4); 7.697(8.7); 7.682(4.4); 7.675(4.1); 7.514(0.4); 7.493(0.4); 7.199(0.6); 7.071(0.5); 6.945(0.5); 3.419(0.4); 3.320(828.4); 3.239(0.4); 2.891(2.9); 2.732(2.6); 2.690(1.1); 2.676(3.3); 2.671(4.6); 2.667(3.5); 2.524(10.0); 2.511(260.7); 2.506(560.6); 2.502(793.5); 2.497(596.2); 2.493(289.3); 2.427(0.4); 2.400(0.3); 2.369(0.3); 2.333(3.4); 2.329(4.7); 2.324(3.5); 0.008(0.5); 0.000(12.4); −0.009(0.5) Example I-1-61: HPLC-MS: mass (m/z): 437.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 18.495(0.4); 15.214(0.4); 14.096(0.5); 14.084(0.7); 14.030(7.5); 13.955(0.4); 8.973(0.4); 8.933(12.1); 8.922(12.2); 8.428(10.2); 8.408(11.0); 8.313(3.8); 8.132(1.1); 7.978(0.5); 7.952(0.9); 7.925(9.1); 7.913(9.7); 7.905(9.3); 7.893(8.4); 7.884(5.0); 7.864(9.5); 7.851(9.6); 7.845(6.9); 7.830(5.7); 7.819(0.4); 7.703(8.0); 7.675(8.8); 7.653(6.4); 7.558(16.0); 7.540(14.1); 7.195(0.7); 7.085(0.4); 7.070(0.6); 6.941(0.6); 3.454(0.4); 3.442(0.4); 3.416(0.4); 3.408(0.5); 3.317(826.6); 3.249(0.5); 2.891(3.5); 2.731(3.1); 2.690(3.1); 2.675(5.8); 2.671(8.0); 2.666(5.9); 2.635(0.5); 2.524(17.9); 2.519(29.0); 2.511(451.3); 2.506(961.8); 2.502(1349.3); 2.497(1000.9); 2.493(474.9); 2.439(0.6); 2.422(0.5); 2.390(0.4); 2.361(0.4); 2.337(2.8); 2.333(5.8); 2.328(7.9); 2.324(5.8); 2.319(2.8); 2.251(0.4); 1.755(0.4); 1.243(0.4); 0.000(16.0) Example I-1-62: See Synthesis Example 11 Example I-1-63: HPLC-MS: mass (m/z): 418.9; 420.9 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.035(3.0); 12.753(1.2); 8.924(2.0); 8.444(1.8); 8.312(7.8); 8.130(2.3); 7.965(1.1); 7.900(2.1); 7.748(1.0); 7.638(5.3); 7.619(8.3); 7.577(3.3); 7.560(2.9); 6.512(6.3); 4.074(1.2); 3.534(1.0); 3.314(1368.5); 3.278(3.9); 3.259(1.7); 2.891(1.2); 2.730(1.5); 2.674(11.9); 2.670(16.0); 2.666(12.7); 2.602(1.7); 2.509(980.8); 2.505(2041.9); 2.501(2876.5); 2.496(2202.0); 2.403(1.3); 2.348(1.4); 2.332(11.9); 2.328(15.9); 2.323(12.0); 2.300(1.2); 0.000(75.1) Example I-1-64: HPLC-MS: mass (m/z): 437.1 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.049(16.0); 8.952(14.0); 8.940(14.1); 8.442(12.9); 8.423(13.5); 8.313(4.7); 8.025(10.0); 8.012(10.0); 8.004(10.8); 7.990(10.5); 7.942(10.6); 7.930(10.7); 7.923(10.5); 7.911(9.7); 7.738(9.3); 7.732(11.0); 7.715(10.0); 7.709(10.6); 7.639(5.3); 7.633(5.0); 7.618(9.8); 7.596(5.1); 7.499(0.8); 7.406(0.6); 3.524(0.7); 3.460(0.9); 3.396(0.8); 3.315(1531.8); 3.256(0.8); 2.721(0.7); 2.670(12.3); 2.666(10.1); 2.631(0.9); 2.605(1.2); 2.569(1.9); 2.506(1446.8); 2.501(2088.1); 2.497(1661.7); 2.440(1.0); 2.333(8.5); 2.328(12.0); 2.324(9.3); 2.086(0.7); 1.398(12.0); 1.237(1.4); 1.227(0.7); 0.146(10.0); 0.008(82.1); 0.000(2296.1); −0.008(104.1); −0.024(3.1); −0.066(0.8); −0.150(10.1) Example I-1-65: See Synthesis Example 12 Example I-1-66: See Synthesis Example 12 Example I-1-67: See Synthesis Example 13 Example I-1-68: HPLC-MS: mass (m/z): 364.1 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 7.946(2.2); 7.927(2.5); 7.903(0.8); 7.885(2.0); 7.874(1.0); 7.856(1.6); 7.834(1.4); 7.8131.1); 7.795(0.4); 7.411(0.4); 7.392(1.2); 7.378(1.5); 7.375(1.9); 7.363(2.5); 7.349(1.6); 7.332(1.3); 7.312(0.5); 3.379(193.6); 3.366(121.8); 2.679(0.3); 2.674(0.4); 2.613(16.0); 2.528(1.0); 2.514(26.6); 2.510(55.6); 2.506(74.4); 2.501(53.3); 2.497(25.3); 2.332(0.4) Example I-1-69: HPLC-MS: mass (m/z): 436.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.929(8.0); 8.314(0.7); 8.024(8.4); 8.011(8.8); 8.002(9.4); 7.989(9.1); 7.950(9.2); 7.932(13.4); 7.928(15.1); 7.922(8.4); 7.904(14.2); 7.879(5.7); 7.864(12.2); 7.842(13.3); 7.822(8.6); 7.804(2.8); 7.735(7.9); 7.728(8.9); 7.712(8.2); 7.705(8.6); 7.637(4.5); 7.631(3.9); 7.616(8.1); 7.610(6.8); 7.595(4.1); 7.588(3.4); 3.324(376.2); 2.677(1.2); 2.672(1.6); 2.667(1.2); 2.525(3.8); 2.512(92.4); 2.507(197.2); 2.503(277.4); 2.498(205.2); 2.494(96.8); 2.334(1.2); 2.330(1.6); 2.325(1.1); 2.074(16.0); 0.146(0.9); 0.008(6.3); 0.000(205.6); −0.008(6.6); −0.150(0.9) Example I-1-70: HPLC-MS: mass (m/z): 434.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.884(10.8); 8.316(0.4); 8.111(10.5); 8.107(11.3); 8.092(11.8); 8.087(11.8); 7.946(8.8); 7.925(14.9); 7.901(13.6); 7.879(5.6); 7.863(11.3); 7.841(11.2); 7.819(8.2); 7.801(2.7); 7.690(4.0); 7.685(4.3); 7.670(9.7); 7.666(9.9); 7.651(8.8); 7.646(8.4); 7.597(9.1); 7.578(13.8); 7.559(16.0); 7.538(7.8); 7.051(0.7); 3.324(136.0); 2.678(0.7); 2.673(1.0); 2.669(0.7); 2.526(2.2); 2.508(122.6); 2.504(170.1); 2.500(127.5); 2.331(1.0); 2.327(0.8); 2.076(1.7); 1.234(0.7); 1.216(0.8); 1.208(1.1); 1.191(1.0); 0.896(0.7); 0.879(0.7); 0.146(0.6); 0.008(3.9); 0.000(117.7); −0.008(4.3); −0.150(0.6) Example I-1-71: HPLC-MS: mass (m/z): 386.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.899(11.4); 8.313(1.5); 8.179(5.1); 8.162(6.3); 8.157(10.9); 8.140(10.8); 8.135(6.7); 8.118(5.5); 8.093(0.5); 7.941(10.0); 7.922(13.8); 7.905(6.9); 7.887(16.0); 7.874(7.0); 7.858(13.1); 7.835(11.5); 7.813(8.9); 7.795(3.1); 7.484(0.5); 7.469(5.3); 7.463(5.8); 7.445(6.0); 7.440(9.6); 7.435(6.4); 7.417(5.2); 7.411(5.3); 7.374(0.4); 7.291(4.9); 7.285(4.8); 7.270(9.1); 7.264(8.7); 7.249(4.7); 7.243(4.5); 7.148(0.4); 3.320(1090.3); 2.676(3.2); 2.671(4.5); 2.667(3.4); 2.524(11.0); 2.506(540.9); 2.502(757.5); 2.498(576.4); 2.333(3.1); 2.329(4.3); 2.324(3.2); 1.235(0.4); 1.216(0.4); 0.146(1.8); 0.008(12.7); 0.000(376.4); −0.008(13.9); −0.150(1.8) Example I-1-72: HPLC-MS: mass (m/z): 380.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.791(1.8); 7.934(1.2); 7.916(1.6); 7.890(0.7); 7.871(2.0); 7.849(1.6); 7.826(1.4); 7.806(1.0); 7.788(0.4); 7.731(1.5); 7.727(1.6); 7.712(1.6); 7.708(1.7); 7.505(0.7); 7.500(0.7); 7.482(1.3); 7.480(1.1); 7.466(0.9); 7.461(0.9); 7.191(2.1); 7.170(1.8); 7.078(1.1); 7.059(2.0); 7.042(0.9); 7.040(1.0); 3.815(16.0); 3.318(36.1); 2.524(0.8); 2.510(17.7); 2.506(36.9); 2.502(51.4); 2.497(39.2); 2.493(19.4); 0.008(2.4); 0.000(69.6); −0.008(2.7) Example I-1-73: HPLC-MS: mass (m/z): 368.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.899(14.7); 8.315(0.7); 8.109(5.3); 8.105(5.9); 8.090(10.3); 8.086(11.4); 8.070(5.7); 8.066(6.0); 7.943(9.7); 7.924(13.5); 7.911(7.1); 7.893(15.1); 7.876(6.4); 7.860(12.4); 7.838(11.5); 7.816(8.9); 7.798(2.9); 7.605(2.5); 7.601(2.7); 7.593(2.9); 7.587(5.6); 7.584(5.7); 7.573(5.7); 7.567(6.5); 7.562(4.1); 7.554(3.6); 7.550(3.3); 7.407(8.2); 7.386(16.0); 7.381(10.2); 7.368(15.8); 7.360(7.3); 7.349(7.2); 3.319(155.0); 2.672(2.0); 2.542(3.0); 2.507(246.6); 2.503(339.8); 2.499(266.8); 2.330(1.9); 1.235(1.3); 0.146(2.0); 0.008(15.4); 0.000(392.5); −0.149(1.9) Example I-1-74: HPLC-MS: mass (m/z): 392.1 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.771(2.3); 7.943(1.4); 7.921(2.3); 7.899(2.1); 7.874(0.8); 7.858(1.7); 7.835(1.7); 7.814(1.3); 7.795(0.4); 7.693(1.8); 7.676(2.0); 7.673(1.9); 7.510(1.0); 7.494(2.5); 7.491(2.5); 7.482(1.4); 7.479(1.4); 7.462(1.7); 7.445(0.6); 7.320(1.1); 7.316(1.1); 7.300(1.6); 7.283(0.8); 7.279(0.8); 3.765(0.4); 3.748(1.0); 3.731(1.3); 3.714(1.0); 3.696(0.4); 3.317(92.1); 2.675(0.5); 2.671(0.7); 2.666(0.5); 2.524(1.8); 2.506(86.6); 2.501(120.4); 2.497(91.7); 2.332(0.5); 2.328(0.7); 2.324(0.5); 1.235(0.5); 1.207(16.0); 1.190(15.9); 0.146(0.7); 0.008(4.8); 0.000(146.0); −0.008(5.8); −0.150(0.7) Example I-1-75: HPLC-MS: mass (m/z): 436.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.888(11.0); 8.313(0.9); 7.948(8.7); 7.937(6.5); 7.928(16.0); 7.902(10.4); 7.876(4.0); 7.860(8.8); 7.848(7.5); 7.842(15.3); 7.825(8.1); 7.819(13.2); 7.800(2.1); 7.725(3.8); 7.718(3.5); 7.704(6.7); 7.697(6.0); 7.683(3.2); 7.676(2.8); 3.319(255.2); 2.676(1.4); 2.671(2.0); 2.667(1.4); 2.525(5.0); 2.511(114.9); 2.507(240.3); 2.502(334.2); 2.498(248.7); 2.493(118.9); 2.333(1.4); 2.329(2.0); 2.324(1.4); 1.398(2.0); 1.236(0.8); 0.146(2.0); 0.008(15.3); 0.000(459.6); −0.009(16.0); −0.150(2.0) Example I-1-76: HPLC-MS: mass (m/z): 436.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.905(12.9); 8.314(1.8); 7.946(8.0); 7.925(16.0); 7.905(12.4); 7.889(3.4); 7.870(8.1); 7.856(16.0); 7.836(15.6); 7.817(7.3); 7.800(2.3); 7.711(6.0); 7.690(5.3); 7.682(6.4); 7.661(4.8); 7.561(11.5); 7.542(10.2); 3.732(0.8); 3.318(789.3); 2.675(3.9); 2.671(5.3); 2.666(3.9); 2.611(0.6); 2.575(1.0); 2.524(14.6); 2.511(303.2); 2.506(631.6); 2.502(876.1); 2.497(651.1); 2.493(309.5); 2.333(3.6); 2.329(5.0); 2.324(3.6); 1.398(1.4); 1.236(4.6); 1.192(0.4); 0.854(0.7); 0.146(5.2); 0.060(0.4); 0.008(40.0); 0.000(1180.2); −0.008(40.7); −0.150(5.1) Example I-1-77: HPLC-MS: mass(m/z): 420.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.972(9.9); 8.315(0.4); 7.956(4.9); 7.936(6.9); 7.874(3.3); 7.854(7.6); 7.834(6.5); 7.823(8.1); 7.805(3.2); 7.679(1.2); 7.658(3.2); 7.641(5.4); 7.621(3.5); 7.604(1.4); 7.317(9.1); 7.296(16.0); 7.275(7.7); 7.206(0.9); 7.079(1.0); 6.950(0.9); 3.319(518.0); 2.670(4.6); 2.638(0.4); 2.501(750.0); 2.497(611.0); 2.328(4.3); 2.074(2.5); 1.235(0.3); 0.146(0.7); 0.000(132.2); −0.150(0.7) Example I-1-78: See Synthesis Example 13 Example I-2-1: HPLC-MS: mass (m/z): 420.9 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.207(6.4); 9.104(9.3); 9.102(9.0); 8.825(0.4); 8.717(9.3); 8.713(9.0); 7.773(1.3); 7.756(2.8); 7.752(2.6); 7.735(5.1); 7.718(2.7); 7.714(3.0); 7.697(1.3); 7.371(9.1); 7.350(16.0); 7.330(7.7); 7.233(0.5); 7.212(0.7); 5.758(1.6); 4.022(0.3); 3.490(0.5); 3.472(0.5); 3.329(18.9); 3.166(0.4); 3.148(0.4); 3.027(0.4); 2.679(0.4); 2.674(0.5); 2.670(0.4); 2.544(0.4); 2.527(1.7); 2.514(31.6); 2.510(62.9); 2.505(82.0); 2.501(58.4); 2.496(27.6); 2.336(0.4); 2.332(0.5); 2.327(0.4); 1.991(1.4); 1.357(1.2); 1.232(1.6); 1.194(0.4); 1.177(0.8); 1.165(0.6); 1.159(0.4); 1.147(1.2); 1.129(0.6); 1.025(0.5); 1.008(1.0); 0.990(0.5); 0.000(3.7) Example I-2-2: HPLC-MS: mass (m/z): 452.9 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.028(13.4); 9.117(0.6); 9.101(15.2); 9.098(15.2); 8.822(0.4); 8.715(15.5); 8.712(15.1); 8.317(0.6); 7.960(8.1); 7.939(16.0); 7.919(12.1); 7.892(5.0); 7.876(10.4); 7.858(7.1); 7.853(9.3); 7.848(8.0); 7.830(7.8); 7.811(3.1); 7.789(0.8); 7.736(0.7); 7.719(0.5); 7.656(0.4); 7.636(0.6); 7.461(0.6); 7.442(0.6); 3.326(105.2); 3.066(0.3); 2.677(1.1); 2.672(1.5); 2.668(1.1); 2.663(0.6); 2.542(1.5); 2.525(6.0); 2.512(89.4); 2.508(179.0); 2.503(235.8); 2.498(168.6); 2.494(80.8); 2.334(1.0); 2.330(1.4); 2.325(1.0); 2.321(0.5); 1.990(1.2); 1.730(0.4); 1.234(0.8); 1.193(0.4); 1.176(0.7); 1.158(0.4); 1.139(1.5); 1.121(3.2); 1.103(1.5); 1.001(1.5); 0.983(3.3); 0.965(1.5); 0.000(0.9) Example I-2-3: HPLC-MS: mass (m/z): 453.9 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.160(8.2); 9.104(15.6); 9.101(15.3); 8.966(10.0); 8.956(9.7); 8.954(9.8); 8.825(0.3); 8.719(16.0); 8.716(15.2); 8.454(9.3); 8.437(9.9); 8.434(9.8); 8.317(0.7); 7.962(8.6); 7.950(8.6); 7.942(8.3); 7.930(7.9); 5.757(6.0); 3.327(61.6); 2.677(1.2); 2.672(1.6); 2.668(1.2); 2.542(1.2); 2.525(5.5); 2.512(98.1); 2.508(195.7); 2.503(255.6); 2.499(182.1); 2.494(86.4); 2.334(1.2); 2.330(1.6); 2.325(1.2); 2.076(3.1); 1.234(0.4); 1.196(0.4); 1.178(0.7); 1.159(0.4); 0.008(2.4); 0.000(60.7); −0.009(2.0) Example I-2-4: HPLC-MS: mass (m/z): 385.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.995(0.4); 13.928(13.3); 13.894(0.4); 8.670(12.3); 8.659(11.8); 8.315(1.2); 8.276(0.4); 8.153(11.1); 8.132(11.8); 8.082(0.4); 7.951(9.0); 7.931(15.2); 7.909(12.8); 7.885(5.6); 7.866(10.5); 7.843(9.0); 7.821(7.9); 7.801(2.6); 7.745(0.3); 7.705(0.4); 7.654(0.5); 7.623(9.0); 7.611(9.0); 7.602(8.3); 7.591(7.4); 7.520(0.4); 4.197(0.3); 4.056(1.5); 4.038(4.0); 4.020(4.0); 4.002(1.5); 3.883(0.4); 3.745(0.5); 3.599(0.7); 3.571(0.4); 3.495(0.4); 3.477(0.4); 3.466(0.4); 3.376(0.7); 3.319(167.1); 3.055(0.3); 2.998(0.4); 2.891(0.7); 2.785(0.5); 2.767(0.5); 2.731(0.8); 2.671(5.3); 2.624(1.0); 2.505(747.9); 2.501(820.6); 2.328(4.4); 1.989(16.0); 1.900(0.3); 1.637(0.3); 1.398(1.7); 1.332(0.3); 1.298(0.8); 1.276(1.3); 1.260(1.8); 1.237(2.7); 1.193(4.6); 1.175(8.6); 1.158(4.3); 1.122(0.5); 1.029(0.3); 0.855(0.7); 0.792(0.3); 0.146(0.7); 0.004(73.3); 0.000(134.9); −0.149(0.6) Example I-2-5: HPLC-MS: mass (m/z): 386.9 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.078(1.2); 14.061(4.0); 8.956(3.9); 8.947(3.8); 8.811(0.9); 8.800(1.1); 8.670(5.6); 8.662(5.5); 8.659(5.6); 8.445(3.1); 8.425(3.5); 8.314(6.5); 8.156(4.9); 8.133(5.3); 8.023(0.8); 7.952(2.9); 7.939(3.1); 7.931(2.7); 7.919(2.6); 7.807(1.2); 7.777(0.9); 7.627(4.5); 7.616(4.1); 7.606(4.0); 7.595(4.0); 3.462(0.9); 3.446(0.9); 3.428(0.9); 3.404(0.9); 3.319(1110.5); 3.184(1.4); 2.748(1.0); 2.732(1.4); 2.675(11.6); 2.670(16.0); 2.666(12.0); 2.540(9.3); 2.524(45.3); 2.510(928.6); 2.506(1932.5); 2.501(2683.3); 2.497(2033.1); 2.493(1006.0); 2.333(10.8); 2.328(15.3); 2.324(11.4); 2.074(0.9); 1.237(1.1); 1.193(1.7); 1.175(2.9); 1.158(1.8); 1.100(2.8); 1.084(3.2); 1.072(2.7); 0.935(1.4); 0.000(12.2) Example I-2-6: See Synthesis Example 15 Example I-2-7: HPLC-MS: mass (m/z): 388.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.117(6.5); 8.961(9.4); 8.949(9.4); 8.685(15.6); 8.679(16.0); 8.435(8.8); 8.416(9.4); 8.196(5.0); 8.190(4.8); 8.174(5.5); 8.169(8.2); 8.164(5.3); 8.147(5.0); 8.141(4.7); 7.955(7.9); 7.943(7.9); 7.936(7.5); 7.924(7.2); 3.322(316.5); 3.052(1.5); 3.016(1.0); 2.753(1.0); 2.676(1.4); 2.672(1.9); 2.667(1.4); 2.641(0.4); 2.525(4.9); 2.511(106.7); 2.507(227.4); 2.502(321.3); 2.498(245.0); 2.494(119.7); 2.334(1.3); 2.329(1.8); 2.325(1.3); 2.075(6.7); 1.168(0.3); 1.151(0.3); 0.146(0.4); 0.008(2.9); 0.000(88.7); −0.009(3.2); −0.150(0.4) Example I-3-1: HPLC-MS: mass (m/z): 385.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 13.972(16.0); 8.577(12.3); 8.573(13.6); 8.565(13.9); 8.561(13.6); 8.318(12.7); 8.313(12.8); 8.299(14.3); 8.294(13.4); 7.951(9.6); 7.933(14.0); 7.921(8.8); 7.904(15.2); 7.883(6.8); 7.867(12.6); 7.845(13.2); 7.824(9.7); 7.806(3.6); 7.627(12.5); 7.615(12.8); 7.608(12.9); 7.596(12.2); 3.325(92.0); 2.673(1.2); 2.543(2.4); 2.508(149.9); 2.504(199.6); 2.500(157.3); 2.331(1.2); 2.076(0.4); 1.531(0.4); 0.146(0.6); 0.000(138.3); −0.150(0.6) Example I-3-2: HPLC-MS: mass (m/z): 386.0 (M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.104(14.2); 8.960(12.5); 8.948(12.5); 8.689(0.3); 8.678(0.4); 8.581(14.0); 8.577(15.4); 8.569(15.1); 8.565(15.2); 8.440(11.8); 8.421(12.5); 8.326(14.5); 8.321(14.8); 8.307(16.0); 8.302(15.1); 7.953(10.5); 7.941(10.5); 7.933(10.1); 7.921(9.6); 7.888(0.4); 7.706(0.3); 7.631(15.2); 7.619(14.8); 7.611(14.7); 7.600(14.3); 3.327(68.1); 2.677(1.2); 2.673(1.6); 2.668(1.2); 2.643(2.3); 2.543(1.0); 2.526(4.6); 2.512(94.9); 2.508(197.5); 2.504(275.6); 2.499(209.1); 2.495(103.3); 2.335(1.2); 2.331(1.6); 2.326(1.2); 2.076(10.3); 1.169(2.5); 1.152(2.4); 1.102(0.5); 0.146(1.0); 0.008(8.0); 0.000(222.7); −0.008(8.9); −0.150(1.0) Example I-3-3: HPLC-MS: mass(m/z): 351.9, 353.8 1H-NMR(400.0 MHz, d6-DMSO): δ = 14.004(10.3); 8.633(10.6); 8.628(11.4); 8.621(11.3); 8.616(11.2); 8.578(11.5); 8.573(12.4); 8.566(12.3); 8.562(12.0); 8.317(12.8); 8.312(12.5); 8.298(13.8); 8.293(12.8); 8.280(11.4); 8.275(11.4); 8.261(12.4); 8.256(11.7); 7.651(11.0); 7.639(11.1); 7.630(15.8); 7.618(16.0); 7.610(12.0); 7.598(11.4); 3.323(190.0); 2.672(2.6); 2.667(2.0); 2.525(8.0); 2.507(319.4); 2.503(432.2); 2.498(326.6); 2.334(1.8); 2.330(2.5); 2.325(1.9); 2.075(2.5); 0.146(0.7); 0.008(5.7); 0.000(145.6); −0.007(5.3); −0.150(0.7) Example I-3-4: HPLC-MS: mass(m/z): 409.0(M + H)+ 1H-NMR(400.0 MHz, d6-DMSO): δ = 16.430(0.7); 14.043(12.5); 12.248(0.8); 8.564(10.6); 8.553(10.9); 8.314(5.0); 8.304(10.7); 8.285(11.3); 8.140(1.0); 7.615(7.7); 7.601(9.2); 7.584(7.5); 5.755(3.1); 4.464(16.0); 3.504(0.9); 3.476(0.8); 3.394(1.5); 3.321(845.6); 3.263(1.2); 3.087(0.8); 2.914(0.7); 2.821(0.8); 2.754(0.9); 2.732(1.0); 2.712(1.1); 2.671(13.0); 2.647(1.4); 2.561(4.8); 2.541(53.9); 2.502(2145.6); 2.328(12.0); 2.075(1.2); 1.235(2.5); 0.147(2.5); 0.000(535.5); −0.048(0.8); −0.150(2.6) Example I-3-5: HPLC-MS: mass(m/z): 442.9, 444.9 1H-NMR(400.0 MHz, d6-DMSO): δ = 20.002(0.6); 13.793(12.8); 8.573(11.9); 8.569(12.6); 8.562(12.5); 8.557(12.6); 8.311(13.0); 8.306(12.8); 8.292(13.7); 8.287(12.9); 8.208(0.8); 8.190(0.9); 8.017(14.3); 7.998(15.0); 7.762(0.6); 7.671(9.5); 7.667(10.0); 7.652(14.5); 7.648(14.0); 7.624(12.6); 7.612(13.5); 7.605(12.6); 7.593(12.1); 7.579(8.0); 7.561(14.0); 7.542(6.7); 7.346(6.2); 7.342(6.3); 7.323(10.2); 7.308(5.1); 7.304(5.0); 3.471(0.6); 3.321(991.2); 2.786(0.6); 2.739(0.6); 2.675(8.5); 2.671(11.0); 2.666(8.3); 2.619(1.3); 2.541(13.6); 2.506(1401.2); 2.502(1904.3); 2.497(1434.7); 2.333(8.0); 2.328(10.9); 2.324(8.0); 2.074(16.0); 0.146(2.9); 0.008(25.4); 0.000(624.4); −0.008(22.5); −0.149(2.5) BIOLOGICAL EXAMPLES